

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

New England Journal of Medicine

364, 1195-1206

DOI: [10.1056/nejmoa1010494](https://doi.org/10.1056/nejmoa1010494)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dilantin in the treatment of lightning pains. <i>Neurology</i> , 1961, 11, 257-257.	1.1	10
2	Will direct-acting antivirals make a difference in HIV/HCV coinfecting patients?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 699-701.	4.4	0
3	Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1085-1093.	1.9	35
4	Boceprevir: A User's Guide. <i>Clinics in Liver Disease</i> , 2011, 15, 537-553.	2.1	8
5	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. <i>Gastroenterology</i> , 2011, 141, 1656-1664.	1.3	40
6	Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2011, 15, 497-513.	2.1	14
7	Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 536-538.	4.4	4
8	Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations. <i>Clinics in Liver Disease</i> , 2011, 15, 573-583.	2.1	2
9	Emerging Therapies in Hepatitis C: Dawn of the Era of the Direct-Acting Antivirals. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 481-494.	2.2	5
10	Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. <i>Clinics in Liver Disease</i> , 2011, 15, 665-675.	2.1	5
11	Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1009-1026.	3.0	203
12	Mixing and Matching Drugs: What Makes Sense?. <i>Clinics in Liver Disease</i> , 2011, 15, 657-664.	2.1	5
13	Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S46-S51.	1.5	9
14	Direct-acting antiviral (DAA) actions in treatment-naïve patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S52-S58.	1.5	2
15	Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S59-S63.	1.5	11
16	Management of treatment with direct-acting antiviral (DAA) in clinical practice. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S64-S68.	1.5	0
17	Management of side-effects. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S69-S74.	1.5	8
18	Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S75-S83.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Chronic hepatitis C: Treatments of the future. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S84-S95.	1.5	20
20	Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection. Gastroenterology, 2011, 141, 2047-2055.	1.3	127
21	Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?. Gastroenterology, 2011, 141, 1963-1967.	1.3	13
22	Resistance to anti-HCV protease inhibitors. Current Opinion in Virology, 2011, 1, 599-606.	5.4	36
23	Antiviral drugs and antiviral drug resistance. Current Opinion in Virology, 2011, 1, 545-547.	5.4	15
24	Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology, 2011, 1, 590-598.	5.4	101
25	Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 364, 1207-1217.	27.0	1,538
26	Chronic Hepatitis C Infection. New England Journal of Medicine, 2011, 364, 2429-2438.	27.0	403
27	Multiplexed Quantification of Nucleic Acids with Large Dynamic Range Using Multivolume Digital RT-PCR on a Rotational SlipChip Tested with HIV and Hepatitis C Viral Load. Journal of the American Chemical Society, 2011, 133, 17705-17712.	13.7	198
28	Second-wave Protease Inhibitors: Choosing an Heir. Clinics in Liver Disease, 2011, 15, 597-609.	2.1	27
29	Hepatitis C therapy in 2011: is less more, is more less?. Brazilian Journal of Infectious Diseases, 2011, 15, 508-512.	0.6	0
30	Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology, 2011, 52, 321-327.	3.1	110
31	A sprint to increase response to HCV treatment: Expectancies but caution. Journal of Hepatology, 2011, 55, 1154-1158.	3.7	8
32	Realize the advance in HCV treatment, but remain cautious. Journal of Hepatology, 2011, 55, 1457-1460.	3.7	7
33	Boceprevir for Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 365, 176-178.	27.0	23
34	BocÃ©prÃ©vir, nouveau traitement contre lâ€™hÃ©patite C chronique. Actualites Pharmaceutiques Hospitalieres, 2011, 7, 4.	0.1	0
36	An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Clinics in Liver Disease, 2011, 15, 515-536.	2.1	20
37	Thiazolidines as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication. Journal of Medicinal Chemistry, 2011, 54, 8670-8680.	6.4	35

#	ARTICLE	IF	CITATIONS
38	What's fueling the biotech engineâ€”2010 to 2011. Nature Biotechnology, 2011, 29, 1083-1089.	17.5	67
40	Tratamiento de las hepatitis virales. Medicine, 2011, 10, 6249-6254.	0.0	0
41	Boceprevir for previously treated chronic hepatitis C virus genotype 1 infection. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 122-123.	0.6	2
42	HBV & HCV Immunopathogenesis. , 2011, , .		0
43	European Association for the Study of the Liver Berlin, Germany, 30 Marchâ€”3 April. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 251-251.	0.5	0
44	Toll Like Receptors in Chronic Viral Hepatitis â€” Friend and Foe. , 2011, , .		0
45	Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus. Journal of Managed Care Pharmacy, 2011, 17, 685-694.	2.2	31
46	Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Preference and Adherence, 2011, 5, 587.	1.8	5
48	Directly acting antivirals for hepatitis C and antiretrovirals. Current Opinion in HIV and AIDS, 2011, 6, 514-526.	3.8	35
49	Future of hepatitis C therapy. Current Opinion in HIV and AIDS, 2011, 6, 508-513.	3.8	28
50	Diagnosis and Management of Hepatitis C Virusâ€”infected Children. Pediatric Infectious Disease Journal, 2011, 30, 983-985.	2.0	21
51	Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV and AIDS, 2011, 6, 501-507.	3.8	68
52	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. Yearbook of Gastroenterology, 2011, 2011, 240-242.	0.1	0
53	Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. Clinical Investigation, 2011, 1, 1717-1729.	0.0	1
54	New clinical guidelines for management of hepatitis C infection. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 251-251.	0.5	0
55	Does Antiviral Therapy Prevent Hepatocellular Carcinoma?. Antiviral Therapy, 2011, 16, 787-795.	1.0	29
56	Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection. Antiviral Therapy, 2011, 16, 1187-1201.	1.0	30
57	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. Antiviral Therapy, 2011, 16, 1021-1033.	1.0	59

#	ARTICLE	IF	CITATIONS
58	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
59	Predicted effect of direct acting antivirals in the current HIV+HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.	1.0	13
60	Interleukin 28B genetic variations and response to interferon-based therapy: Asian perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1348-1353.	2.8	6
61	First-line treatments for hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1383-1385.	3.7	9
62	Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 443-453.	3.7	49
63	Bocoprevir, nouveau traitement contre l'hépatite C chronique. <i>Option/Bio</i> , 2011, 22, 8.	0.0	0
64	Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974.	2.6	8
65	Hepatitis C virus and non-Hodgkin's lymphoma: biology, epidemiology and therapy. <i>Oncology Reviews</i> , 2011, 5, 249-260.	1.8	2
66	Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3032-3037.	2.3	3
68	Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. <i>BMC Infectious Diseases</i> , 2011, 11, 315.	2.9	18
69	Mixed results from combination therapy. <i>Reviews in Medical Virology</i> , 2011, 21, 333-335.	8.3	0
71	Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011, 54, 789-800.	7.3	58
72	Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. <i>Hepatology</i> , 2011, 54, 1518-1526.	7.3	30
73	An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444.	7.3	961
74	Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. <i>Hepatology</i> , 2011, 54, 1966-1974.	7.3	28
75	Boceprevir (Victrelis) for HCV: V is for victory and very complex. <i>Hepatology</i> , 2011, 54, 1882-1886.	7.3	5
76	Boceprevir. <i>Hepatology</i> , 2011, 54, 2254-2258.	7.3	7
77	Drugs in development for chronic hepatitis C: a promising future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1611-1622.	3.1	31

#	ARTICLE	IF	CITATIONS
78	IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. <i>Biomarkers in Medicine</i> , 2011, 5, 461-478.	1.4	4
79	The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. <i>Seminars in Liver Disease</i> , 2011, 31, 375-386.	3.6	19
80	A New Era of Hepatitis C Therapy Begins. <i>New England Journal of Medicine</i> , 2011, 364, 1272-1274.	27.0	64
81	Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV. <i>Science Translational Medicine</i> , 2011, 3, 91ps30.	12.4	12
82	The Conundrum of Relapse in STAT-C Therapy: Does HCV Play the Red Queen or Rip Van Winkle?. <i>Seminars in Liver Disease</i> , 2011, 31, 410-419.	3.6	8
83	The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?. <i>Seminars in Liver Disease</i> , 2011, 31, 399-409.	3.6	30
84	Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. <i>BMJ: British Medical Journal</i> , 2011, 343, d6972-d6972.	2.3	10
85	Dysfunction of Autophagy Participates in Vacuole Formation and Cell Death in Cells Replicating Hepatitis C Virus. <i>Journal of Virology</i> , 2011, 85, 13185-13194.	3.4	71
86	Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1111-1114.	5.8	3
87	Hepatitis C—Removing Barriers to Diagnosing the “Silent Epidemic”. <i>Clinical Chemistry</i> , 2011, 57, 939-940.	3.2	1
88	Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 294-301.	7.4	41
89	Clinical round-up. <i>Sexually Transmitted Infections</i> , 2011, 87, 449-449.	1.9	0
90	Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.	3.0	81
91	Challenges and opportunities for hepatitis C drug development in HIV—“hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208.	2.2	33
92	Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114.	4.4	12
93	Staging Liver Fibrosis in Hepatitis C: A Challenge for This Decade. <i>American Journal of Gastroenterology</i> , 2011, 106, 2121-2122.	0.4	14
94	Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leaders™ Meeting-28th July 2011-Tehran, IR Iran. <i>Hepatitis Monthly</i> , 2011, 11, 703-713.	0.2	2
95	Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.	0.2	10

#	ARTICLE	IF	CITATIONS
96	RNA-Sequencing Analysis of 5' Capped RNAs Identifies Many New Differentially Expressed Genes in Acute Hepatitis C Virus Infection. <i>Viruses</i> , 2012, 4, 581-612.	3.3	42
97	Pathogenesis of Hepatitis C During Pregnancy and Childhood. <i>Viruses</i> , 2012, 4, 3531-3550.	3.3	62
98	Boceprevir in chronic hepatitis C infection: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 113-121.	2.5	17
99	It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274.	5.8	6
100	Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8.	7.4	180
101	Telaprevir triple combination therapy, and dual peginterferon α -2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. <i>Evidence-Based Medicine</i> , 2012, 17, 143-144.	0.6	1
102	Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
103	Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. <i>Hepatitis Monthly</i> , 2012, 12, 361-368.	0.2	9
104	Boceprevir and personalized medicine in hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, Volume 5, 125-137.	0.7	4
105	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. <i>PLoS Pathogens</i> , 2012, 8, e1002880.	4.7	74
106	Statins in the Treatment of Hepatitis C. <i>Hepatitis Monthly</i> , 2012, 12, 369-371.	0.2	10
109	Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
110	Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	55
111	Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.7	7
113	Identification of Novel α -(Morpholine-4-Carboxyloxy) Amidine Compounds as Potent Inhibitors against Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1315-1323.	3.2	8
114	Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274.	7.4	134
115	Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373.	3.2	117
116	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.	3.9	176

#	ARTICLE	IF	CITATIONS
117	HIV and viral hepatitis C coinfection in people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 339-344.	3.8	20
118	Hepatitis C therapy update. Current Opinion in Gastroenterology, 2012, 28, 188-192.	2.3	27
119	Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Current Opinion in Organ Transplantation, 2012, 17, 216-224.	1.6	23
120	Performance of the Abbott RealTime HCV Genotype II RUO Assay. Journal of Clinical Microbiology, 2012, 50, 3099-3101.	3.9	16
121	Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therapeutic Advances in Gastroenterology, 2012, 5, 179-188.	3.2	10
122	The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans. Antimicrobial Agents and Chemotherapy, 2012, 56, 5381-5386.	3.2	20
123	Clinical round-up. Sexually Transmitted Infections, 2012, 88, 394-394.	1.9	0
124	Interferon Responsiveness Does Not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions. Clinical Infectious Diseases, 2012, 55, 639-644.	5.8	8
125	Association of ITPA Gene Polymorphisms and the Risk of Ribavirin-Induced Anemia in HIV/Hepatitis C Virus (HCV)-Coinfected Patients Receiving HCV Combination Therapy. Antimicrobial Agents and Chemotherapy, 2012, 56, 2987-2993.	3.2	21
126	Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir. Antimicrobial Agents and Chemotherapy, 2012, 56, 5494-5502.	3.2	27
127	Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals. Journal of Clinical Microbiology, 2012, 50, 281-287.	3.9	48
130	The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. Expert Review of Clinical Pharmacology, 2012, 5, 587-593.	3.1	5
131	<i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335. Antimicrobial Agents and Chemotherapy, 2012, 56, 569-572.	3.2	45
132	A Watershed Moment in the Treatment of Hepatitis C. New England Journal of Medicine, 2012, 366, 273-275.	27.0	51
133	Chronic Viral and Autoimmune Hepatitis. , 2012, , 973-979.		2
135	Therapeutic vaccination to treat chronic infectious diseases. Human Vaccines and Immunotherapeutics, 2012, 8, 1746-1757.	3.3	26
136	New challenges in viral hepatitis. Gut, 2012, 61, i1-i5.	12.1	24
137	Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection. American Journal of Health-System Pharmacy, 2012, 69, 2135-2139.	1.0	4

#	ARTICLE	IF	CITATIONS
138	Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Expert Review of Anti-Infective Therapy, 2012, 10, 269-279.	4.4	6
139	Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 335-343.	1.4	32
140	Drug resistance testing in hepatitis C therapy. Future Virology, 2012, 7, 309-321.	1.8	9
141	Genomic variation-guided management in chronic hepatitis C. Expert Review of Gastroenterology and Hepatology, 2012, 6, 497-506.	3.0	9
142	Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model. Molecular Therapy, 2012, 20, 1737-1749.	8.2	46
143	Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. American Journal of Clinical Nutrition, 2012, 96, 1025-1031.	4.7	26
144	Evaluation of Phosphatidylinositol-4-Kinase III β as a Hepatitis C Virus Drug Target. Journal of Virology, 2012, 86, 11595-11607.	3.4	53
145	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19757-19762.	7.1	109
146	New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table A1. Gut, 2012, 61, 1647-1652.	12.1	23
147	Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution. Antimicrobial Agents and Chemotherapy, 2012, 56, 271-279.	3.2	37
148	Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2012, 47, 1115-1119.	1.5	3
149	Vitamins? The magic bullet against hepatitis C. Expert Review of Anti-Infective Therapy, 2012, 10, 1273-1277.	4.4	2
150	Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C. Expert Review of Gastroenterology and Hepatology, 2012, 6, 259-261.	3.0	0
151	Significant publications on infectious diseases pharmacotherapy in 2011. American Journal of Health-System Pharmacy, 2012, 69, 1671-1681.	1.0	11
153	The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. PLoS Pathogens, 2012, 8, e1002832.	4.7	179
154	A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. Journal of Infectious Diseases, 2012, 206, 654-661.	4.0	28
155	SASLT practice guidelines: Management of hepatitis C virus infection. Saudi Journal of Gastroenterology, 2012, 18, 1.	1.1	8
156	Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis. Scientifica, 2012, 2012, 1-22.	1.7	5

#	ARTICLE	IF	CITATIONS
157	Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C. Clinical and Developmental Immunology, 2012, 2012, 1-15.	3.3	5
158	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. Hepatitis Research and Treatment, 2012, 2012, 1-21.	2.0	4
159	In Vitro Systems for the Study of Hepatitis C Virus Infection. International Journal of Hepatology, 2012, 2012, 1-8.	1.1	20
160	Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients. Kidney and Blood Pressure Research, 2012, 35, 454-467.	2.0	14
161	Host Factors in Viral Life Cycles. Mathematical Modelling of Natural Phenomena, 2012, 7, 123-132.	2.4	3
162	Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 6372-6378.	3.2	15
163	Management of chronic hepatitis C infection in children. Current Opinion in Pediatrics, 2012, 24, 113-120.	2.0	10
164	Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update. Clinical Infectious Diseases, 2012, 55, S49-S53.	5.8	38
165	Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. Clinical Infectious Diseases, 2012, 54, 979-983.	5.8	27
166	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 308, 2584.	7.4	1,327
167	Cancer and the "other" noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings. Aids, 2012, 26, S65-S75.	2.2	38
168	HIV protease inhibitors in combination with boceprevir. Aids, 2012, 26, 1845-1846.	2.2	5
169	Limitations of proposed novel trial design. Aids, 2012, 26, 1846-1847.	2.2	1
170	Novel serine protease inhibitors. Pharmaceutical Patent Analyst, 2012, 1, 457-468.	1.1	3
171	A Formula to Estimate the Optimal Dosage of Ribavirin for the Treatment of Chronic Hepatitis C: Influence of Itpa Polymorphisms. Antiviral Therapy, 2012, 17, 1581-1592.	1.0	6
172	New Antiviral Therapies in the Management of HCV Infection. Antiviral Therapy, 2012, 17, 771-783.	1.0	24
174	"Author TBD" Radical Collaboration in Contemporary Biomedical Research. Philosophy of Science, 2012, 79, 845-858.	1.0	41
175	Differences in Virological Response to Peginterferon- α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 117-123.	2.1	12

#	ARTICLE	IF	CITATIONS
176	The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S6792.	0.4	0
177	HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents. Antiviral Therapy, 2012, 17, 1133-1146.	1.0	7
178	Future perspectives: towards interferon-free regimens for HCV. Antiviral Therapy, 2012, 17, 1201-1210.	1.0	16
179	Alisporivir for the treatment of chronic HCV. Future Virology, 2012, 7, 9-18.	1.8	1
181	NASPGHAN Practice Guidelines. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 838-855.	1.8	176
182	Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e47-e49.	2.1	12
183	Acute congestive heart failure and death secondary to itraconazole therapy. Aids, 2012, 26, 1848-1850.	2.2	4
184	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 2012, 17, 849-854.	1.0	2
185	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. Antiviral Therapy, 2012, 17, 1059-1067.	1.0	23
186	Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. Antiviral Therapy, 2012, 17, 1163-1170.	1.0	7
187	Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA Polymerase. Antiviral Therapy, 2012, 17, 411-423.	1.0	34
188	The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antiviral Therapy, 2012, 17, 1119-1131.	1.0	28
189	Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. Antiviral Therapy, 2012, 17, 1397-1401.	1.0	12
190	Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor. Antiviral Therapy, 2012, 17, 633-642.	1.0	6
191	A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. Antiviral Therapy, 2013, 18, 311-319.	1.0	11
192	Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. Antiviral Therapy, 2012, 17, 1171-1182.	1.0	58
193	The science of direct-acting antiviral and host-targeted agent therapy. Antiviral Therapy, 2012, 17, 1109-1117.	1.0	26
194	Direct-acting antiviral agents for the treatment of HCV. Antiviral Therapy, 2012, 17, 1105-1107.	1.0	3

#	ARTICLE	IF	CITATIONS
195	Hepatitis C: The End of the Beginning and Possibly the Beginning of the End. <i>Annals of Internal Medicine</i> , 2012, 156, 317.	3.9	31
196	Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. <i>International Journal of Circumpolar Health</i> , 2012, 71, 18445.	1.2	10
197	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012, 23, 1-12.	0.6	109
198	Predictors of response to chronic hepatitis C treatment. <i>Future Virology</i> , 2012, 7, 1089-1101.	1.8	7
199	HEPATOLOGY: Triple therapy for hepatitis C. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 59-61.	0.3	0
200	Novel clinical trial designs for the development of new antiretroviral agents. <i>Aids</i> , 2012, 26, 1847-1848.	2.2	2
201	Escitalopram for the Prevention of Peginterferon-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 94.	3.9	59
202	Hepatitis C Virus Testing of Persons Born During 1945-1965: Recommendations From the Centers for Disease Control and Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 817.	3.9	263
203	Telaprevir for retreatment of HCV infection: review of the REALIZE trial. <i>Future Virology</i> , 2012, 7, 435-440.	1.8	0
204	HCV protease inhibitors: using the evidence to guide clinical practice. <i>Clinical Investigation</i> , 2012, 2, 923-937.	0.0	2
206	Interferon-Stimulated Genes, but Not USP18, Are Expressed in Livers of Patients With Acute Hepatitis C. <i>Gastroenterology</i> , 2012, 143, 777-786.e6.	1.3	57
207	Therapeutic vaccination against chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2012, 96, 36-50.	4.1	26
208	Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. <i>Liver International</i> , 2012, 32, 1477-1492.	3.9	45
209	Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 677-684.	2.0	33
210	Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 111-118.	4.1	8
211	The disordered N-terminal region of dengue virus capsid protein contains a lipid-droplet-binding motif. <i>Biochemical Journal</i> , 2012, 444, 405-415.	3.7	83
212	Limited effect on NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease. <i>Journal of General Virology</i> , 2012, 93, 1680-1686.	2.9	0
213	Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 670-679.	3.7	5

#	ARTICLE	IF	CITATIONS
214	An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 615-622.	2.0	24
215	Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. <i>Journal of Viral Hepatitis</i> , 2012, 19, 623-634.	2.0	9
216	Antiviral strategies in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2012, 56, S88-S100.	3.7	261
217	Natural killer cells in hepatitis C virus infection. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 775-788.	3.0	9
218	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	1.3	1,486
219	The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2995-3003.	2.3	37
220	Clinical relevance of HCV antiviral drug resistance. <i>Current Opinion in Virology</i> , 2012, 2, 651-655.	5.4	21
221	Hepatitis C virus host cell entry. <i>Current Opinion in Virology</i> , 2012, 2, 14-19.	5.4	79
222	Identification and evaluation of anti Hepatitis C virus phytochemicals from <i>Eclipta alba</i> . <i>Journal of Ethnopharmacology</i> , 2012, 144, 545-554.	4.1	91
223	Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. <i>Hepatology</i> , 2012, 56, 373-381.	7.3	28
224	UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 647-662.	3.7	76
225	Anti-Hepatitis C Virus Drugs in Development. <i>Gastroenterology</i> , 2012, 142, 1340-1350.e1.	1.3	83
226	Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i> , 2012, 56, 1622-1630.	7.3	98
227	Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 1641-1650.	7.3	60
228	Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. <i>Hepatology</i> , 2012, 56, 2398-2403.	7.3	31
229	New therapeutic paradigm for patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 1983-1992.	7.3	108
230	Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. <i>Hepatology</i> , 2012, 56, 1591-1592.	7.3	24
231	Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data. <i>Liver Transplantation</i> , 2012, 18, 1464-1470.	2.4	76

#	ARTICLE	IF	CITATIONS
233	Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. <i>Clinical Pharmacokinetics</i> , 2012, 51, 619-628.	3.5	34
234	Liver Transplantation: From Inception to Clinical Practice. <i>Cell</i> , 2012, 150, 1096-1099.	28.9	21
235	Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. <i>Journal of Pediatrics</i> , 2012, 161, 915-921.	1.8	59
236	Integration of substance use treatment and medical care: A special issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 377-381.	2.8	9
237	Treating hepatitis C infection by targeting the host. <i>Translational Research</i> , 2012, 159, 421-429.	5.0	11
238	Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. <i>Virology</i> , 2012, 433, 479-488.	2.4	45
239	Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14.	2.2	76
240	Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. <i>Journal of Hepatology</i> , 2012, 57, 1379-1390.	3.7	194
241	Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 717-728.	9.1	95
242	Recomendações para a terapêutica da hepatite C. <i>GE Jornal Português De Gastreenterologia</i> , 2012, 19, 133-139.	0.0	2
243	The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 879-891.	5.1	0
244	Stratégies antivirales dans l'hépatite chronique C. <i>Journal Des Anti-infectieux</i> , 2012, 14, 78-88.	0.1	0
245	NS5A inhibitors to treat hepatitis C virus infection. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 648-649.	9.1	0
246	Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1270-1277.e3.	4.4	16
247	New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting. <i>Journal of Hepatology</i> , 2012, 57, 1361-1367.	3.7	11
248	An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.	3.3	42
250	Update on alisporivir in treatment of viral hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 375-382.	4.1	44
251	TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4676-4684.	3.2	40

#	ARTICLE	IF	CITATIONS
252	Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2327-2337.	3.0	12
253	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521.	1.5	13
255	Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323.	1.8	30
256	Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1101-10.	7.1	78
257	Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 35-40.	2.7	9
258	Care of the Cirrhotic Patient. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 979-994.	5.1	5
259	Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 893-901.	5.1	0
260	GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV. <i>Future Virology</i> , 2012, 7, 537-546.	1.8	7
261	Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1838-1844.	3.2	50
262	Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5230-5239.	3.2	68
263	Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 289-294.	8.7	51
264	New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46.	12.1	168
265	The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment. <i>Biomarkers in Medicine</i> , 2012, 6, 141-150.	1.4	7
266	Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , 2012, 32, 712-731.	3.9	19
267	HIV and HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. <i>Liver International</i> , 2012, 32, 1194-1199.	3.9	18
268	Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.	3.9	27
269	Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. <i>Liver International</i> , 2012, 32, 1270-1277.	3.9	10
270	Peripheral blood cytopenia before treatment in HCV patients: is it a limitation for HCV treatment in the era of DAA? <i>Liver International</i> , 2012, 32, 1033-1036.	3.9	2

#	ARTICLE	IF	CITATIONS
271	Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5387-5396.	3.2	173
272	Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 105.	2.0	20
273	Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. <i>Current Medical Research and Opinion</i> , 2012, 28, 1841-1856.	1.9	14
274	Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5728-5734.	3.2	51
275	Basic answers to complicated questions for the course of chronic hepatitis C treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 371-382.	3.0	3
276	Bacterial proteolytic complexes as therapeutic targets. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 777-789.	46.4	98
277	Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 282-284.	3.7	4
278	Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. <i>Journal of Hepatology</i> , 2012, 56, 455-463.	3.7	135
279	The invaders and the barrier. <i>Journal of Hepatology</i> , 2012, 56, 11-13.	3.7	4
280	Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. <i>Journal of Hepatology</i> , 2012, 56, 557-563.	3.7	24
281	Understanding silibinin's modes of action against HCV using viral kinetic modeling. <i>Journal of Hepatology</i> , 2012, 56, 1019-1024.	3.7	47
282	A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 24-31.	3.7	147
283	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. <i>Journal of Hepatology</i> , 2012, 57, 17-23.	3.7	72
284	National patterns and predictors of liver biopsy use for management of hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 252-259.	3.7	7
285	Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. <i>Journal of Hepatology</i> , 2012, 57, 946-952.	3.7	56
286	Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. <i>Journal of Virological Methods</i> , 2012, 185, 94-100.	2.1	29
289	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. <i>Journal of Clinical Virology</i> , 2012, 54, 352-354.	3.1	108
290	Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.	3.1	12

#	ARTICLE	IF	CITATIONS
291	Interferon signaling in the liver during hepatitis C virus infection. <i>Cytokine</i> , 2012, 59, 460-466.	3.2	10
295	Elevated D-Dimer is Independently Associated with Endothelial Dysfunction: A Cross-Sectional Study in HIV-Infected Adults on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1345-1349.	1.0	32
296	Comparison of hepatitis C virus treatment between incarcerated and community patients. <i>Hepatology</i> , 2012, 56, 1252-1260.	7.3	32
297	High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050.	7.3	92
298	A great time to invest in baby Boomer's hepatitis C!. <i>Hepatology</i> , 2012, 56, 1575-1577.	7.3	0
299	IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. <i>Journal of Medical Virology</i> , 2012, 84, 1522-1527.	5.0	2
300	Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. <i>Liver Transplantation</i> , 2012, 18, 1053-1059.	2.4	66
301	The race for interferon-free HCV therapies: a snapshot by the spring of 2012. <i>Reviews in Medical Virology</i> , 2012, 22, 392-411.	8.3	18
302	Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1 α and PKR. <i>BMC Structural Biology</i> , 2012, 12, 28.	2.3	13
303	Hepatitis C Virus Drug Resistance. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 967-978.	5.1	1
304	To Market, To Market—2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.9	23
305	A new standard of care and the race towards IFN-free therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 67-68.	17.8	6
306	Boceprevir. <i>Drugs</i> , 2012, 72, 2431-2456.	10.9	17
307	Interferon-Free Hepatitis C Therapy. <i>Drugs</i> , 2012, 72, 1825-1831.	10.9	20
308	New Pharmacotherapy for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 294-305.	4.7	24
309	Systems Biology Analyses to Define Host Responses to HCV Infection and Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2012, 363, 143-167.	1.1	3
310	Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. <i>American Journal of Gastroenterology</i> , 2012, 107, 669-689.	0.4	84
311	Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?. <i>Gastroenterology</i> , 2012, 142, 1369-1372.	1.3	9

#	ARTICLE	IF	CITATIONS
312	Hepatic Cellâ€“Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype. <i>Gastroenterology</i> , 2012, 142, 1122-1131.e1.	1.3	61
313	Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339.	1.3	16
314	Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3.	1.3	78
315	Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. <i>Gastroenterology</i> , 2012, 142, 1314-1323.e1.	1.3	50
316	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. <i>Gastroenterology</i> , 2012, 143, 608-618.e5.	1.3	179
317	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	1.3	107
318	Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virusâ€“Infected Patients Following TMC435 Monotherapy. <i>Gastroenterology</i> , 2012, 143, 1176-1178.e6.	1.3	37
319	Data to Guide the â€œTest and Treat Eraâ€“of Hepatitis C. <i>Gastroenterology</i> , 2012, 143, 887-889.	1.3	8
320	Gastrointestinal, Hepatobiliary, Pancreatic, and Iron-Related Diseases in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation. <i>Seminars in Hematology</i> , 2012, 49, 43-58.	3.4	29
321	Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 1886-1892.	2.4	8
322	Triple therapy with boceprevir or telaprevir for treatment naÃ“ve HCV patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 445-453.	2.4	14
323	Response guided therapy in patients with chronic hepatitis C â€“ Yesterday, today and tomorrow. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 463-469.	2.4	12
324	The role of viral and host genetics in natural history andÂtreatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427.	2.4	24
325	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.	2.4	14
326	Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 471-485.	2.4	11
327	The role of resistance in HCV treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 487-503.	2.4	108
328	Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2012, 34, 1883-1891.	2.5	6
329	Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C. <i>Clinical Therapeutics</i> , 2012, 34, 2021-2038.	2.5	22

#	ARTICLE	IF	CITATIONS
330	Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). <i>Current Opinion in Pharmacology</i> , 2012, 12, 556-561.	3.5	19
331	Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2012, 44, 438-441.	0.9	15
332	Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. <i>Digestive and Liver Disease</i> , 2012, 44, 497-503.	0.9	72
334	Genomics and HCV infection: Progression of fibrosis and treatment response. <i>Journal of Hepatology</i> , 2012, 57, 1110-1125.	3.7	89
335	PIN32 Economic Evaluation of Boceprevir for the Treatment of Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Value in Health</i> , 2012, 15, A390.	0.3	1
336	Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1. <i>American Journal of Gastroenterology</i> , 2012, 107, 1675-1683.	0.4	16
337	Hepatitis virus infections. , 2012, , 411-420.		0
340	Non-interferon Therapies for Hepatitis C. <i>Current Hepatitis Reports</i> , 2012, 11, 146-152.	0.3	1
341	Impact of Ethnicity and Race on Treatment Response: Past, Present and Future. <i>Current Hepatitis Reports</i> , 2012, 11, 128-135.	0.3	1
342	IL28B: Current and Future Use. <i>Current Hepatitis Reports</i> , 2012, 11, 136-145.	0.3	0
343	Cyclophilin Inhibitors. <i>Current Hepatitis Reports</i> , 2012, 11, 153-159.	0.3	4
344	Second Generation Protease Inhibitors and Nucleotide Inhibitors. <i>Current Hepatitis Reports</i> , 2012, 11, 172-180.	0.3	0
345	Resistance to Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2012, 11, 188-194.	0.3	0
346	Telaprevir and Boceprevir: The Future Is Now. <i>Current Hepatitis Reports</i> , 2012, 11, 160-171.	0.3	2
347	Hepatitis C Therapy: Lessons of the Last Two Decades. <i>Current Hepatitis Reports</i> , 2012, 11, 119-127.	0.3	1
348	Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 197-205.	0.3	0
349	Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. <i>Gut</i> , 2012, 61, 290-296.	12.1	17
350	Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 671-677.	9.1	139

#	ARTICLE	IF	CITATIONS
351	Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. Current HIV/AIDS Reports, 2012, 9, 231-237.	3.1	10
352	IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment. Infectious Disease Clinics of North America, 2012, 26, 863-877.	5.1	12
353	New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut, 2012, 61, i25-i35.	12.1	67
354	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. Expert Opinion on Pharmacotherapy, 2012, 13, 2355-2367.	1.8	2
355	Hepatitis C virus: current concepts and future challenges. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 29-32.	0.5	19
356	Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients. Clinical Infectious Diseases, 2012, 54, 96-104.	5.8	86
357	Chronic Hepatitis C Virus. , 2012, , .		3
358	Future Classes of Hepatitis C Virus Therapeutic Agents. Infectious Disease Clinics of North America, 2012, 26, 949-966.	5.1	2
359	TMC435 for the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs, 2012, 21, 1193-1209.	4.1	22
360	Viral Hepatitis in the Elderly. American Journal of Gastroenterology, 2012, 107, 691-697.	0.4	40
361	Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. BMC Infectious Diseases, 2012, 12, S3.	2.9	9
362	Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infectious Diseases, 2012, 12, 324.	2.9	7
363	Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. Infectious Disease Clinics of North America, 2012, 26, 931-948.	5.1	7
364	ARF1 and GBF1 Generate a PI4P-Enriched Environment Supportive of Hepatitis C Virus Replication. PLoS ONE, 2012, 7, e32135.	2.5	57
365	Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture. PLoS ONE, 2012, 7, e35351.	2.5	12
366	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60
367	Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir. PLoS ONE, 2012, 7, e41191.	2.5	23
368	High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. PLoS ONE, 2012, 7, e41206.	2.5	43

#	ARTICLE	IF	CITATIONS
369	Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. PLoS ONE, 2012, 7, e45176.	2.5	52
370	Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 205-210.	1.7	50
371	An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 359-375.	1.7	101
372	Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Annals of Hepatology, 2012, 11, 186-193.	1.5	4
374	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology, 2012, 11, 284-293.	1.5	22
375	A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Annals of Hepatology, 2012, 11, 179-185.	1.5	67
377	Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. ClinicoEconomics and Outcomes Research, 2012, 4, 349.	1.9	9
378	Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 2012, 196, 633-637.	1.7	27
379	Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon- α 2a (40 KD) plus ribavirin. Antiviral Therapy, 2012, 17, 927-932.	1.0	3
380	Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clinical and Experimental Gastroenterology, 2012, 5, 11.	2.3	16
381	New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics: Targets and Therapy, 2012, 6, 249.	3.2	2
382	Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Preference and Adherence, 2012, 6, 285.	1.8	17
383	Interferon-alpha inhibits airway eosinophila and hyperresponsiveness in an animal asthma model. Asia Pacific Allergy, 2012, 2, 256-263.	1.3	16
384	Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C. Southern Medical Journal, 2012, 105, 431-436.	0.7	5
385	Evaluation and Treatment of Hepatitis C in Patients with Human Immunodeficiency Virus. Southern Medical Journal, 2012, 105, 500-503.	0.7	1
386	Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Pharmacotherapy, 2012, 32, 173-190.	2.6	18
387	Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir. Antimicrobial Agents and Chemotherapy, 2012, 56, 3670-3681.	3.2	103
388	3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 300-304.	2.2	18

#	ARTICLE	IF	CITATIONS
389	Efficient, Chemoenzymatic Process for Manufacture of the Boceprevir Bicyclic [3.1.0]Proline Intermediate Based on Amine Oxidase-Catalyzed Desymmetrization. Journal of the American Chemical Society, 2012, 134, 6467-6472.	13.7	170
390	Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor. Bulletin of Mathematical Biology, 2012, 74, 1789-1817.	1.9	38
391	Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. Journal of Medical Virology, 2012, 84, 1376-1387.	5.0	21
392	Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology, 2012, 55, 1038-1047.	7.3	36
393	Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology, 2012, 55, 1030-1037.	7.3	51
394	Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology, 2012, 55, 1048-1057.	7.3	62
395	Clinical trials and their translation in hepatology: Past, present, and future. Hepatology, 2012, 56, 399-410.	7.3	1
396	Review and management of drug interactions with boceprevir and telaprevir. Hepatology, 2012, 55, 1620-1628.	7.3	123
397	A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology, 2012, 56, 507-515.	7.3	49
398	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	7.3	97
399	Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. Hepatology, 2012, 56, 884-893.	7.3	52
400	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55, 2005-2023.	7.3	2,935
401	Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology, 2012, 56, 567-575.	7.3	47
402	A brief history of the treatment of viral hepatitis C. Clinical Liver Disease, 2012, 1, 6-11.	2.1	32
403	Predicting the response to the treatment of hepatitis C virus infection. Clinical Liver Disease, 2012, 1, 46-48.	2.1	1
404	Issues in selecting HCV-infected candidates for anti-viral treatment. Clinical Liver Disease, 2012, 1, 29-31.	2.1	0
405	The horizon: New targets and new agents. Clinical Liver Disease, 2012, 1, 24-27.	2.1	1
406	Demographics of hepatitis C virus today. Clinical Liver Disease, 2012, 1, 2-5.	2.1	1

#	ARTICLE	IF	CITATIONS
407	Is there still a role for liver biopsy in managing hepatitis C virus infections?. Clinical Liver Disease, 2012, 1, 32-35.	2.1	0
408	Management of adverse events during the treatment of chronic hepatitis C infection. Clinical Liver Disease, 2012, 1, 54-57.	2.1	5
409	HCV infection on-treatment viral kinetics: Do they still have a role?. Clinical Liver Disease, 2012, 1, 51-53.	2.1	0
410	The new standard of HCV therapy: Retreatment in experienced patients. Clinical Liver Disease, 2012, 1, 16-19.	2.1	0
411	Hepatitis C viral infection in patients with cirrhosis. Clinical Liver Disease, 2012, 1, 65-68.	2.1	0
412	The long-term horizon: Patients who will remain untreated in the era of triple therapy. Clinical Liver Disease, 2012, 1, 20-23.	2.1	1
413	Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. Clinical Liver Disease, 2012, 1, 69-72.	2.1	0
414	Hepatitis C viral infection in patients with chronic kidney disease. Clinical Liver Disease, 2012, 1, 91-94.	2.1	0
415	The new standard of HCV therapy: Treatment in therapy-naïve patients. Clinical Liver Disease, 2012, 1, 12-15.	2.1	0
416	Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. Clinical Liver Disease, 2012, 1, 58-61.	2.1	2
417	Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C. Clinical Infectious Diseases, 2012, 55, S16-S24.	5.8	24
418	Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. Clinical Infectious Diseases, 2012, 55, S58-S63.	5.8	36
419	Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. Annual Review of Medicine, 2012, 63, 373-387.	12.2	36
421	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. Digestive Diseases and Sciences, 2012, 57, 1083-1091.	2.3	27
422	Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C. Digestive Diseases and Sciences, 2012, 57, 832-834.	2.3	2
423	Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. Digestive Diseases and Sciences, 2012, 57, 1469-1474.	2.3	33
425	APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International, 2012, 6, 409-435.	4.2	152
426	Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver International, 2012, 32, 88-102.	3.9	119

#	ARTICLE	IF	CITATIONS
427	Future treatment of patients with <sc>HCV</sc> cirrhosis. Liver International, 2012, 32, 113-119.	3.9	23
428	Treatment of chronic hepatitis C “ are interferons really necessary?. Liver International, 2012, 32, 108-112.	3.9	20
429	Barriers to hepatitis <sc>C</sc> treatment. Liver International, 2012, 32, 151-156.	3.9	141
430	Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver International, 2012, 32, 32-38.	3.9	53
431	Phase <sc>III</sc> results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver International, 2012, 32, 39-43.	3.9	21
432	<i><sc>IL28B</sc></i> genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis <sc>C</sc>: ten years too late?. Liver International, 2012, 32, 74-78.	3.9	19
433	Responseâ€‘guided and â€‘unguided treatment of chronic hepatitis <sc>C</sc>. Liver International, 2012, 32, 64-73.	3.9	12
434	Hepatitis <sc>C</sc> virus treatment preâ€‘and postâ€‘liver transplantation. Liver International, 2012, 32, 120-128.	3.9	62
435	Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: â€‘Leadâ€‘in or no leadâ€‘inâ€‘? Liver International, 2012, 32, 61-63.	3.9	2
436	Triple therapy for <sc>HCV</sc> genotype 1 infection: telaprevir or boceprevir?. Liver International, 2012, 32, 54-60.	3.9	24
437	Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Liver International, 2012, 32, 27-31.	3.9	32
438	Host genomics and HCV treatment response. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 212-222.	2.8	29
439	Implications of rapid virological response in hepatitis C therapy in the US veteran population. Alimentary Pharmacology and Therapeutics, 2012, 35, 105-115.	3.7	10
440	5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. European Journal of Medicinal Chemistry, 2012, 53, 83-97.	5.5	24
441	Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1095-1098.	2.2	9
442	Discovery of 4â€‘-azido-2â€‘-deoxy-2â€‘-C-methyl cytidine and prodrugs thereof: A potent inhibitor of Hepatitis C virus replication. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3265-3268.	2.2	15
443	Responseâ€‘guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatology Research, 2012, 42, 549-557.	3.4	10
444	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143

#	ARTICLE	IF	CITATIONS
445	Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. <i>Virology</i> , 2012, 422, 174-184.	2.4	29
446	Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. <i>Virology</i> , 2012, 429, 57-62.	2.4	21
447	The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1209-1220.	3.7	7
448	Randomised clinical trial: pre-treating with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 370-378.	3.7	3
449	Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV genotype 2 and 3 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 353-362.	3.7	37
450	Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. <i>Journal of Viral Hepatitis</i> , 2012, 19, 236-243.	2.0	13
451	High-dose silybinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. <i>Journal of Viral Hepatitis</i> , 2012, 19, 547-553.	2.0	23
452	Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , 2012, 19, 537-546.	2.0	62
453	A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-26.	2.0	71
454	Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2012, 19, 449-464.	2.0	160
455	Hepatitis C therapy in non-genotype 1 patients: the near future. <i>Journal of Viral Hepatitis</i> , 2012, 19, 525-536.	2.0	23
456	Current status and future directions in the management of chronic hepatitis C. <i>Virology Journal</i> , 2012, 9, 57.	3.4	36
457	A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. <i>Hepatology</i> , 2012, 55, 364-372.	7.3	116
458	Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. <i>Hepatology</i> , 2012, 55, 742-748.	7.3	318
459	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012, 55, 749-758.	7.3	108
461	Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. <i>Hepatology</i> , 2012, 55, 634-641.	7.3	54
462	An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. <i>Hepatology</i> , 2012, 55, 979-980.	7.3	7
464	Rapid virological response: Is it four or eight weeks?. <i>Hepatology</i> , 2012, 55, 979.	7.3	0

#	ARTICLE	IF	CITATIONS
465	Yttrium 90 therapy for hepatocellular carcinoma: Is it any better than conventional external beam radiotherapy?. Hepatology, 2012, 55, 981-981.	7.3	1
467	Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. Current Gastroenterology Reports, 2012, 14, 74-77.	2.5	8
468	Treatment of Non-Genotype 1 Hepatitis C Virus Patients. Current Gastroenterology Reports, 2012, 14, 87-93.	2.5	8
469	Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease Inhibitors. Current Gastroenterology Reports, 2012, 14, 47-54.	2.5	11
470	Management of Hepatitis C in Patients with Chronic Kidney Disease. Current Gastroenterology Reports, 2012, 14, 78-86.	2.5	12
471	HCV and Chemotherapy: Does Infection Change Management?. Current Hepatitis Reports, 2012, 11, 34-40.	0.3	0
472	HCV In At Risk Populations: Who Can be Treated and How?. Current Hepatitis Reports, 2012, 11, 1-9.	0.3	0
473	HCV Therapy in 2011: Development of New Treatment Paradigms for Na ⁺ ve and Non-Responder Patients. Current Hepatitis Reports, 2012, 11, 48-54.	0.3	0
474	Boceprevir versus Telaprevir: A New Era of Directly Acting Antiviral Therapy. Current Hepatitis Reports, 2012, 11, 23-33.	0.3	1
475	Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Research and Therapy, 2013, 10, 9.	1.7	19
476	The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. Virology Journal, 2013, 10, 98.	3.4	11
477	Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virology Journal, 2013, 10, 57.	3.4	17
478	Approved and experimental countermeasures against pestiviral diseases: Bovine viral diarrhea, classical swine fever and border disease. Antiviral Research, 2013, 100, 133-150.	4.1	28
479	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection, 2013, 41, 21-26.	4.7	6
480	Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era. Clinics in Liver Disease, 2013, 17, 27-45.	2.1	7
481	Novel therapies for hepatitis C “one pill fits all?”. Nature Reviews Drug Discovery, 2013, 12, 595-610.	46.4	174
482	Global control of hepatitis C: where challenge meets opportunity. Nature Medicine, 2013, 19, 850-858.	30.7	250
483	The presence of resistance mutations to protease and polymerase inhibitors in <sc>H</sc>epatitis <sc>C</sc> virus sequences from the <i><sc>L</sc>os <sc>A</sc>mos</i> databank. Journal of Viral Hepatitis, 2013, 20, 414-421.	2.0	42

#	ARTICLE	IF	CITATIONS
484	Viral Hepatitis in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 147-168.	4.7	72
485	Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172. Organic Letters, 2013, 15, 4174-4177.	4.6	51
486	A new era in the treatment of chronic hepatitis C infection. Indian Journal of Gastroenterology, 2013, 32, 71-79.	1.4	4
487	Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. BMC Medical Research Methodology, 2013, 13, 60.	3.1	18
488	Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterology, 2013, 13, 86.	2.0	18
489	Multicenter comparison of PEG-IFN α 2a or α 2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterology, 2013, 13, 74.	2.0	16
490	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infectious Diseases, 2013, 13, 190.	2.9	48
491	Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy. Expert Review of Proteomics, 2013, 10, 275-287.	3.0	6
492	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatology International, 2013, 7, 153-161.	4.2	4
493	HCV Therapy: Treat now or wait?. Current Hepatitis Reports, 2013, 12, 7-12.	0.3	1
494	Hepatitis C: Management of Side Effects in the Era of Direct-Acting Antivirals. Current Gastroenterology Reports, 2013, 15, 305.	2.5	11
495	IL28B Genotype on HCV Infection in Asia. Current Hepatitis Reports, 2013, 12, 149-156.	0.3	3
496	Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. Current Hepatitis Reports, 2013, 12, 13-19.	0.3	0
497	Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63, 145-150.	3.2	6
498	Durability of SVR in chronic hepatitis C patients treated with peginterferon α 2a/ribavirin in combination with a direct-acting antiviral. Alimentary Pharmacology and Therapeutics, 2013, 38, 118-123.	3.7	28
499	Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon α 2b/ribavirin. Alimentary Pharmacology and Therapeutics, 2013, 38, 16-27.	3.7	19
500	Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine, 2013, 2, 9.	4.0	27
501	Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. New England Journal of Medicine, 2013, 369, 630-639.	27.0	215

#	ARTICLE	IF	CITATIONS
502	Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials. <i>Clinical Therapeutics</i> , 2013, 35, 190-197.	2.5	26
503	NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1337-1346.	4.1	34
504	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 597-605.	9.1	175
505	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 804.	7.4	265
506	A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. <i>Journal of Hepatology</i> , 2013, 59, 11-17.	3.7	31
507	A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 926-933.	3.7	33
508	Hypersensibilit� aux nouveaux traitements de lâ€™h�patite C. <i>Revue Francaise D'allergologie</i> , 2013, 53, 171-173.	0.2	0
509	Optimizing DAA management in daily practice. <i>Digestive and Liver Disease</i> , 2013, 45, S318-S322.	0.9	6
511	Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 194-204.	0.6	15
512	Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. <i>Journal of Hepatology</i> , 2013, 59, 169-177.	3.7	163
513	IL28B testing in a rapidly changing world: Still relevant?. <i>Journal of Hepatology</i> , 2013, 58, 847-849.	3.7	5
514	50 IS ADDING HCV SCREENING TO THE ANTENATAL NATIONAL SCREENING PROGRAM IN AMSTERDAM, THE NETHERLANDS COST-EFFECTIVE?. <i>Journal of Hepatology</i> , 2013, 58, S22.	3.7	0
515	Evolutionary dynamics of hepatitis C virus <sc>NS</sc>3 protease domain during and following treatment with narlaprevir, a potent <sc>NS</sc>3 protease inhibitor. <i>Journal of Viral Hepatitis</i> , 2013, 20, 779-789.	2.0	0
516	In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Disposition</i> , 2013, 41, 668-681.	3.3	50
517	Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients. <i>Clinics in Liver Disease</i> , 2013, 17, 737-747.	2.1	8
519	Discovery of Hepatitis�C Virus NS3 Helicase Inhibitors by a Multiplexed, High�Throughput Helicase Activity Assay Based on Graphene Oxide. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 2340-2344.	13.8	64
520	Increasing antiviral treatment through integrated hepatitis C care: A randomized multicenter trial. <i>Contemporary Clinical Trials</i> , 2013, 35, 97-107.	1.8	27
521	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	3.7	35

#	ARTICLE	IF	CITATIONS
522	The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1647-1657.	3.3	6
523	Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 2013, 145, 790-800.e3.	1.3	27
524	The importance of HCV RNA measurement for tailoring treatment duration. Digestive and Liver Disease, 2013, 45, S323-S331.	0.9	14
525	Safety of direct antiviral agents in real life. Digestive and Liver Disease, 2013, 45, S363-S366.	0.9	14
526	Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. Journal of Medicinal Chemistry, 2013, 56, 8163-8182.	6.4	29
527	Novel Therapeutic Approaches for Hepatitis C. Clinical Pharmacology and Therapeutics, 2013, 95, 78-88.	4.7	74
528	Determining the Cellular Diversity of Hepatitis C Virus Quasispecies by Single-Cell Viral Sequencing. Journal of Virology, 2013, 87, 12648-12655.	3.4	21
529	The Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. Digestive Diseases and Sciences, 2013, 58, 621-629.	2.3	4
530	Perspectives and challenges of interferon-free therapy for chronic hepatitis C. Journal of Hepatology, 2013, 58, 583-592.	3.7	87
531	Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 10-16.	1.5	24
532	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1427-1435.	2.9	10
533	Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology, 2013, 57, 2143-2154.	7.3	102
534	Lead-in treatment with interferon- α 2b/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 443-449.	2.8	2
535	Efficacy and safety of boceprevir plus peginterferon- α 2b/ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology, 2013, 58, 479-487.	3.7	52
536	Boceprevir With Peginterferon Alfa-2a/Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 81-87.e4.	4.4	61
537	Cost-effectiveness of viral hepatitis B & C treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 973-985.	2.4	12
538	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. Journal of Hepatology, 2013, 58, 646-654.	3.7	160
539	Containing "The Great Houdini" of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. Drug Resistance Updates, 2013, 16, 60-67.	14.4	15

#	ARTICLE	IF	CITATIONS
540	Discovery of novel HCV inhibitors: Synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3947-3953.	2.2	30
541	Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis. <i>Virology</i> , 2013, 443, 278-284.	2.4	19
542	Virologic response and characterisation of HCV genotype 2 in patients receiving TMC435 monotherapy (study TMC435-C202). <i>Journal of Hepatology</i> , 2013, 58, 445-451.	3.7	82
543	NS5A inhibitors in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 375-382.	3.7	172
544	No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfecting patients using deep sequencing. <i>Journal of Clinical Virology</i> , 2013, 58, 726-729.	3.1	17
545	Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. <i>Journal of Clinical Virology</i> , 2013, 57, 13-18.	3.1	87
546	Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1415-1422.	3.0	4
547	Anemia Management in Patients with Chronic Viral Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2013, 47, 228-236.	1.9	12
548	Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. <i>Virology</i> , 2013, 444, 329-336.	2.4	61
549	Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. <i>Virology</i> , 2013, 444, 384-393.	2.4	2
550	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	3.3	10
551	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. <i>Journal of Hepatology</i> , 2013, 58, 655-662.	3.7	225
552	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet</i> , 2013, 381, 2100-2107.	13.7	265
553	Simeprevir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2581-2589.	1.8	41
554	Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1076-1085.	3.7	23
555	Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 690-700.	2.4	99
556	Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. <i>Journal of Viral Hepatitis</i> , 2013, 20, 395-403.	2.0	18
557	Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2013, 33, 325-331.	2.2	28

#	ARTICLE	IF	CITATIONS
558	Antiviral activity of boceprevir monotherapy in treatment-naïve subjects with chronic hepatitis C genotype 2/3. <i>Journal of Hepatology</i> , 2013, 59, 31-37.	3.7	46
559	Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1021-1027.	4.4	25
560	Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.	3.7	19
561	“Favourable” IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. <i>Journal of General Virology</i> , 2013, 94, 1259-1265.	2.9	19
562	Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475.	2.4	30
563	Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32.	4.0	48
564	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929.	7.3	255
565	Hepatitis C virus: Antiviral therapy in wait-listed patients. <i>Clinical Liver Disease</i> , 2013, 2, 173-176.	2.1	0
566	Study of hepatitis C virus entry in genetically humanized mice. <i>Methods</i> , 2013, 59, 249-257.	3.8	16
567	Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 388-396.	2.5	48
568	Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3348-3358.	2.3	10
569	Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and “experienced patients. <i>BMC Gastroenterology</i> , 2013, 13, 148.	2.0	3
570	Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382.	2.3	7
571	Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3620-3625.	2.3	35
572	Direct-Acting Antiviral-Associated Dermatitis During Chronic Hepatitis C Virus Treatment. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 497-502.	6.7	13
573	Recent Therapeutic Advances in Gastroenterology and Hepatology. <i>Advances in Therapy</i> , 2013, 30, 855-857.	2.9	0
574	Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. <i>American Journal of Medicine</i> , 2013, 126, 718-722.	1.5	36
575	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection” A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	1.3	51

#	ARTICLE	IF	CITATIONS
576	Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection. <i>Hepatology</i> , 2013, 58, 822-826.	7.3	2
577	Therapy for Hepatitis C Virus-Related Cryoglobulinemic Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 1035-1045.	27.0	159
578	All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naïve genotype 1 hepatitis C (NUCLEAR). <i>Journal of Viral Hepatitis</i> , 2013, 20, 699-707.	2.0	25
579	Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naïve Hepatitis C Patients. <i>Pharmacoeconomics</i> , 2013, 31, 919-931.	3.3	36
580	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
581	Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?. <i>Journal of Clinical Virology</i> , 2013, 56, 146-149.	3.1	64
582	Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 713-728.	17.8	17
583	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 401-408.	9.1	313
584	Hepatitis C Virus. <i>Advances in Pharmacology</i> , 2013, 67, 169-215.	2.0	46
585	Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. <i>Current Opinion in Virology</i> , 2013, 3, 508-513.	5.4	14
586	HCV, Ribavirin, and Anemia: A New Dawn. <i>Gastroenterology</i> , 2013, 145, 930-933.	1.3	1
587	Limited Access to Protease Inhibitors Therapy for Chronic HCV in the Region: YES. <i>Current Hepatitis Reports</i> , 2013, 12, 280-287.	0.3	3
588	Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. <i>Current Hepatitis Reports</i> , 2013, 12, 236-245.	0.3	1
589	The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2013, 12, 220-226.	0.3	0
590	Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection – What Technology do we Really Need in Clinical Practice?. <i>Current Hepatitis Reports</i> , 2013, 12, 195-199.	0.3	0
591	Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2013, 12, 189-194.	0.3	0
592	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. <i>Current Hepatitis Reports</i> , 2013, 12, 261-268.	0.3	0
594	HCV NS3/4a Protease Inhibitors: Simeprevir (TMC435350), Vaniprevir (MK7009) and MK5172. <i>RSC Drug Discovery Series</i> , 2013, , 189-247.	0.3	1

#	ARTICLE	IF	CITATIONS
595	Meloxicam as an adjuvant to peginterferon- α 2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. <i>Hepatology Research</i> , 2013, 43, 925-932.	3.4	0
596	Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 153-163.	0.5	30
597	Perspectivas a largo plazo: pacientes que seguir�n sin tratamiento en la era de la terapia triple. <i>Clinical Liver Disease</i> , 2013, 2, S16�S19�.	2.1	0
598	A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing. <i>American Journal of Gastroenterology</i> , 2013, 108, 1464-1472.	0.4	16
599	Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell�epatite cronica di tipo C genotipo 1 in pazienti adulti na�ve con fibrosi F0�F2. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 111-122.	0.2	1
600	The discovery and development of boceprevir. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1439-1447.	5.0	18
601	Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. <i>Nature Medicine</i> , 2013, 19, 837-849.	30.7	497
602	Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. <i>Current HIV/AIDS Reports</i> , 2013, 10, 408-419.	3.1	17
603	A Note on Partial Covariate-Adjustment and Design Considerations in Noninferiority Trials When Patient-Level Data are not Available. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 1042-1053.	0.8	1
604	Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus. <i>Journal of Pediatrics</i> , 2013, 162, 148-154.	1.8	24
605	Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 115-119.	2.8	10
606	Barriers of hepatitis C virus interspecies transmission. <i>Virology</i> , 2013, 435, 70-80.	2.4	19
607	Vitamin B12supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. <i>Gut</i> , 2013, 62, 766-773.	12.1	26
608	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	4.4	30
609	A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8+ T Cell Responses in Wild-Type and NS5A-Transgenic Mice. <i>Journal of Immunology</i> , 2013, 190, 1113-1124.	0.8	11
610	Innate immunity and HCV. <i>Journal of Hepatology</i> , 2013, 58, 564-574.	3.7	124
611	Cyclophilin Inhibitors for Hepatitis C Therapy. <i>Clinics in Liver Disease</i> , 2013, 17, 129-139.	2.1	23
612	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298.	3.1	20

#	ARTICLE	IF	CITATIONS
613	Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30.	5.1	28
614	Revisiting the Predictors of a Sustained Virologic Response in the Era of Direct-Acting Antiviral Therapy for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, 118-122.	5.8	19
615	Antivirals: Past, present and future. <i>Biochemical Pharmacology</i> , 2013, 85, 727-744.	4.4	115
616	The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11.	2.1	52
617	Hepatitis C Viral Kinetics. <i>Clinics in Liver Disease</i> , 2013, 17, 13-26.	2.1	25
618	Boceprevir and Treatment of Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2013, 17, 63-72.	2.1	2
619	Management of the Transplant Recipient with Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2013, 17, 73-91.	2.1	28
621	Screening and Rational Design of Hepatitis C Virus Entry Inhibitory Peptides Derived from GB Virus A NS5A. <i>Journal of Virology</i> , 2013, 87, 1649-1657.	3.4	18
622	Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103.	2.7	6
624	Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. <i>Journal of Infectious Diseases</i> , 2013, 207, S33-S39.	4.0	90
625	Future therapies for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 268-276.	17.8	36
626	Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 51-56.	2.8	20
627	Mathematical modeling: A tool for selecting agents with complementary modes of action?. <i>Journal of Hepatology</i> , 2013, 59, 1346-1348.	3.7	1
628	Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there?. <i>Journal of Hepatology</i> , 2013, 58, 412-414.	3.7	4
629	Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?. <i>Journal of Hepatology</i> , 2013, 58, 391-394.	3.7	8
631	Emerging Therapeutic Targets for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 612-619.e1.	4.4	14
632	Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. <i>Antiviral Research</i> , 2013, 99, 214-220.	4.1	28
633	Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFN α . <i>Presse Medicale</i> , 2013, 42, 694-695.	1.9	1

#	ARTICLE	IF	CITATIONS
634	Preparing the patient for success: Treat or wait?. Digestive and Liver Disease, 2013, 45, S332-S336.	0.9	1
636	Management of Recurrent Hepatitis C in Orthotopic Liver Transplant Recipients. Infectious Disease Clinics of North America, 2013, 27, 285-304.	5.1	2
637	Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Review of Anti-Infective Therapy, 2013, 11, 1269-1279.	4.4	35
640	HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4428-4435.	2.2	17
641	Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Experimental and Molecular Pathology, 2013, 95, 18-22.	2.1	19
642	Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. Journal of Clinical Virology, 2013, 58, 391-395.	3.1	10
644	Bibliometrics of the Top 100 Clinical Articles in Digestive Disease. Gastroenterology, 2013, 144, 673-676.e5.	1.3	29
645	Boceprevir for HCV in patients with HIV: where next?. Lancet Infectious Diseases, The, 2013, 13, 563-564.	9.1	4
646	The effect of stimulant use on antiviral treatment in an integrated hepatitis clinic. General Hospital Psychiatry, 2013, 35, 387-392.	2.4	2
648	Inoculating communities against vaccine scare stories. Lancet Infectious Diseases, The, 2013, 13, 564-565.	9.1	7
649	Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. Digestive and Liver Disease, 2013, 45, 356-361.	0.9	8
650	Management of anaemia and other treatment complications. Digestive and Liver Disease, 2013, 45, S337-S342.	0.9	7
652	Is the HCV Pipeline Heading in the Right Direction?. Gastroenterology, 2013, 144, 482-485.	1.3	4
654	HCV Enters the Twenty-First Century. Current Infectious Disease Reports, 2013, 15, 52-60.	3.0	0
655	Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2013, 37, 81-90.	3.7	26
656	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Alimentary Pharmacology and Therapeutics, 2013, 37, 74-80.	3.7	18
657	Commentary: efficacy and safety of ribavirin plus pegylated interferon α in geriatric patients with chronic hepatitis C – authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 492-492.	3.7	0
658	Effect of peginterferon alfa $2a$ (40KD) on cytochrome P450 isoenzyme activity. British Journal of Clinical Pharmacology, 2013, 75, 497-506.	2.4	22

#	ARTICLE	IF	CITATIONS
659	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. Journal of Viral Hepatitis, 2013, 20, 113-121.	2.0	16
660	Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 2013, 48, 254-268.	5.1	21
661	Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2013, 7, 171-185.	3.0	12
662	Interplay between Hepatitis C Virus and Redox Cell Signaling. International Journal of Molecular Sciences, 2013, 14, 4705-4721.	4.1	24
663	Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. The Cochrane Library, 2013, , CD003617.	2.8	23
664	Synthesis and Hepatitis C Antiviral Activity of 1-Aminobenzyl-1 <i>H</i> -indazole-3-carboxamide Analogues. ChemMedChem, 2013, 8, 722-725.	3.2	8
665	Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Alimentary Pharmacology and Therapeutics, 2013, 37, 659-671.	3.7	13
666	Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 38-45.	2.8	70
667	How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver International, 2013, 33, 23-29.	3.9	19
668	New therapeutic strategies in HCV: second-generation protease inhibitors. Liver International, 2013, 33, 80-84.	3.9	43
669	Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International, 2013, 33, 105-110.	3.9	26
670	How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver International, 2013, 33, 46-55.	3.9	28
671	New therapeutic strategies in HCV: polymerase inhibitors. Liver International, 2013, 33, 85-92.	3.9	51
672	Optimal treatment with boceprevir for chronic HCV infection. Liver International, 2013, 33, 14-22.	3.9	9
673	How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver International, 2013, 33, 30-34.	3.9	41
674	HCV therapy in HIV-infected patients. Liver International, 2013, 33, 63-67.	3.9	30
675	Treatment of viral hepatitis: a new era. Liver International, 2013, 33, 1-2.	3.9	2
676	Hepatitis C Virus Proteins: From Structure to Function. Current Topics in Microbiology and Immunology, 2013, 369, 113-142.	1.1	227

#	ARTICLE	IF	CITATIONS
677	Treatment of Chronic Hepatitis C: Current and Future. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 321-342.	1.1	79
678	RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. <i>Infection, Genetics and Evolution</i> , 2013, 14, 247-257.	2.3	22
679	A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , 2013, 57, 1325-1332.	7.3	89
680	Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. <i>New England Journal of Medicine</i> , 2013, 368, 45-53.	27.0	271
681	Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 5673-5681.	3.4	16
682	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495.	1.5	38
683	HCV infection: an enigma, recent advances and new paradigms for its treatment. <i>Future Virology</i> , 2013, 8, 381-389.	1.8	0
684	Prise en charge de l'hepatite C chronique: les dernières avancées thérapeutiques. <i>Pharmacien Hospitalier Et Clinicien</i> , 2013, 48, 131-143.	0.3	0
685	Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 427-449.	9.4	84
686	Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536.	4.1	71
687	Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 378-379.	9.1	33
688	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	3.7	44
689	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.	7.3	67
690	Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936.	3.7	105
691	Hepatitis C virus vaccines – Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	2.9	34
692	PegIFN-2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.	4.4	15
693	Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance. <i>ACS Chemical Biology</i> , 2013, 8, 1469-1478.	3.4	58
694	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.	3.7	52

#	ARTICLE	IF	CITATIONS
695	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	7.3	21
696	HCV NS5A Inhibitors in Development. <i>Clinics in Liver Disease</i> , 2013, 17, 111-121.	2.1	38
697	Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. <i>Hepatology</i> , 2013, 58, 1236-1244.	7.3	26
698	Treatment of HCV Infection by Targeting MicroRNA. <i>New England Journal of Medicine</i> , 2013, 368, 1685-1694.	27.0	1,939
699	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	27.0	1,605
700	<sc>IFN</sc> subtypes: distinct biological activities in anti-viral therapy. <i>British Journal of Pharmacology</i> , 2013, 168, 1048-1058.	5.4	157
701	Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole. <i>Biochemistry</i> , 2013, 52, 3752-3764.	2.5	37
702	HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2013, 108, 471-475.	0.4	26
703	Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1503-1510.	4.4	60
704	Human Immunodeficiency Virus Infection. , 2013, , 217-247.		0
706	Hepatitis C Virus, Cholesterol and Lipoproteins – Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. <i>Viruses</i> , 2013, 5, 1292-1324.	3.3	126
707	Assessing the cost-effectiveness of treating chronic hepatitis <sc>C</sc> virus in people who inject drugs in <sc>A</sc>ustralia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 707-716.	2.8	24
708	Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. <i>Transplant International</i> , 2013, 26, 527-534.	1.6	8
709	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.	2.1	34
710	Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917.	27.0	418
711	Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies. <i>Gastroenterology</i> , 2013, 144, 1450-1455.e2.	1.3	153
712	The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. <i>Nature Reviews Microbiology</i> , 2013, 11, 482-496.	28.6	336
713	Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121.	4.1	67

#	ARTICLE	IF	CITATIONS
714	25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. <i>Nature Reviews Immunology</i> , 2013, 13, 535-542.	22.7	134
715	Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. <i>Digestive and Liver Disease</i> , 2013, 45, 1-7.	0.9	26
716	Advances in the management of hepatitis C. <i>Internal Medicine Journal</i> , 2013, 43, 1265-1271.	0.8	3
717	Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2582-2588.	3.2	25
718	IL28B expression depends on a novel TT/G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013, 210, 1109-1116.	8.5	193
719	Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1312-1322.	3.2	49
720	The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. <i>Clinical Infectious Diseases</i> , 2013, 56, 228-235.	5.8	24
721	Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 806-816.	5.8	127
722	Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. <i>Clinical Infectious Diseases</i> , 2013, 56, 718-726.	5.8	69
723	Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1466-1470.	5.8	10
724	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	3.2	22
725	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. <i>Value in Health</i> , 2013, 16, 973-986.	0.3	63
726	Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 69-76.	3.8	8
727	Protease Inhibitors for Hepatitis C: Economic Implications. <i>Pharmacoeconomics</i> , 2013, 31, 739-751.	3.3	4
728	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.	5.8	80
729	Affinity Labeling of Hepatitis C Virus Replicase with a Nucleotide Analogue: Identification of Binding Site. <i>Biochemistry</i> , 2013, 52, 432-444.	2.5	7
730	Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2691-2704.	2.3	27
731	Drug-drug interactions during antiviral therapy for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 596-606.	17.8	117

#	ARTICLE	IF	CITATIONS
732	Hepatitis and Cirrhosis. , 2013, , 343-351.		0
733	Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. Aids, 2013, 27, 2485-2488.	2.2	21
734	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. Hepatology, 2013, 57, 451-460.	7.3	51
735	The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. Aids, 2013, 27, 1941-1947.	2.2	6
736	IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 9-16.	2.1	13
737	Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open, 2013, 3, e003231.	1.9	8
738	Information leaflets for patients with hepatitis C receiving treatment with triple therapy. European Journal of Hospital Pharmacy, 2013, 20, 13-19.	1.1	1
739	<i>In Vitro</i> Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2013, 57, 5216-5224.	3.2	19
740	Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. Journal of Clinical Microbiology, 2013, 51, 571-577.	3.9	60
743	Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepatitis Monthly, 2013, 13, e14872.	0.2	13
744	Pleuro-Pulmonary Nocardiosis as Opportunistic Infection in a Patient with Chronic Hepatitis C under Combination Treatment with Pegylated Interferon, Ribavirin, and Boceprevir. Case Reports in Hepatology, 2013, 2013, 1-4.	0.7	1
745	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	1.9	3
746	Association of Biochemical Markers, Hepatitis C Virus and Diabetes Mellitus in Pakistani Males. Tropical Journal of Pharmaceutical Research, 2013, 12, .	0.3	0
747	Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. Hepatitis Monthly, 2013, 13, .	0.2	3
748	Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. Scandinavian Journal of Gastroenterology, 2013, 48, 1074-1081.	1.5	4
749	Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies. PLoS Pathogens, 2013, 9, e1003244.	4.7	67
750	Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 100 Hepatitis C. Antimicrobial Agents and Chemotherapy, 2013, 57, 4727-4735.	3.2	22
751	Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virusâ€œCoinfected Patients With Compensated Cirrhosis. Clinical Infectious Diseases, 2013, 56, 1646-1653.	5.8	77

#	ARTICLE	IF	CITATIONS
752	Various Predictors of Sustained Virologic Response in Different Age Groups of Patients With Genotype-1 Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 794-799.	2.2	1
753	A novel program for treating patients with trimorbidity. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1377-1384.	1.6	18
754	Hepatitis C virus therapy update 2013. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 1.	2.3	55
755	A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 800-806.	2.2	3
756	Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 271-278.	1.6	5
757	The Evolution of Liver Transplantation During 3 Decades. <i>Annals of Surgery</i> , 2013, 258, 409-421.	4.2	177
758	The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 791-795.	2.0	7
759	Sexually transmitted hepatitis C infection. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 66-72.	3.1	100
760	Measuring Ribavirin Concentrations During the Earliest Stages of Antiviral Therapy for Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 546-551.	2.0	7
761	Hepatitis C Virus. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, L1-L14.	2.0	0
762	An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 191-208.	1.8	13
763	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 230-236.	5.8	206
764	Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1401-1408.	5.8	25
765	The Hepatitis C Self-Management Program. <i>Health Education and Behavior</i> , 2013, 40, 730-740.	2.5	12
766	Drug-Drug Interactions and Drug Resistance Will Limit Access to Treatment in Patients With HIV and Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2013, 57, 156-157.	5.8	4
767	New agents for the treatment of hepatitis C in patients co-infected with HIV. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 71-80.	1.8	4
768	Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5037-5044.	3.2	20
769	What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636.	5.8	23

#	ARTICLE	IF	CITATIONS
770	The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1078-1082.	3.9	35
771	Sigma-1 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2013, 87, 6377-6390.	3.4	44
772	HCV Infection and NS-3 Serine Protease Inhibitors. , 2013, 02, .		1
774	Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon- α 1 and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. <i>Hepatology Research</i> , 2013, 43, 1005-1012.	3.4	4
775	Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus. <i>Journal of Clinical Oncology</i> , 2013, 31, 766-773.	1.6	42
776	Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area. <i>Intervirology</i> , 2013, 56, 178-183.	2.8	4
777	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, i.	2.0	46
778	Focus on drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 50-57.	3.1	14
779	Short Communication: Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 223-225.	1.1	1
780	Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137.	5.8	99
781	Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day Monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 436-444.	3.2	2
782	Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1115-1120.	3.2	14
783	Prediction of sustained virologic responses to combination therapy of pegylated interferon- α 1 and ribavirin in patients with chronic hepatitis C infection. <i>Journal of Family and Community Medicine</i> , 2013, 20, 35.	1.1	21
784	Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. <i>Public Health Genomics</i> , 2013, 16, 192-197.	1.0	8
785	Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. <i>Drug Discoveries and Therapeutics</i> , 2013, , .	1.5	5
786	Ophthalmologic complications of antiviral therapy in hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013, 19, 8227.	3.3	9
787	High-Throughput Profiling of Alpha Interferon- and Interleukin-28B-Regulated MicroRNAs and Identification of let-7s with Anti-Hepatitis C Virus Activity by Targeting IGF2BP1. <i>Journal of Virology</i> , 2013, 87, 9707-9718.	3.4	53
789	Influence of <i>a priori</i> Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	2.5	4

#	ARTICLE	IF	CITATIONS
790	Segue desempeñando algún papel la cinética viral durante el tratamiento de la infección por el VHC?. Clinical Liver Disease, 2013, 2, S24-S27.	2.1	0
791	Hepatitis B and C in liver transplantation: new strategies to combat the enemies. Reviews in Medical Virology, 2013, 23, 172-193.	8.3	9
792	Current approaches to the management of hepatitis C. The Prescriber, 2013, 24, 30-34.	0.3	0
793	Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2013, 20, 550-555.	2.0	34
794	Hepatitis C Co-infection and Severity of Liver Disease as Risk Factors for Osteoporotic Fractures Among HIV-Infected Patients. Journal of Bone and Mineral Research, 2013, 28, 2577-2583.	2.8	40
795	Criterios para seleccionar a los pacientes infectados por el VHC que son candidatos al tratamiento antiviral. Clinical Liver Disease, 2013, 2, S20-S23.	2.1	1
796	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. Journal of Viral Hepatitis, 2013, 20, 790-800.	2.0	11
797	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Journal of Viral Hepatitis, 2013, 20, 745-760.	2.0	78
798	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 915-921.	3.0	4
799	Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study. Drug Development Research, 2013, 74, 306-315.	2.9	1
800	Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis. Hepatology Research, 2013, 43, 1255-1263.	3.4	3
801	Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in mono-infected and HCV/HIV co-infected adults. Journal of Viral Hepatitis, 2013, 20, 708-714.	2.0	32
802	Características demográficas actuales del virus de la hepatitis C. Clinical Liver Disease, 2013, 2, S12-S15.	2.1	0
804	Current and emerging antiviral treatments for hepatitis C infection. British Journal of Clinical Pharmacology, 2013, 75, 931-943.	2.4	42
805	Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. Clinical Pharmacology in Drug Development, 2013, 2, 316-327.	1.6	18
806	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7844-7849.	7.1	57
807	Discovery of Hepatitis C Virus NS3 Helicase Inhibitors by a Multiplexed, High-Throughput Helicase Activity Assay Based on Graphene Oxide. Angewandte Chemie, 2013, 125, 2396-2400.	2.0	3
808	The Association of Cytopenias and Weight Loss with Hepatitis C Virus Virologic Response in HIV/HCV-Coinfected Patients Treated with PEG-IFN and RBV. Journal of the International Association of Providers of AIDS Care, 2013, 12, 354-362.	1.5	2

#	ARTICLE	IF	CITATIONS
809	Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. <i>Clinical Infectious Diseases</i> , 2013, 56, 300-306.	5.8	29
810	Oral antiviral therapies for chronic hepatitis C infection. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 107-116.	1.8	10
811	Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6333-6340.	3.2	89
813	Sustained and rapid virological responses in hepatitis C clinical trials. <i>Clinical Investigation</i> , 2013, 3, 1083-1093.	0.0	2
814	Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114.	3.9	99
815	Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2013, 158, 329.	3.9	734
816	Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials. <i>Clinical Investigation</i> , 2013, 3, 191-207.	0.0	7
817	Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life. <i>Future Virology</i> , 2013, 8, 735-743.	1.8	0
818	Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.	2.0	24
819	Non-Hodgkin's Lymphomas, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 257-273.	4.9	53
820	Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. <i>Antiviral Therapy</i> , 2014, 19, 527-531.	1.0	18
821	JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 514-523.	7.3	49
822	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	7.3	431
823	The FDA, bridging data, and hepatitis C. <i>Hepatology</i> , 2013, 57, 875-877.	7.3	1
824	Potential consequences of healthcare recommendations: A focus on the U.S. Preventive Services Task Force. <i>Hepatology</i> , 2013, 58, 422-427.	7.3	2
825	Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials. <i>Hepatology</i> , 2013, 58, 488-490.	7.3	2
826	Boceprevir dosing for late responders and null responders: The role of bridging data between treatment-naïve and -experienced subjects. <i>Hepatology</i> , 2013, 57, 903-907.	7.3	13
827	PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.	7.3	39

#	ARTICLE	IF	CITATIONS
828	Hepatitis C screening: Getting it right. <i>Hepatology</i> , 2013, 57, 1644-1650.	7.3	11
829	Potential role for statins in the treatment of chronic HCV infection. <i>Future Virology</i> , 2013, 8, 727-729.	1.8	4
830	Intensified Peginterferon α -2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 271-279.	2.2	3
831	Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013, 27, 2541-2549.	2.2	29
832	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.	2.2	7
833	IL28B in the Era of Direct-acting Antivirals for Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 222-227.	2.2	18
834	Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 67-73.	2.1	27
835	Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 587-593.	1.6	10
836	Telaprevir is Effective Given Every 12 H at 750 Mg with Pegylated Interferon- α 2B and Ribavirin to Japanese Patients with HCV-1B IL28B Rs8099917 Tt. <i>Antiviral Therapy</i> , 2014, 19, 277-285.	1.0	12
837	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	1.0	12
838	Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon- α 2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial F. <i>Antiviral Chemistry and Chemotherapy</i> , 2013, 18, 387-397.	0.6	14
839	Bioinformatics methods for the analysis of hepatitis viruses. <i>Antiviral Therapy</i> , 2013, 18, 531-539.	1.0	3
840	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	1.0	5
841	Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	1.0	44
843	Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
844	Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate. <i>Antiviral Therapy</i> , 2014, 19, 511-519.	1.0	14
845	Long-term Combined Therapy with Very-low-dose Peginterferon and Ursodeoxycholic Acid Decreased the Spleen Size in a Patient with Hepatitis C Virus-related Cirrhosis. <i>Internal Medicine</i> , 2013, 52, 363-367.	0.7	2
846	Hepatitis C virus: virology and life cycle. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 17.	8.9	134

#	ARTICLE	IF	CITATIONS
847	The Natural Killer Cell Response to HCV Infection. Immune Network, 2013, 13, 168.	3.6	18
848	Spontaneous Weight Change during Chronic Hepatitis C Treatment: Association with Virologic Response Rates. International Journal of Medical Sciences, 2013, 10, 1830-1836.	2.5	3
849	Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 48-53.	1.6	16
850	Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepatic Medicine: Evidence and Research, 2013, 5, 53.	2.5	8
851	Hepatitis C, stigma and cure. World Journal of Gastroenterology, 2013, 19, 6703.	3.3	84
852	Platelet count and sustained virological response in hepatitis C treatment. World Journal of Hepatology, 2013, 5, 182.	2.0	11
853	Profound jaundice in a patient with acute hepatitis C. BMJ Case Reports, 2013, 2013, bcr2013200233-bcr2013200233.	0.5	1
854	Viral hepatitis and HIV: update and management. Antiviral Therapy, 2013, 18, 451-458.	1.0	4
855	Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. Antiviral Therapy, 2013, 18, 1033-1035.	1.0	10
856	Intracellular Nucleic Acid Delivery by the Supercharged Dengue Virus Capsid Protein. PLoS ONE, 2013, 8, e81450.	2.5	36
857	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2013, 8, e56991.	2.5	12
858	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. PLoS ONE, 2013, 8, e58380.	2.5	1
859	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. PLoS ONE, 2013, 8, e58975.	2.5	61
860	In-Cell Protease Assay Systems Based on Trans-Localizing Molecular Beacon Proteins Using HCV Protease as a Model System. PLoS ONE, 2013, 8, e59710.	2.5	3
861	Nonresponse to Interferon- α Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis. PLoS ONE, 2013, 8, e61568.	2.5	8
862	Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. PLoS ONE, 2013, 8, e62674.	2.5	8
863	Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. PLoS ONE, 2013, 8, e66831.	2.5	12
864	Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. PLoS ONE, 2013, 8, e69698.	2.5	11

#	ARTICLE	IF	CITATIONS
865	New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication. PLoS ONE, 2013, 8, e72519.	2.5	7
866	Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients. PLoS ONE, 2013, 8, e72600.	2.5	9
867	Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism. PLoS ONE, 2013, 8, e80304.	2.5	31
868	A Screen for Genetic Suppressor Elements of Hepatitis C Virus Identifies a Supercharged Protein Inhibitor of Viral Replication. PLoS ONE, 2013, 8, e84022.	2.5	2
869	Hepatitis C virus (HCV) infection in Africa: a review. Pan African Medical Journal, 2013, 2, 44.	0.8	119
870	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. Annals of Internal Medicine, 2013, 159, 86-96.	3.9	179
871	Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World Journal of Gastroenterology, 2013, 19, 1085.	3.3	22
873	Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. Scientific World Journal, The, 2013, 2013, 1-9.	2.1	28
874	Hepatitis C Virus Infection: Looking for Interferon Free Regimens. Scientific World Journal, The, 2013, 2013, 1-11.	2.1	11
875	Epidemiology and Treatment of Hepatitis C Genotypes 5 and 6. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, e8-e12.	1.7	21
876	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 217-238.	1.9	10
877	Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clinical Epidemiology, 2013, 5, 173.	3.0	11
878	Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Annals of Hepatology, 2013, 12, 380-391.	1.5	54
880	Syncope during boceprevir treatment in hepatitis C. Annals of Hepatology, 2013, 12, 837-838.	1.5	1
881	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology, 2013, 12, 190-198.	1.5	2
882	First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Annals of Hepatology, 2013, 12, 156-160.	1.5	16
883	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology, 2013, 12, S3-S35.	1.5	9
884	Raloxifene hydrochloride as hepatitis C treatment. Annals of Hepatology, 2013, 12, 164-165.	1.5	0

#	ARTICLE	IF	CITATIONS
885	Patients younger than forty years old with hepatitis C virus genotypeâ€‘1 chronic infection had treatment responses similar to genotypeâ€‘2 infection and not related to interleukinâ€‘28B polymorphism. <i>Annals of Hepatology</i> , 2013, 12, 62-69.	1.5	5
887	Treatment of Chronic HCV Infection in the Era of Protease Inhibitors. , 2013, , .		0
888	Management of HCV Infection in the Elderly. , 2013, , .		0
889	The Skin and Viral Liver Disease. , 2013, , .		0
890	Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. <i>Italian Journal of Medicine</i> , 2014, , .	0.3	0
891	Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 37.	2.5	37
892	Hepatitis C in Argentina: epidemiology and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 35.	2.5	6
893	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 493.	2.0	29
894	Hepatic HMOX1 Expression Positively Correlates with Bach-1 and miR-122 in Patients with HCV Mono and HIV/HCV Coinfection. <i>PLoS ONE</i> , 2014, 9, e95564.	2.5	9
895	Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin. <i>PLoS ONE</i> , 2014, 9, e103370.	2.5	4
896	The Dynamic Relationship between Innate Immune Biomarkers and Interferon-Based Treatment Effects and Outcome in Hepatitis C Virus Infection Is Altered by Telaprevir. <i>PLoS ONE</i> , 2014, 9, e105665.	2.5	7
897	Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 445-451.	1.9	62
898	Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 529-534.	1.9	5
899	Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, e1-e4.	1.9	1
900	Hepatitis C Worldwide and in Brazil: Silent Epidemicâ€‘Data on Disease including Incidence, Transmission, Prevention, and Treatment. <i>Scientific World Journal, The</i> , 2014, 2014, 1-10.	2.1	25
901	Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. <i>Reviews on Recent Clinical Trials</i> , 2014, 9, 1-7.	0.8	26
902	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633.	3.3	135
903	PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase. <i>Molecules</i> , 2014, 19, 4006-4020.	3.8	7

#	ARTICLE	IF	CITATIONS
904	Chronic hepatitis C: future treatment. Clinical Pharmacology: Advances and Applications, 2014, 6, 1.	1.2	45
905	A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System. Journal of Managed Care Pharmacy, 2014, 20, 533-540.	2.2	15
906	Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World Journal of Gastroenterology, 2014, 20, 15992.	3.3	45
907	SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clinical Epidemiology, 2014, 6, 49.	3.0	8
908	Patient adherence issues in the treatment of hepatitis C. Patient Preference and Adherence, 2014, 8, 763.	1.8	16
909	Boceprevir in Mexico: Experience in a Series of Cases. , 2014, 05, .		0
910	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 311-320.	1.9	8
911	Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World Journal of Gastroenterology, 2014, 20, 2876.	3.3	26
913	Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response. Recent Patents on Biomarkers, 2014, 4, 11-20.	0.2	1
914	Current issues in comparative effectiveness research for hepatitis C. Comparative Effectiveness Research, 2014, , 13.	0.2	0
915	Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	0
916	A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Annals of Hepatology, 2014, 13, 364-375.	1.5	18
917	Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. Annals of Hepatology, 2014, 13, 196-203.	1.5	4
918	Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients. Annals of Hepatology, 2014, 13, 219-230.	1.5	0
919	Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology, 2014, 13, S4-S66.	1.5	28
920	The good, the bad and the ugly of the new treatments for hepatitis C virus. Annals of Hepatology, 2014, 13, 574-575.	1.5	3
923	Serum 25-hydroxyvitamin D levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. Hepatology Research, 2014, 44, 1277-1285.	3.4	10
924	Recent advances in HCV entry. Future Virology, 2014, 9, 189-205.	1.8	2

#	ARTICLE	IF	CITATIONS
925	Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study. <i>Leukemia and Lymphoma</i> , 2014, 55, 1061-1066.	1.3	16
927	Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a+Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1136-1145.	3.2	19
929	Sofosbuvir as backbone of interferon free treatments. <i>Digestive and Liver Disease</i> , 2014, 46, S212-S220.	0.9	23
930	The future of dual therapy for hepatitis C virus. <i>Future Virology</i> , 2014, 9, 905-912.	1.8	1
931	Barriers to Hepatitis C Antiviral Therapy in HIV/HCV Co-Infected Patients in the United States: A Review. <i>AIDS Patient Care and STDs</i> , 2014, 28, 228-239.	2.5	24
932	Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 38-47.	3.2	25
933	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014, 159, 3345-3351.	2.1	3
934	National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996-2010 in the United States: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2014, 14, 536.	2.9	11
935	LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. <i>Clinical Proteomics</i> , 2014, 11, 44.	2.1	1
936	Effectiveness Research in the Evolving HCV Landscape. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2845-2847.	2.3	1
938	Editorial Commentary: Management of Hepatitis C Virus in HIV-Infected Patients in the Era of Direct-Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2014, 58, 880-882.	5.8	9
939	Efficacy of daclatasvir in hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1025-1031.	4.4	11
940	Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. <i>Journal of Hepatology</i> , 2014, 61, S98-S107.	3.7	28
941	Hepatitis C Virus in Pregnancy and Early Childhood: Current Understanding and Knowledge Deficits. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, S13-S18.	1.3	18
942	National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2014, 59, 755-764.	5.8	64
943	Actualizaci3n en el tratamiento de la hepatitis C. <i>Medicine</i> , 2014, 11, 4103-4111.	0.0	0
944	Optimal Management of HCV Genotype 4. <i>Current Hepatology Reports</i> , 2014, 13, 286-294.	0.9	0
945	Current and future targets of antiviral therapy in the hepatitis C virus life cycle. <i>Future Virology</i> , 2014, 9, 947-965.	1.8	3

#	ARTICLE	IF	CITATIONS
946	A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity. PLoS Pathogens, 2014, 10, e1004064.	4.7	66
947	Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. Seminars in Liver Disease, 2014, 34, 072-078.	3.6	6
948	Quasispecies and Drug Resistance. , 2014, , 1-22.		0
949	Resistance to Cyclophilin Inhibitors. , 2014, , 1-24.		0
950	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut, 2014, 63, 1150-1158.	12.1	41
951	Cleavage of the T Cell Protein Tyrosine Phosphatase by the Hepatitis C Virus Nonstructural 3/4A Protease Induces a Th1 to Th2 Shift Reversible by Ribavirin Therapy. Journal of Immunology, 2014, 192, 1671-1680.	0.8	12
952	Inhibition of Hepatitis C Virus Replication In Vitro by Xanthohumol, A Natural Product Present in Hops. Planta Medica, 2014, 80, 171-176.	1.3	14
953	Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. Annals of Pharmacotherapy, 2014, 48, 826-836.	1.9	2
955	Interferon-Free Regimens in the Liver-Transplant Setting. Seminars in Liver Disease, 2014, 34, 058-071.	3.6	34
956	Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmacogenomics and Personalized Medicine, 2014, 7, 387.	0.7	31
957	Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. Journal of Dermatological Case Reports, 2014, 8, 95-102.	1.1	5
958	Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. PLoS Pathogens, 2014, 10, e1004128.	4.7	97
959	Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infectious Diseases, 2014, 1, ofu078.	0.9	15
960	Antiviral Agentsâ††. , 2014, , 176-176.		0
961	Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries and Therapeutics, 2014, 8, 89-95.	1.5	12
962	Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C. Seminars in Liver Disease, 2014, 34, 030-036.	3.6	11
963	Simeprevir for the treatment of hepatitis C virus infection. Pharmacogenomics and Personalized Medicine, 2014, 7, 241.	0.7	29
964	The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease. International Journal of Molecular Sciences, 2014, 15, 4747-4779.	4.1	23

#	ARTICLE	IF	CITATIONS
965	Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. <i>BMJ Open</i> , 2014, 4, e006255.	1.9	2
966	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	3.9	129
969	Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. <i>Journal of Medical Economics</i> , 2014, 17, 862-871.	2.1	15
970	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α -2a and Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436.	3.2	13
971	Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis. <i>Gut</i> , 2014, 63, 1033-1034.	12.1	5
972	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , 2014, 46, S197-S205.	0.9	9
974	Targets for Antiviral Therapy of Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 009-021.	3.6	40
975	Treatment of Recurrent Genotype 1 Hepatitis C Post-Liver Transplantation: Single Center Experience with Telaprevir-Based Triple Therapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2014, 52, 27-34.	0.5	19
978	Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. <i>Hepatology International</i> , 2014, 8, 560-566.	4.2	9
979	Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 647-653.	3.2	31
980	Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. <i>Gene Therapy</i> , 2014, 21, 739-750.	4.5	15
981	Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. <i>Molecular Therapy</i> , 2014, 22, 881-890.	8.2	30
982	Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 585-589.	2.0	8
983	Is there still a role for <sc>PEG IFN</sc>+<sc>RBV</sc> therapy in patients with <sc>HCV</sc> genotype 1?. <i>Liver International</i> , 2014, 34, 11-12.	3.9	1
984	How to optimize current therapy of <sc>HCV</sc> genotype 1 infection with boceprevir. <i>Liver International</i> , 2014, 34, 4-10.	3.9	0
985	Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. <i>Hepatology</i> , 2014, 59, 1688-1691.	7.3	5
986	Hepatitis C screening beyond <sc>CDC</sc> guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258.	3.9	12
987	Sofosbuvir. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1019-1029.	1.9	52

#	ARTICLE	IF	CITATIONS
988	Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 984-985.	3.7	0
989	Infrequent Development of Resistance in Genotype 1b Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674.	5.8	199
990	Use of first-generation HCV protease inhibitors in patients coinfecting by HIV and HCV genotype 1. <i>Liver International</i> , 2014, 34, 869-889.	3.9	4
991	Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1074-1081.	6.1	12
992	Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1-9.	2.8	67
993	Anti-interferon- λ neutralizing antibody induced telaprevir resistance under the interferon- λ plus telaprevir treatment in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 453-458.	2.1	2
994	Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. <i>Liver International</i> , 2014, 34, 668-671.	3.9	13
995	P12: Factors associated with triple therapy discontinuation due to adverse effects among patients with hepatitis C genotype 1 chronic infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 27-28.	2.0	0
996	Adjuvant epoetin- α with peginterferon- α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. <i>Hepatology Research</i> , 2014, 44, E290-6.	3.4	1
997	Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. <i>Digestive and Liver Disease</i> , 2014, 46, S179-S185.	0.9	26
998	Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon- α and ribavirin. <i>Journal of Viral Hepatitis</i> , 2014, 21, 624-632.	2.0	6
999	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	2.0	161
1000	Medical comorbidities and practice. <i>Haemophilia</i> , 2014, 20, 130-136.	2.1	8
1001	Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. <i>Liver Transplantation</i> , 2014, 20, 1106-1117.	2.4	2
1002	Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 545-553.	2.8	113
1003	Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719.	3.9	15
1004	Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions. <i>Journal of Medical Virology</i> , 2014, 86, 1886-1897.	5.0	5
1005	Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. <i>Hepatology Research</i> , 2014, 44, 788-797.	3.4	10

#	ARTICLE	IF	CITATIONS
1006	Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 543-544.	3.7	1
1007	Management of <scp>HCV</scp> patients with cirrhosis with direct acting antivirals. <i>Liver International</i> , 2014, 34, 38-45.	3.9	22
1008	A pill for <scp>HCV</scp> â€“ myth or foreseeable future?. <i>Liver International</i> , 2014, 34, 6-11.	3.9	20
1009	Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2609-2622.	1.8	17
1010	Progression of liver fibrosis in <scp>HIV</scp>/hepatitis <scp>C</scp> virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. <i>HIV Medicine</i> , 2014, 15, 203-212.	2.2	20
1011	Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2014, 59, 1657-1665.	5.8	34
1012	Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon- α 1 and ribavirin in chronic hepatitis C virus patients. <i>Liver International</i> , 2014, 34, 551-557.	3.9	13
1013	Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy â€“ a pilot randomised clinical trial. <i>Liver International</i> , 2014, 34, 737-747.	3.9	12
1014	Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014, 13, 304-313.	0.9	0
1015	A practical guide for antiviral therapy of chronic Hepatitis C. <i>GE Portuguese Journal of Gastroenterology</i> , 2014, 21, 221-230.	0.8	6
1016	Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. <i>Journal of Hepatology</i> , 2014, 61, S120-S131.	3.7	65
1017	Management of acute and chronic HCV infection in persons with HIV coinfection. <i>Journal of Hepatology</i> , 2014, 61, S108-S119.	3.7	19
1018	Daclatasvir for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 725-738.	3.0	7
1020	HCV Triple Therapy is Equally effective in African-Americans and Non-African-Americans. <i>Journal of Racial and Ethnic Health Disparities</i> , 2014, 1, 319-325.	3.2	1
1021	Advances in and the future of treatments for hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 633-647.	3.0	8
1022	Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. <i>BMC Gastroenterology</i> , 2014, 14, 47.	2.0	10
1023	Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. <i>BMC Health Services Research</i> , 2014, 14, 429.	2.2	5
1024	Validation of the Fatigue Severity Scale in chronic hepatitis C. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 90.	2.4	29

#	ARTICLE	IF	CITATIONS
1025	In vitro blood cell responsiveness to IFN- λ predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. <i>Journal of Translational Medicine</i> , 2014, 12, 206.	4.4	4
1026	Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study. <i>BMC Infectious Diseases</i> , 2014, 14, 716.	2.9	23
1027	Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 80-84.	1.4	8
1028	Hepatitis C Direct-acting Antiviral Agents. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 106-112.	2.2	22
1029	Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 36-45.	3.1	50
1030	Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 548-552.	2.2	0
1031	Patient perspectives on hepatitis C and its treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 74-81.	1.6	25
1032	Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 65-73.	1.6	3
1033	Hepatitis C genotype 1. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 535-539.	3.1	0
1034	Hepatitis C and neutropenia. <i>Current Opinion in Hematology</i> , 2014, 21, 58-63.	2.5	9
1035	Physician Nonadherence With a Hepatitis C Screening Program. <i>Quality Management in Health Care</i> , 2014, 23, 1-9.	0.8	20
1036	Hepatitis C virus therapy in the direct acting antiviral era. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 217-222.	2.3	30
1037	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 836-845.	1.6	24
1038	Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1329-1334.	1.6	0
1039	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1073-1082.	1.6	46
1040	Real-world outcomes in patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 388-395.	1.6	3
1041	Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 781-787.	1.6	3
1042	Boceprevir Plus Peginterferon λ -2b/Ribavirin in Chronic Hepatitis C Genotype 1. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 435-443.	2.2	3

#	ARTICLE	IF	CITATIONS
1043	Delivery of treatment for hepatitis C virus infection in the primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1003-1009.	1.6	16
1044	Pharmacogenetics at 50: Genomic Personalization Comes of Age. <i>Science Translational Medicine</i> , 2014, 6, 220ps1.	12.4	19
1045	Hepatitis C Virus and Liver Transplantation. , 2014, , .		1
1046	Predictors of hepatitis C treatment response: what's new?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 183-191.	4.4	3
1047	Viral Hepatitis and Liver Transplantation: Pathogenesis, Prevention and Therapy of Recurrent Disease. <i>Digestive Diseases</i> , 2014, 32, 538-544.	1.9	3
1048	Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. <i>World Journal of Hepatology</i> , 2014, 6, 870.	2.0	14
1049	Treatment of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 631.	7.4	390
1050	Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. <i>Frontiers in Microbiology</i> , 2014, 5, 690.	3.5	17
1051	New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development. <i>Seminars in Liver Disease</i> , 2014, 34, 022-029.	3.6	89
1052	The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. <i>JAMA Internal Medicine</i> , 2014, 174, 204.	5.1	113
1053	Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury. <i>Case Reports in Nephrology</i> , 2014, 2014, 1-4.	0.4	1
1054	Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C. <i>Pharmacopsychiatry</i> , 2014, 47, 195-201.	3.3	9
1055	Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. <i>Journal of Pharmacy Technology</i> , 2014, 30, 159-167.	1.0	3
1056	Targeted hepatitis <sc>C</sc> screening among exâ€injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
1057	Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 157-164.	4.4	2
1058	Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. <i>BMC Infectious Diseases</i> , 2014, 14, 465.	2.9	17
1059	Cost-Effectiveness of <i>IL28Β</i> Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection. <i>Public Health Genomics</i> , 2014, 17, 306-319.	1.0	6
1060	Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 996-1002.	1.6	4

#	ARTICLE	IF	CITATIONS
1061	Cost of treating hepatitis C in Germany. European Journal of Gastroenterology and Hepatology, 2014, 26, 1278-1285.	1.6	9
1062	Pretreatment prediction of the outcome of response-guided peginterferon- α and ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1996-2005.	2.8	2
1063	Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. Journal of Hepatology, 2014, 60, 78-86.	3.7	182
1064	What is the future of ribavirin therapy for hepatitis C?. Antiviral Research, 2014, 104, 34-39.	4.1	41
1065	Reply to: "Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections". Journal of Hepatology, 2014, 60, 232-234.	3.7	3
1066	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. Journal of Hepatology, 2014, 61, 508-514.	3.7	75
1067	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. Gastroenterology and Hepatology, 2014, 37, 1-8.	0.5	2
1068	Hepatitis C treatment: an incipient therapeutic revolution. Trends in Molecular Medicine, 2014, 20, 315-321.	6.7	42
1069	From the CUPIC study: Great times are not coming (?). Journal of Hepatology, 2014, 60, 234-235.	3.7	1
1070	Acute pancreatitis associated with boceprevir: a case report. Brazilian Journal of Infectious Diseases, 2014, 18, 454-456.	0.6	7
1071	Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial. Journal of Hepatology, 2014, 60, 699-705.	3.7	15
1072	Coût-efficacité et VHC: mise au point. Journal Des Anti-infectieux, 2014, 16, 50-63.	0.1	0
1073	Impact of New Hepatitis C Treatments in Different Regions of the World. Gastroenterology, 2014, 146, 1145-1150.e4.	1.3	48
1074	Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology, 2014, 59, 71-77.	7.3	37
1075	Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. Archives of Virology, 2014, 159, 831-846.	2.1	15
1076	IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Journal of Gastroenterology, 2014, 49, 748-754.	5.1	13
1077	Impact of the peginterferon- α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV co-infected patients with the unfavourable non-CC IL28B genotypes. Journal of Viral Hepatitis, 2014, 21, 178-188.	2.0	6
1078	Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. Journal of Gastroenterology, 2014, 49, 138-147.	5.1	73

#	ARTICLE	IF	CITATIONS
1079	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis <scp>C</scp>. Hepatology Research, 2014, 44, E447-54.	3.4	13
1081	Hepatitis C virus: a silent killer relevant to dentistry. Oral Diseases, 2014, 20, 425-429.	3.0	4
1082	Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B. Antimicrobial Agents and Chemotherapy, 2014, 58, 3399-3410.	3.2	20
1083	MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2014, 23, 719-728.	4.1	32
1084	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology, 2014, 147, 132-142.e4.	1.3	232
1085	Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. Antiviral Research, 2014, 105, 112-117.	4.1	11
1086	Importance of <scp>HCV</scp> genotype 1 subtypes for drug resistance and response to therapy. Journal of Viral Hepatitis, 2014, 21, 229-240.	2.0	65
1087	PCR-Based<i>In Vitro</i> Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors. Journal of Clinical Microbiology, 2014, 52, 1139-1145.	3.9	1
1088	<scp>HCV</scp> F1/F2 patients: treat now or continue to wait. Liver International, 2014, 34, 79-84.	3.9	7
1089	Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Alimentary Pharmacology and Therapeutics, 2014, 39, 209-216.	3.7	16
1090	Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection. Gastroenterology, 2014, 146, 420-429.	1.3	188
1091	Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Alimentary Pharmacology and Therapeutics, 2014, 39, 93-103.	3.7	49
1092	Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 14-24.	1.5	22
1093	Understanding the effect of the <scp>HCV</scp> polymerase inhibitor mericitabine on early viral kinetics in the phase 2 <scp>JUMP</scp> and <scp>PROPEL</scp> studies. British Journal of Clinical Pharmacology, 2014, 78, 533-542.	2.4	2
1094	Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. Journal of Hepatology, 2014, 60, 748-756.	3.7	37
1095	Role of <scp><i>IL28B</i></scp> for chronic hepatitis <scp>C</scp> treatment toward personalized medicine. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 241-249.	2.8	49
1096	Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. Virology, 2014, 448, 229-237.	2.4	13
1097	Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology, 2014, 146, 736-743.e1.	1.3	201

#	ARTICLE	IF	CITATIONS
1098	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naïve patients? A cost-effectiveness analysis (ANRS 95141). <i>Journal of Hepatology</i> , 2014, 61, 7-14.	3.7	57
1099	MicroRNA-targeting therapeutics for hepatitis C. <i>Archives of Pharmacal Research</i> , 2014, 37, 299-305.	6.3	35
1100	All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2014, 59, 872-880.	2.3	42
1101	Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 273-281.	2.3	4
1102	Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. <i>Harm Reduction Journal</i> , 2014, 11, 1.	3.2	96
1103	Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus. <i>Hepatology International</i> , 2014, 8, 112-120.	4.2	7
1104	Interferon-Free Regimens for Hepatitis C: Combine and Conquer. <i>BioDrugs</i> , 2014, 28, 161-169.	4.6	2
1105	Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107.	2.0	23
1106	All-oral combination of ledipasvir, vedoprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64.	7.3	43
1107	Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1673-1693.	6.4	174
1108	Update on Recently Approved Treatments for Hepatitis C. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 211-228.	0.8	7
1109	Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naïve HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 658-667.	4.0	51
1110	Emerging therapies for the treatment of hepatitis C. <i>EMBO Molecular Medicine</i> , 2014, 6, 4-15.	6.9	93
1111	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147.	3.7	74
1112	Mass Balance and Metabolite Profiling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2369-2376.	3.2	9
1113	Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2781-2797.	3.2	55
1114	The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. <i>Journal of Hepatology</i> , 2014, 60, 691-698.	3.7	145
1115	Current race in the development of DAAs (direct-acting antivirals) against HCV. <i>Biochemical Pharmacology</i> , 2014, 89, 441-452.	4.4	83

#	ARTICLE	IF	CITATIONS
1116	Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: â€œA Flood of Opportunityâ€. American Journal of Transplantation, 2014, 14, 994-1002.	4.7	72
1117	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. Journal of Hepatology, 2014, 60, 39-45.	3.7	52
1118	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2014, 59, 1692-1705.	7.3	75
1119	Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5â€™UTR, core and NS5B sequencing. Journal of Clinical Virology, 2014, 60, 22-26.	3.1	28
1120	HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. Journal of Clinical Virology, 2014, 60, 336-340.	3.1	9
1121	Hepatitis C Virus. , 2014, , 859-877.		0
1122	Antiviral drugs. Side Effects of Drugs Annual, 2014, , 503-550.	0.6	1
1123	Long-term stimulation of <sc>T</sc>ollâ€like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly <sc>I</sc>:<sc>C</sc> treatment. Journal of Viral Hepatitis, 2014, 21, 480-490.	2.0	18
1124	Review article: genetic factors that modify the outcome of viral hepatitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 1059-1070.	3.7	50
1125	Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples. Journal of Clinical Virology, 2014, 60, 323-327.	3.1	9
1126	Second wave antiâ€<sc>HCV</sc> protease inhibitors: too little too late?. Liver International, 2014, 34, e168-70.	3.9	3
1127	The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology, 2014, 147, 366-376.e6.	1.3	38
1128	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. New England Journal of Medicine, 2014, 370, 1879-1888.	27.0	1,080
1129	ABT-450/râ€Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. New England Journal of Medicine, 2014, 370, 1973-1982.	27.0	834
1130	Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue. Seminars in Liver Disease, 2014, 34, 047-057.	3.6	14
1131	ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. Gastroenterology, 2014, 147, 359-365.e1.	1.3	336
1132	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. Journal of Hepatology, 2014, 60, 530-537.	3.7	118
1133	Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. European Journal of Clinical Pharmacology, 2014, 70, 775-789.	1.9	8

#	ARTICLE	IF	CITATIONS
1134	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine, 2014, 370, 222-232.	27.0	262
1135	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. New England Journal of Medicine, 2014, 370, 1889-1898.	27.0	1,580
1136	Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clinical Gastroenterology and Hepatology, 2014, 12, 728-737.	4.4	34
1137	Specific Serotonin Reuptake Inhibitors Prevent Interferon-Î±-Induced Depression in Patients With Hepatitis C: A Meta-analysis. Clinical Gastroenterology and Hepatology, 2014, 12, 1452-1460.e3.	4.4	23
1138	Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats. Xenobiotica, 2014, 44, 1014-1025.	1.1	1
1139	ABT-450/râ€“Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine, 2014, 370, 1983-1992.	27.0	669
1140	Therapy of Hepatitis C â€” Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047.	27.0	102
1141	REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Medical Clinics of North America, 2014, 98, 17.	2.5	18
1142	Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. Molecular Diagnosis and Therapy, 2014, 18, 25-38.	3.8	2
1143	Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet, The, 2014, 383, 515-523.	13.7	522
1144	Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. Journal of Infection, 2014, 68, 1-20.	3.3	69
1145	Viruses and Human Cancer. Recent Results in Cancer Research, 2014, , .	1.8	1
1146	Liver cirrhosis. Lancet, The, 2014, 383, 1749-1761.	13.7	1,425
1147	Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. International Journal of Antimicrobial Agents, 2014, 43, 17-25.	2.5	11
1148	Therapeutic vaccines against hepatitis C virus. Infection, Genetics and Evolution, 2014, 22, 120-129.	2.3	19
1149	Phylogeny and molecular evolution of the hepatitis C virus. Infection, Genetics and Evolution, 2014, 21, 67-82.	2.3	59
1150	Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics, 2014, 30, 1104-1111.	4.1	56
1151	Multi-agent model of hepatitis C virus infection. Artificial Intelligence in Medicine, 2014, 60, 123-131.	6.5	17

#	ARTICLE	IF	CITATIONS
1152	Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1880-1892.	6.4	32
1153	Asymmetric Synthesis of 3,4-Disubstituted Proline Derivatives: Application in Synthesis of Hepatitis C Virus Protease Inhibitor Telaprevir. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 8101-8109.	2.4	12
1154	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227.	3.7	25
1155	Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 561-571.	4.1	43
1156	Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 544-545.	3.7	0
1157	Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. <i>Clinical Therapeutics</i> , 2014, 36, 2047-2063.e3.	2.5	10
1158	The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201.	2.6	11
1159	Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 960-969.	5.8	8
1160	What Is the Contribution of Protease Inhibitors to the High Mortality of Patients With Cirrhosis Receiving HCV Treatment?. <i>Gastroenterology</i> , 2014, 147, 1185.	1.3	0
1161	HCV NS5A Inhibitors Disrupt Replication Factory Formation: A Novel Mechanism of Antiviral Action. <i>Gastroenterology</i> , 2014, 147, 959-962.	1.3	11
1162	Risky Business—the Real Life of the Unresolved HCV Therapy. <i>Gastroenterology</i> , 2014, 147, 1185-1186.	1.3	0
1163	Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3043-3052.	2.3	24
1164	Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5386-5394.	3.2	32
1165	Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. <i>Hepatology International</i> , 2014, 8, 540-549.	4.2	6
1166	Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. <i>Liver International</i> , 2014, 34, 1349-1357.	3.9	4
1167	Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. <i>Molecular BioSystems</i> , 2014, 10, 767.	2.9	15
1168	Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. <i>Journal of General Virology</i> , 2014, 95, 2468-2479.	2.9	20
1169	The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. <i>Virology</i> , 2014, 462-463, 42-48.	2.4	99

#	ARTICLE	IF	CITATIONS
1170	Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. <i>Hepatology</i> , 2014, 59, 1706-1714.	7.3	23
1171	A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. <i>Liver International</i> , 2014, 34, 1550-1559.	3.9	6
1172	Cost Utility of Telaprevir+PR (Peginterferon+Ribavirin) Versus Boceprevir+PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 647-659.	2.1	13
1173	Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1653-1666.	2.4	23
1174	Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	8.2	3
1175	Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: Novel insights about targeted genotyping approaches. <i>Journal of Medical Virology</i> , 2014, 86, 1714-1721.	5.0	16
1176	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.	0.9	8
1177	Pegylated interferon ± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014, 46, 826-832.	0.9	12
1178	Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 91-98.	2.0	11
1179	Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 Telaprevir): An Open-Label, Single-Arm, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1768-1776.	5.8	25
1180	The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 533-541.	2.0	12
1181	Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. <i>Antiviral Research</i> , 2014, 109, 141-148.	4.1	16
1182	ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.	7.3	25
1183	Telaprevir-based treatment effects on hepatitis C virus in liver and blood. <i>Hepatology</i> , 2014, 60, 1826-1837.	7.3	22
1184	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.	0.4	33
1185	Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7215-7224.	3.2	12
1186	Treatment of HCV infection with the novel NS3/4A protease inhibitors. <i>Current Opinion in Pharmacology</i> , 2014, 18, 9-17.	3.5	30
1187	Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3105-3114.	3.2	16

#	ARTICLE	IF	CITATIONS
1188	Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program. <i>Journal of Hepatology</i> , 2014, 61, 976-983.	3.7	25
1189	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	3.7	62
1190	Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 8-16.	5.5	13
1191	Recurrent HCV after liver transplantation—mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 710-721.	17.8	33
1192	Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 85-86.	0.9	16
1193	Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 416-423.	2.0	11
1194	A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 577-581.	1.7	5
1195	HCV NS5A Inhibitors: The Devil Is in the Details. <i>Gastroenterology</i> , 2014, 147, 273-277.	1.3	5
1196	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	2.5	11
1197	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	3.2	8
1198	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.	0.9	17
1199	Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1107-1113.	1.9	11
1200	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet</i> , 2014, 384, 1756-1765.	13.7	751
1201	The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. <i>Drug Development Research</i> , 2014, 75, 107-113.	2.9	1
1202	Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 348-356.	2.0	35
1203	Cell and tissue engineering for liver disease. <i>Science Translational Medicine</i> , 2014, 6, 245sr2.	12.4	247
1204	Treating hepatitis C in the elderly: the future is near?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2019-2028.	1.8	3
1205	Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 132-143.	1.9	1

#	ARTICLE	IF	CITATIONS
1206	The role of interferon in the new era of hepatitis C treatments. Expert Review of Gastroenterology and Hepatology, 2014, 8, 649-656.	3.0	7
1207	Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management. Expert Review of Gastroenterology and Hepatology, 2014, 8, 247-266.	3.0	14
1208	Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. Hepatology International, 2014, 8, 352-364.	4.2	1
1209	German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Research and Therapy, 2014, 11, 16.	1.7	10
1210	Antiviral treatment of hepatitis C. BMJ, The, 2014, 349, g3308-g3308.	6.0	175
1211	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 2014, 61, 1238-1246.	3.7	126
1212	Retreatment of HCV with ABT-450/râ€“Ombitasvir and Dasabuvir with Ribavirin. New England Journal of Medicine, 2014, 370, 1604-1614.	27.0	536
1213	Treatment of HCV with ABT-450/râ€“Ombitasvir and Dasabuvir with Ribavirin. New England Journal of Medicine, 2014, 370, 1594-1603.	27.0	816
1214	The Efficacy of a<i>Hansenula</i>-Derived 20â€“kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2014, 34, 727-733.	1.2	3
1215	Peg-IFN±/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases, 2014, 73, 831-837.	0.9	62
1216	Hepatitis C virus and interferon type III (interferon-Î»3/interleukin-28B and interferon-Î»4): genetic basis of susceptibility to infection and response to antiviral treatment. Clinical Microbiology and Infection, 2014, 20, 1237-1245.	6.0	16
1217	Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therapeutic Advances in Gastroenterology, 2014, 7, 131-140.	3.2	85
1218	Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. Journal of Gastroenterology, 2014, 49, 941-953.	5.1	96
1219	Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature. Digestive Diseases and Sciences, 2014, 59, 2007-2012.	2.3	12
1220	Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology, 2014, 59, 2083-2091.	7.3	517
1221	Review article: 2014 UK consensus guidelines â€“ hepatitis C management and directâ€“acting antiâ€“viral therapy. Alimentary Pharmacology and Therapeutics, 2014, 39, 1363-1375.	3.7	32
1222	Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology, 2014, 59, 46-48.	7.3	80
1224	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. Journal of Infection, 2014, 68, 372-377.	3.3	3

#	ARTICLE	IF	CITATIONS
1225	EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology, 2014, 61, 373-395.	3.7	172
1226	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and <scp>HCV</scp> genotype 1 infection. Journal of Viral Hepatitis, 2014, 21, 568-577.	2.0	19
1227	Advances in newly developing therapy for chronic hepatitis C virus infection. Frontiers of Medicine, 2014, 8, 166-174.	3.4	8
1228	Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterology, 2014, 14, 87.	2.0	21
1229	High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Research Notes, 2014, 7, 266.	1.4	8
1231	Natural History and Management of Hepatitis C: Does Sex Play a Role?. Journal of Infectious Diseases, 2014, 209, S81-S85.	4.0	101
1232	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	27.0	1,065
1233	Response-guided therapy in patients with genotype 1 hepatitis <scp>C</scp> virus: Current status and future prospects. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1574-1581.	2.8	17
1235	Is genotype 3 of the hepatitis C virus the new villain?. Hepatology, 2014, 59, 2403-2412.	7.3	116
1236	A near-full length genotypic assay for HCV1b. Journal of Virological Methods, 2014, 209, 126-135.	2.1	11
1237	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut, 2014, 63, 207-215.	12.1	29
1238	Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. Antimicrobial Agents and Chemotherapy, 2014, 58, 6079-6092.	3.2	29
1239	Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis <scp>C</scp> patients with thrombocytopenia and advanced fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1728-1735.	2.8	3
1240	Nitazoxanide for chronic hepatitis C. The Cochrane Library, 2014, 2014, CD009182.	2.8	11
1241	Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 969-972.	2.2	7
1242	Hepatitis B and C in African Americans: Current Status and Continued Challenges. Clinical Gastroenterology and Hepatology, 2014, 12, 738-748.	4.4	38
1243	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 2014, 60, 392-420.	3.7	739
1244	Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. Journal of Hepatology, 2014, 60, 872-884.	3.7	56

#	ARTICLE	IF	CITATIONS
1245	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.9	3
1246	Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 60, 231-232.	3.7	3
1247	New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. <i>Gastroenterology</i> , 2014, 146, 1176-1192.	1.3	458
1248	Paranoid psychosis and cognitive impairment associated with hepatitis C antiviral therapy. <i>General Hospital Psychiatry</i> , 2014, 36, 126.e3-126.e5.	2.4	2
1249	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383.	4.4	16
1250	Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications. <i>Journal of the Association of Nurses in AIDS Care</i> , 2014, 25, 23-31.	1.0	9
1251	Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. <i>Journal of Hepatology</i> , 2014, 61, 200-209.	3.7	26
1252	Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 48-52.	0.6	11
1253	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	3.7	1
1254	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	3.7	18
1255	Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. <i>Gastroenterology</i> , 2014, 146, 1669-1679.e3.	1.3	239
1256	Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1029-1037.e5.	4.4	20
1257	First case of drug rash eosinophilia and systemic symptoms due to boceprevir. <i>Journal of Hepatology</i> , 2014, 60, 891-893.	3.7	13
1258	Entry inhibitors and future treatment of hepatitis C. <i>Antiviral Research</i> , 2014, 104, 136-142.	4.1	20
1259	Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 19-25.	4.0	11
1260	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014, 46, 67-71.	0.9	9
1261	Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126.	3.7	18
1262	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9

#	ARTICLE	IF	CITATIONS
1263	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014, 60, 913-919.	3.7	39
1264	Interferon-free hepatitis C treatment: one pill to fit all?. <i>Lancet, The</i> , 2014, 383, 491-492.	13.7	7
1265	Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. <i>Antiviral Research</i> , 2014, 105, 64-71.	4.1	85
1266	O impacto da hepatite C em Portugal. <i>GE Jornal Português De Gastrenterologia</i> , 2014, 21, 44-54.	0.0	13
1267	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	3.7	40
1268	The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?. <i>Hepatology</i> , 2014, 60, 1126-1129.	7.3	19
1269	Review article: <scp>HCV</scp> genotype 3 “ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	3.7	103
1270	Safety of direct-acting antivirals in the treatment of chronic hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 307-319.	2.4	10
1271	Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. <i>Journal of Medical Economics</i> , 2014, 17, 65-76.	2.1	29
1272	Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 387-402.	1.4	13
1273	The cost-effectiveness of boceprevir for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 319-334.	1.4	1
1274	Synthesis and Anti-HCV Activity of 4-Hydroxyamino 1H-Pyranone Carboxamide Analogues. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 259-263.	2.8	22
1275	Novel Quinoline-Based P2“P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 264-269.	2.8	22
1276	New antiviral agents for the treatment of hepatitis C: ABT-450. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 711-716.	1.8	27
1277	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.	3.1	22
1278	Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post“orthotopic liver transplant. <i>Clinical Transplantation</i> , 2014, 28, 722-727.	1.6	9
1279	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 409-427.	3.5	35
1280	Micro<scp>RNA</scp>“155 controls <scp>T</scp>oll“like receptor 3“and hepatitis <scp>C</scp> virus“induced immune responses in the liver. <i>Journal of Viral Hepatitis</i> , 2014, 21, 99-110.	2.0	45

#	ARTICLE	IF	CITATIONS
1281	Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 331-338.	3.7	53
1282	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014, 384, 414-426.	13.7	376
1283	QUEST for a cure for hepatitis C virus: the end is in sight. <i>Lancet, The</i> , 2014, 384, 381-383.	13.7	7
1284	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.	0.9	88
1285	The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment. <i>Current Infectious Disease Reports</i> , 2014, 16, 413.	3.0	8
1286	Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. <i>Drugs</i> , 2014, 74, 951-961.	10.9	9
1287	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 403-413.	13.7	431
1288	Update on hepatitis C virus resistance to direct-acting antiviral agents. <i>Antiviral Research</i> , 2014, 108, 181-191.	4.1	172
1289	Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 738-743.	0.9	15
1290	Renal impairment and anemia during triple therapy. <i>Journal of Hepatology</i> , 2014, 60, 1099-1100.	3.7	1
1291	Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. <i>Journal of Hepatology</i> , 2014, 61, 530-537.	3.7	76
1292	Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1753-1769.	6.4	123
1293	Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1770-1776.	6.4	29
1295	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV/HIV Coinfection in Interferon-Naïve Patients. <i>Antiviral Therapy</i> , 2014, 19, 735-745.	1.0	5
1296	Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. <i>Antiviral Therapy</i> , 2014, 19, 469-477.	1.0	6
1297	A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2014, 19, 491-499.	1.0	31
1298	Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1. <i>Antiviral Therapy</i> , 2014, 19, 501-510.	1.0	26
1299	Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naïve to direct antivirals. <i>Antiviral Therapy</i> , 2014, 19, 455-461.	1.0	4

#	ARTICLE	IF	CITATIONS
1300	Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938. <i>Antiviral Therapy</i> , 2014, 19, 211-220.	1.0	44
1301	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051.	6.7	19
1302	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546.	3.9	77
1303	Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon- α 2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore. <i>Antiviral Therapy</i> , 2015, 20, 209-216.	1.0	13
1304	Performance Characteristics of the Cobas Ampliprep/Cobas Taqman V2.0 and the Abbott Realtime Hepatitis C Assays - Implications for Response-Guided Therapy in Genotype 1 Infections. <i>Antiviral Therapy</i> , 2014, 19, 449-454.	1.0	13
1305	The clinical management of HCV in the HIV-infected patient. <i>Antiviral Therapy</i> , 2014, 20, 457-467.	1.0	4
1306	HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy. <i>Antiviral Therapy</i> , 2014, 19, 559-567.	1.0	32
1307	Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B. <i>Antiviral Therapy</i> , 2014, 19, 479-490.	1.0	38
1308	Characterization and risk of blood-borne virus transmission in organ transplantation: what are the priorities?. <i>Future Virology</i> , 2014, 9, 1049-1060.	1.8	1
1309	Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125.	2.8	2
1310	A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 439-448.	1.6	4
1311	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 199-208.	1.0	21
1312	IL28B genotyping and treatment of HCV infected subjects. <i>Asian Biomedicine</i> , 2014, 8, 445-452.	0.3	0
1313	A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. <i>Antiviral Therapy</i> , 2015, 20, 469-477.	1.0	7
1314	Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV+HCV Coinfection. <i>Antiviral Therapy</i> , 2015, 20, 407-413.	1.0	0
1315	Prevalence of HCV Infection Among Clients in Community-Based Health Settings in Hawaii, 2002-2010: Assessing Risk Factors. <i>American Journal of Public Health</i> , 2014, 104, 1534-1539.	2.7	8
1316	Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 41-51.	1.6	0
1318	Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132.		4

#	ARTICLE	IF	CITATIONS
1319	Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy. <i>Hepatology</i> , 2014, 59, 13-15.	7.3	13
1320	HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014, 28, 41-47.	2.2	30
1322	Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 42-46.	1.9	7
1323	HCV Kinetic Models and Their Implications in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 231-242.	2.5	16
1324	Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 497-520.	3.7	157
1325	Inhibition of expression of hepatitis C virus 1b genotype core and NS4B genes in HepG2 cells using artificial microRNAs. <i>Molecular Medicine Reports</i> , 2015, 12, 1905-1913.	2.4	1
1326	UEG Week 2015 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2015, 3, 146-687.	3.8	11
1327	Telaprevir enhances ribavirin-induced anaemia through renal function impairment. <i>Antiviral Therapy</i> , 2015, 20, 479-486.	1.0	5
1328	Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection. <i>Antiviral Therapy</i> , 2016, 21, 37-44.	1.0	13
1330	Viral hepatitis in hemodialysis: An update. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 93-105.	2.5	45
1331	The ARRIBA concept: adequate resorption of ribavirin. <i>Antiviral Therapy</i> , 2015, 20, 515-520.	1.0	2
1332	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 465-474.	1.5	0
1333	MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. <i>Biomarker Insights</i> , 2015, 10s4, BMI.S29512.	2.5	26
1334	Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy. <i>Antiviral Therapy</i> , 2016, 21, 153-159.	1.0	5
1335	A new era of therapy for hepatitis C virus infection. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 471-478.	3.1	17
1336	Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. <i>Value in Health Regional Issues</i> , 2015, 7, 42-48.	1.2	5
1337	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. <i>SpringerPlus</i> , 2015, 4, 357.	1.2	8
1338	Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. <i>Journal of Medical Virology</i> , 2015, 87, 1361-1367.	5.0	0

#	ARTICLE	IF	CITATIONS
1339	Resistance to direct-acting antiviral agents. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 381-389.	3.8	22
1340	Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. <i>Journal of Viral Hepatitis</i> , 2015, 22, 481-488.	2.0	9
1341	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. <i>Liver International</i> , 2015, 35, 1833-1844.	3.9	5
1342	Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1 coinfected patients. <i>Liver International</i> , 2015, 35, 2090-2099.	3.9	10
1343	Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. <i>Transplant International</i> , 2015, 28, 980-989.	1.6	21
1344	The birth and potential death of IL28B genotyping for hepatitis C therapy. <i>Personalized Medicine</i> , 2015, 12, 55-57.	1.5	2
1345	The role of HCV proteins on treatment outcomes. <i>Virology Journal</i> , 2015, 12, 217.	3.4	23
1346	Chiral Lactams by Enantioselective Palladium(0)-Catalyzed Cyclopropane Functionalizations. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 11826-11829.	13.8	138
1347	Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 829-844.	3.7	34
1348	Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1759-1767.	2.8	11
1349	Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. <i>Journal of Viral Hepatitis</i> , 2015, 22, 489-495.	2.0	6
1350	Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. <i>Transplant International</i> , 2015, 28, 1011-1024.	1.6	10
1351	Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. <i>Cancer</i> , 2015, 121, 2874-2882.	4.1	63
1352	Randomized trial of low-dose peginterferon α -2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015, 87, 2082-2089.	5.0	0
1353	Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. <i>Journal of Viral Hepatitis</i> , 2015, 22, 691-700.	2.0	13
1354	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon α -2a in hepatitis C null responders. <i>Liver International</i> , 2015, 35, 2275-2284.	3.9	0
1355	The hepatitis C revolution part 1. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 563-571.	3.1	17
1356	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2015, 45, 745-754.	3.4	12

#	ARTICLE	IF	CITATIONS
1358	Hepatitis C Genotype Influences Post-liver Transplant Outcomes. <i>Transplantation</i> , 2015, 99, 835-840.	1.0	19
1359	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	2.2	5
1360	Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. <i>Journal of Addiction Medicine</i> , 2015, 9, 405-410.	2.6	13
1361	Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 517-524.	2.0	6
1362	Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France. <i>Journal of Medical Virology</i> , 2015, 87, 1921-1933.	5.0	2
1363	High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015, 35, 510-517.	3.9	16
1364	Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 861-870.	2.0	74
1365	High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1 Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 745-750.	2.0	6
1366	Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. <i>Gastroenterology Nursing</i> , 2015, 38, 417-428.	0.4	3
1367	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651.	1.0	19
1368	Rate, Delay and Predictors of Hepatitis C Treatment in British Columbia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 315-320.	1.9	16
1369	Rescuing compound bioactivity in a secondary cell-based screening by using γ -cyclodextrin as a molecular carrier. <i>International Journal of Nanomedicine</i> , 2015, 10, 2249.	6.7	4
1370	Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18439-18453.	4.1	22
1371	Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 9163.	3.3	10
1372	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.	3.3	7
1373	Hepatitis C and kidney disease: An overview and approach to management. <i>World Journal of Hepatology</i> , 2015, 7, 78.	2.0	42
1374	Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.	2.0	41
1375	Hepatitis C virus: Virology, diagnosis and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1377.	2.0	127

#	ARTICLE	IF	CITATIONS
1376	Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers. <i>World Journal of Gastroenterology</i> , 2015, 21, 8660.	3.3	5
1377	CARCINOMA HEPATOCELULAR “ UMA REVISÃO BIBLIOGRÁFICA. <i>Revista Médica Da UFPR</i> , 2015, 2, 178.	0.0	0
1378	Treatment Patterns, Health Care Resource Utilization, and Costs in U.S. Patients Diagnosed with Chronic Hepatitis C Infection Who Received Telaprevir or Boceprevir. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 308-316.	0.9	6
1379	Factors Affecting the Response to Interferon Alpha Therapy in Egyptian HCV Patients. <i>American Journal of Immunology</i> , 2015, 11, 92-101.	0.1	0
1381	Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. <i>Vaccines</i> , 2015, 3, 203-220.	4.4	29
1382	Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0117334.	2.5	21
1383	Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype. <i>PLoS ONE</i> , 2015, 10, e0118313.	2.5	6
1384	Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes. <i>PLoS ONE</i> , 2015, 10, e0121734.	2.5	9
1385	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	2.5	2
1386	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.	2.5	12
1387	Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. <i>PLoS ONE</i> , 2015, 10, e0125846.	2.5	16
1388	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.	2.5	3
1389	Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells. <i>PLoS ONE</i> , 2015, 10, e0131358.	2.5	27
1390	Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. <i>PLoS ONE</i> , 2015, 10, e0135232.	2.5	8
1391	Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. <i>PLoS ONE</i> , 2015, 10, e0135963.	2.5	18
1392	A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine. <i>PLoS ONE</i> , 2015, 10, e0142349.	2.5	9
1393	Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. <i>Viruses</i> , 2015, 7, 6716-6729.	3.3	72
1394	An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 19-34.	1.9	67

#	ARTICLE	IF	CITATIONS
1395	Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. International Journal of Hepatology, 2015, 2015, 1-10.	1.1	7
1396	The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 46-48.	1.9	7
1397	Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 125-129.	1.9	5
1400	Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Annals of Hepatology, 2015, 14, 46-57.	1.5	18
1401	Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. Annals of Hepatology, 2015, 14, 132-136.	1.5	4
1402	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. Annals of Hepatology, 2015, 14, S7-S48.	1.5	4
1403	Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World Journal of Hepatology, 2015, 7, 1921.	2.0	11
1405	Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World Journal of Hepatology, 2015, 7, 1936.	2.0	17
1406	Hepatitis C " Overview and Update in Treatment. , 2015, , .		0
1407	New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. , 2015, , .		0
1408	Pegylated interferon based therapy with secondâ€wave directâ€acting antivirals in genotype 1 chronic hepatitis C. Liver International, 2015, 35, 11-17.	3.9	16
1409	Mass Balance, Metabolite Profile, and <i>In Vitro-In Vivo</i> Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 25-37.	3.2	12
1410	TRIPLE THERAPY IN CHRONIC HEPATITIS C: initial series in a public health program in the South of Brazil. Arquivos De Gastroenterologia, 2015, 52, 14-17.	0.8	5
1411	Biomarkers in HCV Infection. Advances in Clinical Chemistry, 2015, 70, 131-196.	3.7	4
1412	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2015, 9, 9-20.	3.0	6
1413	Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opinion on Pharmacotherapy, 2015, 16, 739-748.	1.8	17
1414	New hepatitis C virus therapies. Current Opinion in Organ Transplantation, 2015, 20, 235-241.	1.6	59
1415	Monoclonal Antibodies against Extracellular Domains of Claudin-1 Block Hepatitis C Virus Infection in a Mouse Model. Journal of Virology, 2015, 89, 4866-4879.	3.4	48

#	ARTICLE	IF	CITATIONS
1416	An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTime HCV RNA Assay. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1264-1269.	3.9	13
1417	Hepatitis C virus genetic variability and evolution. <i>World Journal of Hepatology</i> , 2015, 7, 831.	2.0	85
1418	Psychiatric Care During Hepatitis C Treatment: The Changing Role of Psychiatrists in the Era of Direct-Acting Antivirals. <i>American Journal of Psychiatry</i> , 2015, 172, 512-516.	7.2	15
1419	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 11.	2.5	4
1420	Tratamiento de la infección crónica por los virus de la hepatitis C y B. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2015, 22, 264-273.	0.0	0
1421	Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. <i>BMC Research Notes</i> , 2015, 8, 367.	1.4	21
1422	Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2835-2848.	1.8	9
1423	Hepatitis C: pay now or pay later?. <i>Future Virology</i> , 2015, 10, 1285-1290.	1.8	0
1424	Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 314-327.	2.5	13
1426	The health benefits of vitamin K. <i>Open Heart</i> , 2015, 2, e000300.	2.3	71
1428	Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay. <i>BMC Infectious Diseases</i> , 2015, 16, 47.	2.9	2
1429	Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 2021-9.	2.3	10
1430	Effect of IL28B genotype on hepatitis B and C virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 50-55.	5.4	22
1431	Hepatitis C therapy: Looking toward interferon-sparing regimens. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, e72-e86.	1.5	8
1432	Optimal management of patients with chronic hepatitis C and comorbidities. <i>Liver International</i> , 2015, 35, 35-43.	3.9	12
1433	Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus "coinfecting patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015, 61, 1503-1511.	7.3	13
1434	The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2015, 11, 116-123.	0.8	1
1435	Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015, 35, 27-34.	3.9	29

#	ARTICLE	IF	CITATIONS
1436	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. <i>Journal of Infection</i> , 2015, 70, 197-205.	3.3	35
1437	Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2015, 42, 329-338.	2.2	22
1438	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.	0.9	4
1439	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen—The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	1.5	5
1440	Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 671-685.	3.7	24
1441	Hepatitis C. <i>Lancet</i> , The, 2015, 385, 1124-1135.	13.7	424
1442	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.	4.0	10
1443	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 566-581.	1.9	44
1444	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 473-484.	2.4	9
1445	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.	3.7	108
1446	Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2813-2823.	3.3	30
1447	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	3.7	12
1448	Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. <i>Journal of Clinical Virology</i> , 2015, 65, 50-53.	3.1	24
1449	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 656-671.	5.5	36
1450	ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 295-304.	4.4	6
1451	Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. <i>European Journal of Immunology</i> , 2015, 45, 309-316.	2.9	34
1452	Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. <i>Hepatology</i> , 2015, 61, 1523-1532.	7.3	78
1453	Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015, 87, 625-633.	5.0	1

#	ARTICLE	IF	CITATIONS
1454	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	3.7	19
1455	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	3.2	10
1456	AllaCoral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY phase III study. <i>Hepatology</i> , 2015, 61, 1127-1135.	7.3	598
1457	Inhibitory effects of Pycnogenol® on hepatitis C virus replication. <i>Antiviral Research</i> , 2015, 113, 93-102.	4.1	19
1458	A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254.	0.9	5
1459	A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , 2015, 78, 184-192.	2.6	40
1460	Conjugated bilirubin triggers anemia by inducing erythrocyte death. <i>Hepatology</i> , 2015, 61, 275-284.	7.3	141
1461	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.	4.0	54
1462	Innate and adaptive genetic pathways in <sc>HCV</sc> infection. <i>Tissue Antigens</i> , 2015, 85, 231-240.	1.0	13
1463	Revolution in hepatitis C antiviral therapy. <i>British Medical Bulletin</i> , 2015, 113, 31-44.	6.9	34
1464	Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2746-2755.	3.2	13
1465	A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5.	3.0	2
1466	Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1743-1751.	5.8	91
1467	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	2.0	11
1468	Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 303-311.	1.9	20
1469	Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. <i>Gut</i> , 2015, 64, 483-494.	12.1	83
1470	Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121.	2.0	65
1471	Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin. <i>Current Hepatology Reports</i> , 2015, 14, 53-59.	0.9	0

#	ARTICLE	IF	CITATIONS
1472	Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". Clinical Infectious Diseases, 2015, 60, 1829-1836.	5.8	134
1473	Gene Therapies for Hepatitis C Virus. Advances in Experimental Medicine and Biology, 2015, 848, 1-29.	1.6	8
1474	Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV). Current HIV/AIDS Reports, 2015, 12, 68-78.	3.1	29
1475	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. Current Hepatology Reports, 2015, 14, 32-39.	0.9	0
1476	Faldaprevir for the Treatment of Hepatitis C. International Journal of Molecular Sciences, 2015, 16, 4985-4996.	4.1	16
1477	IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. Frontiers in Microbiology, 2015, 6, 153.	3.5	4
1478	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Visceral Medicine, 2015, 31, 290-296.	1.3	19
1479	Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Clinical Therapeutics, 2015, 37, 1529-1540.	2.5	11
1480	Meet the Classes of Directly Acting Antiviral Agents. Clinics in Liver Disease, 2015, 19, 605-617.	2.1	4
1481	Reply to Harrington et al. Clinical Infectious Diseases, 2015, 61, 667-668.	5.8	2
1482	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. International Journal of Antimicrobial Agents, 2015, 45, 657-661.	2.5	10
1483	A signature for immune response correlates with HCV treatment outcome in Caucasian subjects. Journal of Proteomics, 2015, 116, 59-67.	2.4	6
1484	Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. Molecular Diversity, 2015, 19, 829-853.	3.9	8
1485	Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. Molecular BioSystems, 2015, 11, 2568-2578.	2.9	17
1486	Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clinical Therapeutics, 2015, 37, 1713-1725.e3.	2.5	7
1487	Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Annals of Pharmacotherapy, 2015, 49, 1015-1030.	1.9	14
1488	Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Therapeutic Advances in Chronic Disease, 2015, 6, 4-14.	2.5	38
1489	HCV targeting of patients with cirrhosis. Journal of Hepatology, 2015, 63, 1015-1022.	3.7	54

#	ARTICLE	IF	CITATIONS
1490	Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1205-1222.	3.5	42
1491	Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?. <i>Journal of Hepatology</i> , 2015, 63, 1254-1262.	3.7	48
1492	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 971-980.e1.	1.3	77
1493	Paritaprevir in patients with chronic hepatitis C genotype 1. <i>Future Virology</i> , 2015, 10, 679-690.	1.8	1
1494	Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2942-2950.	3.9	11
1495	HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. <i>Clinical Infectious Diseases</i> , 2015, 61, 1127-1134.	5.8	28
1496	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 593-605.	1.4	4
1497	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.4	28
1498	Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings. <i>Social Work in Public Health</i> , 2015, 30, 325-335.	1.4	2
1499	Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.	2.5	3
1500	Ultradeep Pyrosequencing of NS3 To Predict Response to Triple Therapy with Protease Inhibitors in Previously Treated Chronic Hepatitis C Patients. <i>Journal of Clinical Microbiology</i> , 2015, 53, 389-397.	3.9	6
1501	Treatment of hepatitis C in difficult-to-treat patients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 284-292.	17.8	65
1502	From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99.	3.7	284
1503	Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 521-531.	3.7	39
1504	Natural History of Hepatitis C. , 2015, , 120-130.		0
1505	Transplantation for Hepatitis C. , 2015, , 131-152.		0
1506	Recurrent Hepatitis C After Transplantation. , 2015, , 1040-1050.		0
1507	Evaluation of the COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. <i>Journal of Clinical Virology</i> , 2015, 67, 67-72.	3.1	18

#	ARTICLE	IF	CITATIONS
1508	A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 101-114.	1.4	3
1509	Utility of Evaluating HCV in an Uninsured Population. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1092-1097.	2.3	7
1510	Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1045-1051.	2.3	21
1511	Cure of <sc>HCV</sc> related liver disease. <i>Liver International</i> , 2015, 35, 71-77.	3.9	24
1512	EASL Recommendations on Treatment of Hepatitis C 2015. <i>Journal of Hepatology</i> , 2015, 63, 199-236.	3.7	1,052
1513	First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. <i>Virology Journal</i> , 2015, 12, 37.	3.4	11
1514	Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 2015, 162, 407-419.	3.9	186
1515	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC ³ study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717.	2.0	13
1516	Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 267-277.	1.4	12
1517	The Role of L-Tryptophan Kynurenine Pathway Metabolism in Various Infectious Diseases: Focus on Indoleamine 2,3-Dioxygenase 1. <i>Molecular and Integrative Toxicology</i> , 2015, , 95-120.	0.5	1
1518	Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with <i>In Vitro</i> Replicon Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3450-3459.	3.2	29
1519	Drug Interactions With Direct-Acting Antivirals for Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2015, 49, 674-687.	1.9	73
1520	The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 488-497.	1.2	11
1521	<i>IL28B</i> polymorphism and early anemia predict the rapid null response in genotype 1 chronic hepatitis C with dual therapy. <i>Advances in Digestive Medicine</i> , 2015, 2, 128-134.	0.2	0
1522	Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 599-614.	3.5	4
1523	A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon- α and ribavirin in patients infected with genotype 1 Hepatitis C virus. <i>Journal of Medical Economics</i> , 2015, 18, 787-796.	2.1	5
1524	The potential role of simeprevir for the treatment of hepatitis C. <i>Future Virology</i> , 2015, 10, 67-75.	1.8	0
1525	Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. <i>Epidemiologic Reviews</i> , 2015, 37, 131-143.	3.5	53

#	ARTICLE	IF	CITATIONS
1526	Hepatitis C and HIV Co-infection. JAMA - Journal of the American Medical Association, 2015, 313, 1217.	7.4	7
1527	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatology International, 2015, 9, 486-507.	4.2	18
1528	Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. Drugs, 2015, 75, 823-834.	10.9	14
1529	Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens. Journal of Clinical Gastroenterology, 2015, 49, 329-335.	2.2	11
1530	Generation of improved mouse models for the study of hepatitis C virus. European Journal of Pharmacology, 2015, 759, 313-325.	3.5	14
1531	Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naïve Patients Evaluated by Race or Ethnicity. Journal of Clinical Gastroenterology, 2015, 49, 336-344.	2.2	7
1532	Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 218-230.	17.8	79
1533	Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. Medical Clinics of North America, 2015, 99, 575-586.	2.5	6
1534	Faldaprevir and pegylated interferon α -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. Aids, 2015, 29, 571-581.	2.2	17
1535	Liver transplantation in the context of organ shortage. Current Opinion in Critical Care, 2015, 21, 163-170.	3.2	19
1536	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. Annals of Internal Medicine, 2015, 162, 397-406.	3.9	303
1538	Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection. Expert Opinion on Drug Safety, 2015, 14, 713-731.	2.4	1
1539	Management of post transplant hepatitis C in the direct antiviral agents era. Hepatology International, 2015, 9, 192-201.	4.2	7
1540	Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. European Journal of Medicinal Chemistry, 2015, 96, 250-258.	5.5	24
1541	Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology, 2015, 63, 364-369.	3.7	115
1542	Drug-drug interactions of telaprevir and boceprevir in HCV monoinfected and HCV/HIV coinfected patients can modify the adherence. Liver International, 2015, 35, 1557-1565.	3.9	5
1543	Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. Journal of Virological Methods, 2015, 220, 1-4.	2.1	11
1544	In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. Antimicrobial Agents and Chemotherapy, 2015, 59, 988-997.	3.2	108

#	ARTICLE	IF	CITATIONS
1545	Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.	2.4	6
1546	Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 699-704.	1.5	1
1547	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.	0.9	0
1548	Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. <i>BMC Public Health</i> , 2015, 15, 566.	2.9	11
1549	A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors. <i>Antiviral Research</i> , 2015, 117, 1-9.	4.1	7
1550	Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6017-6025.	3.2	11
1551	Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 613-623.	1.9	15
1552	Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. <i>Journal of Viral Hepatitis</i> , 2015, 22, 213-229.	2.0	22
1553	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882.	2.0	54
1554	Direct-Acting Antiviral Agents. <i>Clinics in Liver Disease</i> , 2015, 19, 629-639.	2.1	1
1555	Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. <i>BMC Infectious Diseases</i> , 2015, 15, 344.	2.9	10
1557	Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 63-79.	5.5	38
1558	Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using <i>Escherichia coli</i> lysate. <i>Journal of Virological Methods</i> , 2015, 225, 76-86.	2.1	3
1559	Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 644-654.	0.5	12
1560	Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1307-1317.	4.4	7
1561	Beclabuvir for the treatment of hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1111-1121.	4.1	17
1562	Management of direct-acting antiviral agent failures. <i>Journal of Hepatology</i> , 2015, 63, 1511-1522.	3.7	73
1563	Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. <i>Clinics in Liver Disease</i> , 2015, 19, 641-656.	2.1	9

#	ARTICLE	IF	CITATIONS
1564	Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015, 99, 596-610.	2.1	36
1565	High-resolution genetic profile of viral genomes: why it matters. <i>Current Opinion in Virology</i> , 2015, 14, 62-70.	5.4	13
1566	Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7719-7733.	6.4	69
1567	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269.	3.2	1
1568	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015, 71, 63-66.	3.1	12
1569	Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. <i>Current Gastroenterology Reports</i> , 2015, 17, 462.	2.5	1
1570	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843.	2.2	17
1571	Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. <i>International Journal of Drug Policy</i> , 2015, 26, 1014-1019.	3.3	21
1572	Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1483-1494.	3.0	10
1574	Treatment discontinuation with peg-interferon: what to consider. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 761-768.	3.1	1
1575	Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 705-710.	1.5	2
1576	HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. <i>Journal of Clinical Virology</i> , 2015, 73, 32-35.	3.1	5
1577	Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1815-1825.	2.4	2
1578	Emerging treatments for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 204-215.	1.7	32
1579	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. <i>Journal of Advanced Research</i> , 2015, 6, 301-310.	9.5	40
1580	IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: Systematic review of its prevalence in chronic hepatitis C patients and general population frequency. <i>Pharmacological Reports</i> , 2015, 67, 260-266.	3.3	3
1581	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , 2015, 214, 29-32.	2.1	39
1582	The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 15-22.	0.6	2

#	ARTICLE	IF	CITATIONS
1583	Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. <i>Clinical Infectious Diseases</i> , 2015, 60, 108-116.	5.8	46
1584	Novel Dengue Virus NS2B/NS3 Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1100-1109.	3.2	108
1585	Which therapeutic option for hepatitis C virus genotype 1?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 470-478.	1.5	3
1586	New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 497-506.	5.5	25
1587	Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 27-35.	9.1	60
1588	Hepatitis C virus and lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 246-256.	4.4	23
1589	Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. <i>Virus Research</i> , 2015, 196, 37-43.	2.2	3
1590	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	12.1	30
1591	Barriers to <sc>HCV</sc> treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. <i>Liver International</i> , 2015, 35, 401-408.	3.9	16
1592	Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <sc>SOUND</sc>, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421.	3.9	18
1593	Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase <sc>II</sc> and <sc>III</sc> studies. <i>Journal of Viral Hepatitis</i> , 2015, 22, 366-375.	2.0	17
1594	Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2015, 113, 71-78.	4.1	24
1596	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	1.3	49
1597	Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. <i>Gut</i> , 2015, 64, 1277-1288.	12.1	50
1598	Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 299-306.	0.5	8
1599	Simeprevir (<sc>TMC435</sc>) once daily with peginterferon-2b and ribavirin in patients with genotype 1 hepatitis <sc>C</sc> virus infection: The <sc>CONCERTO</sc> study. <i>Hepatology Research</i> , 2015, 45, 501-513.	3.4	50
1600	<sc>DAUPHINE</sc>: a randomized phase <sc>II</sc> study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in <sc>HCV</sc> genotypes 1 or 4. <i>Liver International</i> , 2015, 35, 108-119.	3.9	22
1601	Management of treatment-naïve chronic hepatitis <sc>C</sc> genotype 1 patients: a cost-effectiveness analysis of treatment options. <i>Journal of Viral Hepatitis</i> , 2015, 22, 175-183.	2.0	19

#	ARTICLE	IF	CITATIONS
1602	Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015, 61, 77-87.	7.3	1,293
1603	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015, 9, 52-57.	4.2	9
1604	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	3.9	13
1605	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	2.3	34
1606	Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 63-72.	2.0	6
1607	Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 21-30.	3.0	4
1608	Sofosbuvir for the treatment of hepatitis C virus infection. <i>Cmaj</i> , 2015, 187, 203-204.	2.0	3
1609	Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.	3.4	15
1610	Undetectable <scp>HCV</scp>â€œ<scp>RNA</scp> at treatmentâ€œweek 8 results in highâ€œsustained virological response in <scp>HCV</scp> G1 treatmentâ€œexperienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	2.0	9
1611	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	3.7	86
1612	Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. <i>Critical Reviews in Microbiology</i> , 2016, 42, 535-547.	6.1	33
1613	Hepatitis C Virus. , 2016, , 1313-1345.		61
1614	Viral Transmission in Organ Transplantation: The Importance of Risk Assessment. , 0, , .		0
1615	Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 863-871.	0.9	1
1616	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-34.	1.9	21
1617	IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 37.	1.1	1
1618	Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. <i>Brazilian Journal of Medical and Biological Research</i> , 2016, 49, .	1.5	5
1619	Conceptual framework for outcomes research studies of hepatitis C: an analytical review. <i>Infection and Drug Resistance</i> , 2016, 9, 101.	2.7	0

#	ARTICLE	IF	CITATIONS
1620	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World Journal of Hepatology, 2016, 8, 1295.	2.0	37
1621	New approaches in the treatment of hepatitis C. World Journal of Gastroenterology, 2016, 22, 1421.	3.3	108
1622	HCVers1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clinical and Experimental Gastroenterology, 2016, Volume 9, 351-363.	2.3	3
1623	Treatment of Hepatitis C with First Generation Protease Inhibitors. Advances in Pharmacoeconomics & Drug Safety, 2016, 05, .	0.1	0
1624	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Revista Espanola De Enfermedades Digestivas, 2016, 109, 17-25.	0.3	15
1625	Advances in hepatitis C therapy: What is the current state - what come's next?. World Journal of Hepatology, 2016, 8, 139.	2.0	85
1626	Serine protease inhibitors. , 2016, , 343-347.		0
1627	Hepatitis C Treatment with Sofosbuvir and Daclatasvir in an 83 Year Old Patient with Ischemic Vasculitis and End Stage Renal Disease on Hemodialysis. Journal of Infectious Diseases and Treatment, 2016, 02, .	0.0	0
1628	Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepatitis Research and Treatment, 2016, 2016, 1-8.	2.0	2
1629	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation, 2016, 2016, 1-11.	3.0	49
1630	Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World Journal of Gastroenterology, 2016, 22, 8050.	3.3	43
1631	Hepatitis C virus: Promising discoveries and new treatments. World Journal of Gastroenterology, 2016, 22, 6393.	3.3	19
1632	A systematic review of community based hepatitis C treatment. BMC Infectious Diseases, 2016, 16, 202.	2.9	41
1633	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM Policy and Practice, 2016, 1, 238146831667194.	0.9	7
1634	C the difference: exploring the learning strategies used by hepatology nurses in the era of new hepatitis C treatments. Gastrointestinal Nursing, 2016, 14, 47-57.	0.1	2
1635	Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (<i>Dimocarpus longan</i>) Tj ETQq1 1 0.784314 rgBT /Overlo	1.2	28
1636	Treatment of Chronic Hepatitis C in the Aged â€œ Does It Impact Life Expectancy? A Decision Analysis. PLoS ONE, 2016, 11, e0157832.	2.5	25
1637	Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PLoS ONE, 2016, 11, e0163945.	2.5	4

#	ARTICLE	IF	CITATIONS
1638	Anti-hepatitis C virus drugs and kidney. World Journal of Hepatology, 2016, 8, 1343.	2.0	16
1639	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlook	1.0	23
1640	New prospects for the treatment and prevention of hepatitis C in children. Current Opinion in Pediatrics, 2016, 28, 93-100.	2.0	24
1641	Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients. Aids, 2016, 30, 975-989.	2.2	5
1642	Extracellular Bacterial Proteases in Chronic Wounds: A Potential Therapeutic Target?. Advances in Wound Care, 2016, 5, 455-463.	5.1	49
1643	NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. Journal of Viral Hepatitis, 2016, 23, 840-849.	2.0	15
1644	On-treatment <scp>HCV RNA</scp> as a predictor of sustained virological response in <scp>HCV</scp> genotype 3a-infected patients treated with daclatasvir and sofosbuvir. Liver International, 2016, 36, 1611-1618.	3.9	20
1645	Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. Journal of Medical Virology, 2016, 88, 481-486.	5.0	6
1646	Ledipasvir+Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. Pharmacotherapy, 2016, 36, 562-574.	2.6	12
1647	Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology, 2016, 63, 428-436.	7.3	33
1648	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Current Infectious Disease Reports, 2016, 18, 22.	3.0	14
1649	Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles. Journal of Medicinal Chemistry, 2016, 59, 6293-6302.	6.4	10
1650	Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. Journal of Medical Virology, 2016, 88, 1659-1671.	5.0	23
1651	Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. Drug Metabolism and Disposition, 2016, 44, 1164-1173.	3.3	14
1652	Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. Experimental and Therapeutic Medicine, 2016, 11, 619-624.	1.8	55
1653	Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon and Cytokine Research, 2016, 36, 635-643.	1.2	9
1655	Systematic review: current concepts and challenges for the directly acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1276-1292.	3.7	124
1656	Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1628-1637.	2.8	10

#	ARTICLE	IF	CITATIONS
1657	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <scp>HCV</scp> genotype 1â€infectd treatmentâ€naive patients. Liver International, 2016, 36, 189-197.	3.9	23
1658	Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. Journal of Interferon and Cytokine Research, 2016, 36, 358-366.	1.2	6
1660	Why is viral eradication so important in patients with HCV-related cirrhosis?. Antiviral Therapy, 2016, 22, 1-12.	1.0	9
1661	Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Scientific Reports, 2016, 6, 20310.	3.3	88
1662	Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evidence-Based Medicine, 2016, 21, 208-213.	0.6	15
1663	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Scientific Reports, 2016, 6, 22995.	3.3	7
1665	Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis. Antiviral Therapy, 2017, 22, 369-379.	1.0	14
1666	Telaprevir: From Drug Discovery to the Manufacture of Drug Substance. ACS Symposium Series, 2016, , 281-323.	0.5	1
1667	Chronic Hepatitis B, C, and D. Microbiology Spectrum, 2016, 4, .	3.0	2
1668	Resistance-Associated Variants in HCV Subtypes 1a and 1b Detected by Ion Torrent Sequencing Platform. Antiviral Therapy, 2016, 21, 653-660.	1.0	11
1669	Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals. Biomedical Reports, 2016, 4, 664-666.	2.0	1
1670	The discovery of indole derivatives as novel hepatitis C virus inhibitors. European Journal of Medicinal Chemistry, 2016, 116, 147-155.	5.5	18
1671	Interferon lambda 4 genotypes and resistanceâ€associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology, 2016, 63, 63-73.	7.3	50
1672	Hepatitis por el virus C. Medicine, 2016, 12, 484-493.	0.0	0
1673	New combination antiviral for the treatment of hepatitis C. American Journal of Health-System Pharmacy, 2016, 73, 1042-1050.	1.0	3
1675	Endpoints for Infections. , 2016, , 437-450.		0
1676	Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics, 2016, 19, 983-994.	2.1	12
1677	A new flavonoid glycoside from Elsholtzia bodinieri. Natural Product Research, 2016, 30, 2278-2284.	1.8	19

#	ARTICLE	IF	CITATIONS
1678	Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 622-630.	1.5	3
1679	A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. <i>Journal of the National Medical Association</i> , 2016, 108, 24-29.	0.8	30
1680	Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1153-1164.	1.8	15
1681	Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1215-1223.	1.8	53
1682	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.9	1
1683	Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. <i>Gastroenterology Y Hepatology (English Edition)</i> , 2016, 39, 377-384.	0.1	0
1684	Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. <i>International Journal of Infectious Diseases</i> , 2016, 50, 1-5.	3.3	6
1685	First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 776-787.	0.3	15
1686	RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies. <i>Chromatographia</i> , 2016, 79, 1605-1613.	1.3	55
1687	Management of HCV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 96-104.	1.3	5
1688	Safety of direct antiviral agents in the management of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1643-1652.	2.4	36
1689	Global genotype distribution of hepatitis C viral infection among people who inject drugs. <i>Journal of Hepatology</i> , 2016, 65, 1094-1103.	3.7	63
1690	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.	0.3	53
1691	Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. <i>Journal of Medical Virology</i> , 2016, 88, 94-99.	5.0	5
1692	Grazoprevir plus peginterferon and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 80-88.	2.0	14
1693	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	3.9	4
1694	HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. <i>Digestive and Liver Disease</i> , 2016, 48, 1200-1207.	0.9	3
1695	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	2.9	2

#	ARTICLE	IF	CITATIONS
1696	Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. European Journal of Clinical Investigation, 2016, 46, 737-748.	3.4	3
1697	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics, 2016, 17, 1587-1594.	1.3	10
1698	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety, 2016, 15, 85-100.	2.4	27
1699	Diagnostics in hepatitis C: The end of response-guided therapy?. Journal of Hepatology, 2016, 65, S67-S81.	3.7	24
1700	Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. Journal of Antimicrobial Chemotherapy, 2016, 71, 3495-3505.	3.0	24
1701	Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. Journal of Viral Hepatitis, 2016, 23, 496-505.	2.0	36
1702	Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. International Journal of Infectious Diseases, 2016, 53, 46-51.	3.3	2
1703	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. , 2016, , 225-241.		0
1705	Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136.		1
1706	ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). Antiviral Therapy, 2016, 22, 461-469.	1.0	0
1707	A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. Medicine (United States), 2016, 95, e5327.	1.0	8
1708	Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. Antiviral Therapy, 2016, 21, 567-577.	1.0	5
1709	The era of first direct-acting antiviral agents: What did we learn?. Clinical Liver Disease, 2016, 8, 72-75.	2.1	1
1710	High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. Antiviral Therapy, 2016, 21, 489-494.	1.0	6
1711	Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon-ribavirin combined therapy. Egyptian Liver Journal, 2016, 6, 7-15.	0.6	0
1712	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. Medicine (United States), 2016, 95, e5048.	1.0	32
1713	Chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2016, 28, 164-172.	1.6	3
1714	The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. European Journal of Gastroenterology and Hepatology, 2016, 28, 173-180.	1.6	18

#	ARTICLE	IF	CITATIONS
1715	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015. European Journal of Gastroenterology and Hepatology, 2016, 28, 1253-1257.	1.6	1
1716	Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial. Journal of Viral Hepatitis, 2016, 23, 105-115.	2.0	9
1717	Ritonavir-boosted danoprevir-based regimens in treatment-naïve and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology International, 2016, 10, 478-487.	4.2	3
1718	Management of HCV Infection. , 2016, , 61-78.		0
1719	A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatology, Medicine and Policy, 2016, 1, 2.	1.7	5
1720	Resurrection of response-guided therapy for sofosbuvir combination therapies. Journal of Hepatology, 2016, 65, 462-464.	3.7	5
1721	Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. Gastroenterology, 2016, 39, 377-384.	0.5	0
1722	Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal of Hepatology, 2016, 65, 259-265.	3.7	22
1723	A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. Vaccine, 2016, 34, 2821-2833.	3.8	8
1724	Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. SpringerPlus, 2016, 5, 518.	1.2	4
1725	Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. Infectious Diseases and Therapy, 2016, 5, 113-124.	4.0	2
1726	New directions for protease inhibitors directed drug discovery. Biopolymers, 2016, 106, 563-579.	2.4	26
1727	Effectiveness of first-generation HCV protease inhibitors. European Journal of Gastroenterology and Hepatology, 2016, 28, 37-41.	1.6	2
1728	Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. Future Virology, 2016, 11, 39-46.	1.8	3
1729	How to Treat Patients with Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis. Current Hepatology Reports, 2016, 15, 60-66.	0.9	1
1730	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatology International, 2016, 10, 258-266.	4.2	9
1731	New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology, 2016, 9, 287-302.	3.1	31
1732	Pediatric liver diseases: current challenges and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 255-265.	3.0	21

#	ARTICLE	IF	CITATIONS
1734	New HCV Therapies and Liver Transplantation. Transplantation, 2016, 100, 260-261.	1.0	5
1735	Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. Laboratory Medicine, 2016, 47, 112-118.	1.2	4
1736	Optimum predictors of therapeutic outcome in HCV patients in Pakistan. Journal of Medical Virology, 2016, 88, 100-108.	5.0	8
1737	Optimizing HCV treatment “Moving beyond the cost conundrum. Journal of Hepatology, 2016, 65, 222-225.	3.7	9
1738	5-Carba-pterocarpens: A new scaffold with anti-HCV activity. European Journal of Medicinal Chemistry, 2016, 112, 33-38.	5.5	8
1739	A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C. Organic Letters, 2016, 18, 1394-1397.	4.6	10
1740	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs, 2016, 25, 557-572.	4.1	19
1741	Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics, 2016, 34, 551-567.	3.3	74
1742	Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. Journal of Hepatology, 2016, 64, 807-812.	3.7	26
1743	Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 111-116.	2.8	31
1744	Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Internal Medicine, 2016, 176, 65.	5.1	118
1745	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology, 2016, 64, 486-504.	3.7	389
1746	Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 285-294.	1.4	14
1747	SUMO1 depletion prevents lipid droplet accumulation and HCV replication. Archives of Virology, 2016, 161, 141-148.	2.1	10
1748	Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals. Journal of Cutaneous Medicine and Surgery, 2016, 20, 58-66.	1.2	14
1749	Feasibility of parameter estimation in hepatitis C viral dynamics models. Journal of Inverse and Ill-Posed Problems, 2017, 25, 69-80.	1.0	9
1750	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Management Science, 2017, 20, 16-32.	2.6	14
1751	Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 229-236.	2.8	61

#	ARTICLE	IF	CITATIONS
1752	25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. United European Gastroenterology Journal, 2017, 5, 69-75.	3.8	10
1753	Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection. Journal of Pharmacy Practice, 2017, 30, 154-161.	1.0	6
1754	Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Education and Behavior, 2017, 44, 113-122.	2.5	6
1755	Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. Journal of Advanced Research, 2017, 8, 131-137.	9.5	15
1756	Hepatitis C: efficacy and safety in real life. Liver International, 2017, 37, 26-32.	3.9	43
1757	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. Journal of Clinical Microbiology, 2017, 55, 1131-1139.	3.9	15
1758	Anti-HCV Activity from Semi-purified Methanolic Root Extracts of <i>Valeriana wallichii</i> . Phytotherapy Research, 2017, 31, 433-440.	5.8	20
1759	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Research, 2017, 142, 83-122.	4.1	135
1760	Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clinical Transplantation, 2017, 31, e12941.	1.6	25
1761	Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. Addiction, 2017, 112, 1290-1299.	3.3	42
1762	Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Review of Gastroenterology and Hepatology, 2017, 11, 593-601.	3.0	6
1763	High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection, 2017, 23, 775.e1-775.e6.	6.0	11
1764	Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. Clinical Drug Investigation, 2017, 37, 647-657.	2.2	4
1765	Chronic hepatitis. , 2017, , 1058-1064.e2.		0
1766	The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2017, 29, 759-766.	1.6	14
1767	ITPA gene polymorphism (<i>94C>A</i>) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. Journal of Medical Virology, 2017, 89, 1823-1829.	5.0	6
1768	Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. BMC Infectious Diseases, 2017, 17, 260.	2.9	20
1769	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery, 2017, 12, 635-642.	5.0	13

#	ARTICLE	IF	CITATIONS
1770	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.	2.8	6
1771	Hepatitis B and C. <i>Pediatric Clinics of North America</i> , 2017, 64, 641-658.	1.8	31
1772	Hepatitis C infection. <i>Nurse Practitioner</i> , 2017, 42, 14-23.	0.3	1
1773	Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1801-1809.	2.9	7
1774	The Management of Anemia in Patients with HCV Treated with DAA. <i>ARS Medica Tomitana</i> , 2017, 23, 62-65.	0.1	0
1775	Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5699-5716.	6.4	36
1776	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017, 18, 126-134.	2.0	31
1777	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2141-2149.	2.3	4
1778	Evaluation of the Abbott RealTime HCV genotype II plus RUO (PLUS) assay with reference to core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2017, 90, 26-31.	3.1	12
1779	Prevalence of Sofosbuvir Resistance-Associated Variants in Brazilian and Worldwide NS5B Sequences of Genotype-1 HCV. <i>Antiviral Therapy</i> , 2017, 22, 447-451.	1.0	13
1780	Protease Inhibitor Resistance. , 2017, , 21-40.		0
1781	Treatment optimization for HIV/HCV co-infected patients. <i>Therapeutic Advances in Infectious Disease</i> , 2017, 4, 18-36.	1.8	13
1782	Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 559-567.	3.0	10
1783	Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 68-73.	3.2	15
1784	Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. <i>Hepatology Research</i> , 2017, 47, 1147-1154.	3.4	2
1785	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 853-861.	2.9	4
1786	Functionalized triazines as potent HCV entry inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1089-1093.	2.2	4
1787	Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. <i>Journal of Clinical Microbiology</i> , 2017, 55, 504-509.	3.9	15

#	ARTICLE	IF	CITATIONS
1788	Time to viral suppression is not related to achievement of <scp>SVR</scp>12 in <scp>HCV GT</scp>1&Einfected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. Journal of Viral Hepatitis, 2017, 24, 280-286.	2.0	8
1789	A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (<i>S</i>)-1-((<i>R</i>)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-<i>N</i>-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. Journal of Medicinal Chemistry, 2017, 60, 228-247.	4.1	1
1790	Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 470-479.	1.3	9
1791	Vedoprevir in the management of hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2017, 26, 1399-1402.	4.1	2
1792	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. International Journal of Drug Policy, 2017, 47, 107-116.	3.3	114
1793	Direct-acting antivirals for chronic hepatitis C. The Cochrane Library, 2017, 2017, CD012143.	2.8	56
1794	Current treatment status and barriers for patients with chronic HCV infection in mainland China. Medicine (United States), 2017, 96, e7885.	1.0	18
1795	Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. Drugs in R and D, 2017, 17, 557-567.	2.2	3
1796	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterolog&A Y Hepatolog&Aa (English Edition), 2017, 40, 433-446.	0.1	7
1797	An&Ailisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C cr&A3nica: antes y despu&A©s del acceso a los agentes antivirales de acci&A3n directa en Espa&Aa. Gastroenterolog&A Y Hepatolog&Aa, 2017, 40, 433-446.	0.5	16
1798	Public&E Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. Gastroenterology, 2017, 153, 626-631.	1.3	20
1799	Direct-acting antivirals for chronic hepatitis C. The Cochrane Library, 2017, 6, CD012143.	2.8	74
1800	Single&E Dose and Multiple&E Dose Pharmacokinetics of Vaniprevir in Healthy Men. Clinical and Translational Science, 2017, 10, 480-486.	3.1	1
1801	Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. European Journal of Gastroenterology and Hepatology, 2017, 29, 1149-1154.	1.6	7
1802	Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. Intervirology, 2017, 60, 82-89.	2.8	8
1804	Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Review of Gastroenterology and Hepatology, 2017, 11, 789-795.	3.0	20
1805	Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC Health Services Research, 2017, 17, 288.	2.2	1
1806	Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. European Journal of Health Economics, 2017, 18, 1001-1011.	2.8	22

#	ARTICLE	IF	CITATIONS
1807	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106.	4.7	11
1808	Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 65-82.	1.4	8
1809	Spending on Hepatitis C Antivirals in the United States, 2009–2015. <i>Pharmacotherapy</i> , 2017, 37, 65-70.	2.6	8
1810	Drugs to Treat Viral Hepatitis. , 2017, , 1327-1332.e1.		3
1811	Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1-14.	1.9	10
1812	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 426-438.	7.3	68
1813	Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocytic Inhibitor of the Hepatitis C Virus NS3 Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	4
1814	Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. <i>Lancet, The</i> , 2017, 389, 1268-1272.	13.7	35
1815	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , 2017, 37, 5-18.	3.9	76
1816	Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. <i>Journal of Medical Economics</i> , 2017, 20, 162-170.	2.1	17
1817	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 45-52.	2.8	20
1818	Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 527-539.	2.4	13
1819	Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. <i>Clinical Infectious Diseases</i> , 2017, 64, 92-99.	5.8	18
1820	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 56-65.	1.5	0
1821	Identification of novel inhibitors of HCV NS3 protease genotype 3 subtype B through molecular docking studies of phytochemicals from <i>Boerhavia diffusa</i> L. <i>Medicinal Chemistry Research</i> , 2017, 26, 327-334.	2.4	2
1822	From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor. <i>Toxicological Sciences</i> , 2017, 155, 348-362.	3.1	6
1825	Viral and host factors associated with outcomes of hepatitis C virus infection. <i>Molecular Medicine Reports</i> , 2017, 15, 2909-2924.	2.4	25
1826	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017, 16, 312-317.	1.5	1

#	ARTICLE	IF	CITATIONS
1827	Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections. , 2017, , .		0
1828	Approaches and Considerations for the Successful Treatment of HCV Infection. , 2017, , .		0
1829	Hepatitis C treatment: where are we now?. International Journal of General Medicine, 2017, Volume 10, 39-52.	1.8	86
1830	Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS ONE, 2017, 12, e0169401.	2.5	25
1831	Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS ONE, 2017, 12, e0184127.	2.5	16
1832	Rapid and large-scale implementation of HCV treatment advances in France, 2007â€“2015. BMC Infectious Diseases, 2017, 17, 784.	2.9	7
1833	Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. , 0, , .		3
1834	The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 595-607.	1.9	3
1835	Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Therapeutics and Clinical Risk Management, 2017, Volume 13, 59-64.	2.0	5
1836	Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. Journal of General Virology, 2017, 98, 962-976.	2.9	6
1837	Current Treatment of Chronic HepatitisÂC. , 2017, , 781-789.		1
1838	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opinion on Pharmacotherapy, 2018, 19, 451-456.	1.8	3
1839	Linear Discriminant Analysis for the <i>in Silico&/i> Discovery of Mechanism-Based Reversible Covalent Inhibitors of a Serine Protease: Application of Hydration Thermodynamics Analysis and Semi-empirical Molecular Orbital Calculation. Chemical and Pharmaceutical Bulletin, 2018, 66, 399-409.	1.3	1
1840	Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Internal and Emergency Medicine, 2018, 13, 775-790.	2.0	4
1841	Alcohol attenuates antiâ€“HCV function of IFNâ€“1 through upâ€“regulation of PLASy expression in human hepatic cells. Journal of Medical Virology, 2018, 90, 1112-1120.	5.0	2
1842	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Infectious Diseases, 2018, 217, 1761-1769.	4.0	11
1843	Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 219-227.	3.3	18
1844	Uptake of directâ€“acting antiviral treatment for chronic hepatitis C in Australia. Journal of Viral Hepatitis, 2018, 25, 640-648.	2.0	68

#	ARTICLE	IF	CITATIONS
1845	Treatment of hepatitis C virus with direct-acting antivirals: Practical aspects and current situation. <i>Revista Clínica Española</i> , 2018, 218, 29-37.	0.5	1
1846	Treatment of hepatitis C in special populations. <i>Journal of Gastroenterology</i> , 2018, 53, 591-605.	5.1	26
1847	Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>Gastroenterología y Hepatología</i> , 2018, 41, 2-11.	0.5	14
1848	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 483-491.	3.3	8
1849	Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2621-2631.	3.0	18
1850	The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. <i>Uppsala Journal of Medical Sciences</i> , 2018, 123, 50-56.	0.9	6
1851	Development of Stability Indicating HPLC-UV Method for Determination of Daclatasvir and Characterization of Forced Degradation Products. <i>Chromatographia</i> , 2018, 81, 785-797.	1.3	25
1852	Biocatalysis for synthesis of pharmaceuticals. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1252-1274.	3.0	127
1853	Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 132-137.	1.1	3
1854	Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials. <i>Hepatology</i> , 2018, 67, 524-533.	7.3	18
1855	Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2018, 90, 907-918.	5.0	15
1856	Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. <i>Revista Clínica Española</i> , 2018, 218, 29-37.	0.6	4
1857	Management of Chronic Hepatitis C in End-stage Renal Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 287-294.	2.2	2
1858	4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium Toluene-4-sulfonate (DMT/NMM/TsO ₃ ⁺) Universal Coupling Reagent for Synthesis in Solution. <i>Helvetica Chimica Acta</i> , 2018, 101, e1700187.	1.6	10
1859	Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. <i>Annals of Hepatology</i> , 2018, 17, 18-32.	1.5	28
1861	Design and Analysis of a Novel 6-URS Self-Reconfigurable All-Dimensional Walking Robot. , 2018, , .		0
1862	Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance. <i>Current Drug Metabolism</i> , 2018, 19, 215-223.	1.2	5
1864	Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881235.	3.2	9

#	ARTICLE	IF	CITATIONS
1865	The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching. <i>European Surgical Research</i> , 2018, 59, 380-390.	1.3	12
1866	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580.	2.9	2
1867	Expression of Duplex shRNAs through a Lentiviral Vector against Cellular and Viral Genes Inflicts Sustained Inhibition of Hepatitis C Virus Replication. <i>Intervirolgy</i> , 2018, 61, 79-91.	2.8	1
1868	Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 14-20.	0.9	2
1869	Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 106-115.	0.9	1
1870	Epidemiology and Elimination of HCV-Related Liver Disease. <i>Viruses</i> , 2018, 10, 545.	3.3	48
1871	Expert opinion on the management of hepatitis C infection in Kuwait. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 117-132.	2.5	2
1872	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. <i>Immunological Reviews</i> , 2018, 285, 55-71.	6.0	11
1873	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	2.0	12
1874	Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 73-85.	2.5	2
1875	First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 146-154.	0.9	2
1876	Transmission genetics of drug-resistant hepatitis C virus. <i>ELife</i> , 2018, 7, .	6.0	7
1877	Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression. <i>Scientific Reports</i> , 2018, 8, 8676.	3.3	7
1878	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. <i>Pharmacogenomics</i> , 2018, 19, 979-995.	1.3	2
1879	Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2018, 41, 2-11.	0.1	0
1880	Hepatitis C Virus: Viral Quasispecies and Genotypes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 23.	4.1	53
1881	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.	1.5	23
1882	Gallic Acid as a Putative Antioxidant in Usage Against Liver Disease. , 2018, , 317-322.		2

#	ARTICLE	IF	CITATIONS
1883	Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e29.	1.1	2
1884	Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 649-657.	3.3	4
1885	Clinical Aspects of Liver Transplantation. , 2018, , 605-627.		0
1886	Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. Progress in Medicinal Chemistry, 2018, 57, 113-233.	10.4	21
1887	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. Health Information and Libraries Journal, 2019, 36, 318-340.	2.5	3
1888	Chronic hepatitis C infection: how much are physicians aware of?. Przegląd Gastroenterologiczny, 2019, 14, 112-120.	0.7	1
1889	<p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>. Drug Design, Development and Therapy, 2019, Volume 13, 2565-2577.	4.3	20
1890	Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections. Topics in Medicinal Chemistry, 2019, , 293-315.	0.8	2
1891	Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975.		2
1892	â€œHere Today, Gone Tomorrowâ€or â€œHere Today, Stay a Long Whileâ€ The Divergent Paths of Two Host Factors Important in Viral Infections. Clinical Therapeutics, 2019, 41, 1907-1911.	2.5	3
1893	Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A singleâ€centre experience. Haemophilia, 2019, 25, 1028-1034.	2.1	8
1894	Synthesis of 1, 2-dihydroazete-3-methyl ester. IOP Conference Series: Earth and Environmental Science, 2019, 252, 022084.	0.3	0
1895	The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir. Topics in Medicinal Chemistry, 2019, , 389-413.	0.8	9
1896	The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry, 2019, , 97-113.	0.8	5
1897	Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)â€Viremic Donors Into HCVâ€Negative Recipients: Outcomes Following Liver Transplant of HCVâ€Viremic Donors. Hepatology, 2019, 69, 2381-2395.	7.3	103
1898	Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Directâ€Acting Antiviral Era. Liver Transplantation, 2019, 25, 598-609.	2.4	70
1899	Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology, 2019, 18, 137-143.	1.5	1
1900	Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in Health Regional Issues, 2019, 20, 95-102.	1.2	2

#	ARTICLE	IF	CITATIONS
1901	Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. <i>Harm Reduction Journal</i> , 2019, 16, 29.	3.2	6
1902	A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. <i>Journal of Chemotherapy</i> , 2019, 31, 274-283.	1.5	1
1903	Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?. <i>Cells</i> , 2019, 8, 305.	4.1	30
1904	O olho na hepatite C: uma revisÃ£o. <i>Arquivos Brasileiros De Oftalmologia</i> , 2019, 82, 161-167.	0.5	3
1905	Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. <i>Statistics in Medicine</i> , 2019, 38, 2505-2523.	1.6	13
1906	Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 700-706.	1.5	6
1907	Review on chemogenomic approaches towards hepatitis C viral targets. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12167-12181.	2.6	4
1908	Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals â€” a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 854-864.	1.6	13
1909	Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. <i>Canadian Liver Journal</i> , 2019, 2, 91-107.	0.9	0
1910	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. <i>Cells</i> , 2019, 8, 317.	4.1	13
1911	An update on the management of hepatitis C virus and human immunodeficiency virus co-infection. <i>Future Virology</i> , 2019, 14, 185-195.	1.8	0
1912	A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. <i>BMC Nephrology</i> , 2019, 20, 36.	1.8	7
1913	<i>In Vitro</i> Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	10
1914	Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach. <i>PLoS ONE</i> , 2019, 14, e0209587.	2.5	7
1915	A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 245-268.	5.5	5
1917	A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 382-388.	1.6	3
1919	The Evolution of Clinical Trials for Hepatitis C. <i>Topics in Medicinal Chemistry</i> , 2019, , 187-235.	0.8	0
1921	Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0218759.	2.5	15

#	ARTICLE	IF	CITATIONS
1922	Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. <i>Pathogens</i> , 2019, 8, 236.	2.8	9
1923	Treatment of Hepatitis C Virus. <i>Orthopaedic Nursing</i> , 2019, 38, 273-277.	0.4	0
1924	HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v2-v4.	3.0	0
1925	Weight loss changed gait kinematics in individuals with obesity and knee pain. <i>Gait and Posture</i> , 2019, 68, 461-465.	1.4	33
1926	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019, 39, 826-834.	3.9	15
1927	Evolution of efficacious pangenotypic hepatitis C virus therapies. <i>Medicinal Research Reviews</i> , 2019, 39, 1091-1136.	10.5	13
1928	A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment?. <i>Women and Health</i> , 2019, 59, 181-195.	1.0	3
1929	Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105527.	2.5	5
1930	Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. <i>Current Drug Safety</i> , 2020, 15, 53-60.	0.6	4
1932	Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study. <i>Annals of Pharmacotherapy</i> , 2020, 54, 113-121.	1.9	5
1933	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	3.7	30
1934	Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. <i>Digestive Diseases</i> , 2020, 38, 137-142.	1.9	19
1935	Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 30-36.	0.9	24
1936	Management of Hepatitis C in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 785-790.	1.3	2
1937	Hepatocellular carcinoma: old friends and new tricks. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1898-1907.	7.7	154
1938	Screening for Hepatitis C Virus: How Universal Is Universal?. <i>Clinical Therapeutics</i> , 2020, 42, 1434-1441.	2.5	7
1939	Post-exposure prophylaxis for Blood-Borne Viral (BBV) Infections. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 83-91.	1.1	3
1940	Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-4.	1.9	6

#	ARTICLE	IF	CITATIONS
1941	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. Journal of Infectious Diseases, 2020, 222, S745-S757.	4.0	9
1942	Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication“from IFN based era to IFN-free DAA era. Hepatobiliary Surgery and Nutrition, 2020, 9, 227-229.	1.5	0
1943	Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. Journal of Immunology Research, 2020, 2020, 1-11.	2.2	3
1944	<p><p>Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure“Activity Relationships</p></p>. Drug Design, Development and Therapy, 2020, Volume 14, 757-771.	4.3	3
1945	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	3.3	7
1946	Frequency of Potential Drug“Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infectious Diseases, 2020, 7, ofaa040.	0.9	17
1947	Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infectious Diseases, 2020, 20, 264.	2.9	4
1948	Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. Journal of Clinical Medicine, 2020, 9, 1030.	2.4	20
1949	Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Biomedicine and Pharmacotherapy, 2021, 133, 111035.	5.6	24
1950	Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 185-198.	4.5	9
1951	Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors. Bulletin of the National Research Centre, 2021, 45, .	1.8	8
1952	Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Advances in Experimental Medicine and Biology, 2021, 1322, 139-157.	1.6	5
1953	Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. Transplantation, 2021, 105, 2482-2489.	1.0	2
1954	Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. Anais Da Academia Brasileira De Ciencias, 2021, 93, e20200632.	0.8	2
1955	A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. PLoS ONE, 2021, 16, e0245962.	2.5	43
1956	Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Medica, 2021, 112, 162-174.	0.9	12
1957	Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir. Organic Process Research and Development, 2021, 25, 838-848.	2.7	6
1958	Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. The Lancet Regional Health - Western Pacific, 2021, 10, 100129.	2.9	6

#	ARTICLE	IF	CITATIONS
1959	Blinding in Clinical Trials for Chronic Liver Diseases. <i>Seminars in Liver Disease</i> , 2021, 41, 163-171.	3.6	1
1960	In Silico Design, Drug-Likeness and ADMET Properties Estimation of Some Substituted Thienopyrimidines as HCV NS3/4A Protease Inhibitors. <i>Chemistry Africa</i> , 2021, 4, 563-574.	2.4	6
1961	Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. <i>Kidney360</i> , 2021, 2, 1316-1325.	2.1	0
1962	A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. <i>New Microbes and New Infections</i> , 2021, 42, 100895.	1.6	9
1963	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , 2021, 27, 4603-4638.	3.3	21
1964	Planning the hepatitis C virus elimination in Cyprus: A modeling study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5219-5231.	3.3	1
1965	Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M ^{pro} for the treatment of COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12848-12862.	3.5	5
1966	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.	8.9	3
1968	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. <i>Methods in Molecular Biology</i> , 2019, 1911, 3-32.	0.9	80
1969	Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 107-140.	1.8	2
1970	<i>Neue Arzneimittel</i> 2011. , 2012, , 43-126.		1
1971	Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , 2014, 193, 113-133.	1.8	16
1972	HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. , 2016, , 257-285.		1
1973	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. , 2017, , 553-627.		2
1974	Discovery of Boceprevir and Narlaprevir: Ketoamide-Derived HCV NS3 Serine Protease Inhibitors for the Treatment of Chronic Hepatitis C. , 2017, , 583-608.		1
1975	<i>Liver Disease</i> . , 2013, , 144-168.		1
1976	<i>Viruses and Human Cancer</i> . , 2014, , 154-168.e7.		1
1977	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	3.1	6

#	ARTICLE	IF	CITATIONS
1978	Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	1.6	34
1979	New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. <i>Journal of General Virology</i> , 2018, 99, 97-102.	2.9	6
1982	Trends in <scp>HCV</scp> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <scp>HIV</scp> Cohort Study. <i>Liver International</i> , 2018, 38, 424-431.	3.9	22
1983	Hepatitis C Virus. , 0, , 1599-1616.		2
1984	Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. <i>F1000Research</i> , 2016, 5, 367.	1.6	11
1985	Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. <i>F1000Research</i> , 2016, 5, 223.	1.6	4
1986	Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. <i>F1000Research</i> , 0, 5, 223.	1.6	3
1987	Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010. <i>Universal Journal of Medical Science</i> , 2016, 4, 10-20.	0.4	1
1988	Simeprevir for the treatment of genotype 1 chronic hepatitis C virus. <i>Drugs of Today</i> , 2013, 49, 769.	1.1	14
1989	Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. <i>PLoS Computational Biology</i> , 2013, 9, e1002959.	3.2	83
1990	Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. <i>PLoS ONE</i> , 2012, 7, e30796.	2.5	78
1991	The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function. <i>PLoS ONE</i> , 2012, 7, e39163.	2.5	41
1992	HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652.	2.5	78
1993	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048.	2.5	23
1994	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285.	2.5	91
1995	Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil. <i>PLoS ONE</i> , 2013, 8, e67734.	2.5	6
1996	Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?. <i>PLoS ONE</i> , 2013, 8, e70319.	2.5	21
1997	Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e71262.	2.5	11

#	ARTICLE	IF	CITATIONS
1998	HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil. PLoS ONE, 2014, 9, e86413.	2.5	30
1999	Impact of Donor and Recipient Single Nucleotide Polymorphisms of IL28B rs8099917 in Living Donor Liver Transplantation for Hepatitis C. PLoS ONE, 2014, 9, e90462.	2.5	4
2000	Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. PLoS ONE, 2014, 9, e91822.	2.5	30
2001	Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS ONE, 2014, 9, e94542.	2.5	33
2002	Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis. PLoS ONE, 2014, 9, e100128.	2.5	14
2003	HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e103748.	2.5	3
2004	Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. PLoS ONE, 2014, 9, e110284.	2.5	5
2005	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE, 2014, 9, e110857.	2.5	15
2006	Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE, 2014, 9, e112592.	2.5	20
2007	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2015, 10, e0137852.	2.5	5
2008	24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140853.	2.5	2
2009	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS ONE, 2015, 10, e0141660.	2.5	13
2010	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.	2.5	5
2011	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS ONE, 2016, 11, e0145409.	2.5	6
2012	Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS ONE, 2016, 11, e0150299.	2.5	2
2013	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731.	2.5	5
2014	Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098.	2.5	16
2015	Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study. PLoS ONE, 2016, 11, e0159976.	2.5	7

#	ARTICLE	IF	CITATIONS
2016	Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS ONE, 2016, 11, e0161821.	2.5	8
2017	A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PLoS ONE, 2016, 11, e0164563.	2.5	7
2018	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS ONE, 2016, 11, e0166631.	2.5	5
2019	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infectionsâ€”A Scandinavian real-life study. PLoS ONE, 2017, 12, e0179764.	2.5	28
2020	Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. PLoS Pathogens, 2016, 12, e1005894.	4.7	31
2021	Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. Journal of Clinical and Translational Hepatology, 2014, 2, 1-6.	1.4	20
2022	The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease. Journal of Clinical and Translational Hepatology, 2013, 1, 22-32.	1.4	27
2023	Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. Journal of Clinical and Translational Hepatology, 2014, 2, 124-33.	1.4	17
2024	Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. Journal of Clinical and Translational Hepatology, 2015, 3, 36-41.	1.4	8
2025	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	1.4	18
2026	Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. Gastroenterology Research, 2018, 11, 31-35.	1.3	2
2027	Therapeutic Response of Triple Drug Therapy in Hepatitis C Infection. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, .	0.2	1
2028	Benefits of Curing Hepatitis C Infection. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 85-90.	0.9	15
2032	EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION â€œUNDER REAL LIFEâ€œ CONDITIONS. Medicinos Teorija Ir Praktika, 2014, 21, 23-32.	0.0	1
2033	HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. , 2017, , 45-66.		18
2034	Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. Revista Espanola De Enfermedades Digestivas, 2015, 107, 591-7.	0.3	5
2035	Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1. Journal of Gastroenterology and Hepatology Research, 2014, 3, 1335-1339.	0.2	6
2036	The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget, 2017, 8, 41764-41777.	1.8	28

#	ARTICLE	IF	CITATIONS
2037	Treating hepatitis C – what’s new?. Australian Prescriber, 2015, 38, 191-197.	1.0	7
2038	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology, 2017, 30, 327-343.	0.6	6
2039	Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. Clinical Pharmacokinetics, 2012, 51, 619-628.	3.5	3
2040	Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design. Current Pharmaceutical Design, 2014, 20, 694-703.	1.9	10
2041	Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. Current Drug Safety, 2019, 14, 67-71.	0.6	1
2042	A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. Open Medicine Journal, 2016, 3, 70-78.	0.7	1
2043	"Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. JMIR Research Protocols, 2015, 4, e13.	1.0	6
2044	Hepatitis C cr�nica: aspectos cl�nicos, serol�gicos y de tratamiento en dos centros de atenci�n en Bogot�, Colombia. Revista Colombiana De Gastroenterologia, 2014, 29, 424-432.	0.2	2
2045	Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C. Jurnal Infektologii, 2019, 11, 65-71.	0.3	1
2046	Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-na�ve chronic patients from Romania. Romanian Journal of Laboratory Medicine, 2018, 26, 443-449.	0.2	1
2047	Assessing the Population Impact of Published Intervention Studies. NAM Perspectives, 2015, 5, .	2.9	1
2048	Current Standards in the Treatment of Chronic Hepatitis C. Deutsches Ärztblatt International, 2012, 109, 352-8.	0.9	20
2049	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-410.	2.8	130
2050	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clinical and Molecular Hepatology, 2013, 19, 60.	8.9	8
2051	KASL clinical practice guidelines: Management of Hepatitis C. Clinical and Molecular Hepatology, 2014, 20, 89.	8.9	35
2052	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clinical and Molecular Hepatology, 2015, 21, 358.	8.9	12
2053	Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clinical and Molecular Hepatology, 2016, 22, 259-266.	8.9	8
2054	Recent trends in the treatment of chronic hepatitis C. The Korean Journal of Hepatology, 2012, 18, 22.	1.5	12

#	ARTICLE	IF	CITATIONS
2055	Therapy Implications of Hepatitis C Virus Genetic Diversity. <i>Viruses</i> , 2021, 13, 41.	3.3	32
2056	New Antiviral Agents for Hepatitis C. <i>F1000 Biology Reports</i> , 2012, 4, 5.	4.0	30
2057	Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 62-82.	1.2	2
2058	Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 239-253.	1.2	9
2059	Current treatment options and response rates in children with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 99.	3.3	41
2060	Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012, 18, 5514.	3.3	21
2061	Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 6060.	3.3	28
2062	Telaprevir/boceprevir era: From bench to bed and back. <i>World Journal of Gastroenterology</i> , 2012, 18, 6183.	3.3	22
2063	Sofosbuvir and ABT-450: Terminator of hepatitis C virus?. <i>World Journal of Gastroenterology</i> , 2013, 19, 3199.	3.3	23
2064	Prevalence of hepatitis C infection among intravenous drug users in Shanghai. <i>World Journal of Gastroenterology</i> , 2013, 19, 5320.	3.3	10
2065	Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2013, 19, 6947.	3.3	11
2066	Scotomas in molecular virology and epidemiology of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 7910.	3.3	10
2067	Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. <i>World Journal of Gastroenterology</i> , 2013, 19, 8940.	3.3	33
2068	Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8963.	3.3	41
2069	Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014, 20, 2839.	3.3	9
2070	Chronic hepatitis C genotype 1 virus: Who should wait for treatment?. <i>World Journal of Gastroenterology</i> , 2014, 20, 2867.	3.3	6
2071	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <i>World Journal of Gastroenterology</i> , 2014, 20, 2913.	3.3	28
2072	Challenges of recurrent hepatitis C in the liver transplant patient. <i>World Journal of Gastroenterology</i> , 2014, 20, 3391.	3.3	7

#	ARTICLE	IF	CITATIONS
2073	How hepatitis C virus invades hepatocytes: The mystery of viral entry. World Journal of Gastroenterology, 2014, 20, 3457.	3.3	51
2074	Emerging therapeutic options for the management of hepatitis C infection. World Journal of Gastroenterology, 2014, 20, 7079.	3.3	10
2075	Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World Journal of Gastroenterology, 2014, 20, 9245-52.	3.3	10
2076	Recurrent hepatitis C after liver transplant. World Journal of Gastroenterology, 2014, 20, 10668.	3.3	17
2077	Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World Journal of Gastroenterology, 2014, 20, 10984.	3.3	20
2078	Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 12722.	3.3	24
2079	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World Journal of Gastroenterology, 2014, 20, 13146.	3.3	20
2080	New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology, 2014, 20, 15965.	3.3	14
2081	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World Journal of Gastroenterology, 2014, 20, 16726.	3.3	2
2082	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. World Journal of Gastroenterology, 2015, 21, 3013.	3.3	12
2083	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World Journal of Gastroenterology, 2015, 21, 4696-4706.	3.3	4
2084	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World Journal of Gastroenterology, 2015, 21, 5647.	3.3	13
2085	Management of hepatitis C in patients with chronic kidney disease. World Journal of Gastroenterology, 2015, 21, 408.	3.3	33
2086	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology, 2015, 21, 7412.	3.3	42
2087	Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology, 2015, 21, 8293.	3.3	24
2088	Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 10215-10223.	3.3	8
2089	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World Journal of Gastroenterology, 2015, 21, 10749.	3.3	23
2090	Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology, 2015, 21, 10760.	3.3	24

#	ARTICLE	IF	CITATIONS
2091	Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World Journal of Gastroenterology, 2015, 21, 12430.	3.3	4
2092	Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World Journal of Gastroenterology, 2015, 21, 1972.	3.3	9
2093	Retreatment with peginterferon and ribavirin in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 1994.	3.3	2
2094	Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World Journal of Gastroenterology, 2016, 22, 1393.	3.3	24
2095	Alcoholic liver disease and hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 1411.	3.3	41
2096	Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model. World Journal of Gastroenterology, 2017, 23, 5158.	3.3	3
2097	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World Journal of Gastroenterology, 2017, 23, 8120-8127.	3.3	6
2098	Mononuclear phagocyte system in hepatitis C virus infection. World Journal of Gastroenterology, 2018, 24, 4962-4973.	3.3	10
2099	Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 2020, 26, 2931-2947.	3.3	11
2100	Protease inhibitors: Silver bullets for chronic hepatitis C infection?. Cleveland Clinic Journal of Medicine, 2012, 79, 213-222.	1.3	22
2101	Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. Materiales De Construccion, 1957, 7, 131.	0.7	1
2102	Protease Inhibitor and Metabolic Alteration. International Journal of Morphology, 2012, 30, 439-444.	0.2	3
2103	The new era of hepatitis C virus therapy. Saudi Journal of Gastroenterology, 2015, 21, 345.	1.1	2
2104	SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi Journal of Gastroenterology, 2016, 22, 25.	1.1	21
2105	Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World Journal of Hepatology, 2013, 5, 120.	2.0	25
2106	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 332.	2.0	2
2107	Complementary and alternative medications in hepatitis C infection. World Journal of Hepatology, 2014, 6, 9.	2.0	7
2108	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World Journal of Hepatology, 2014, 6, 759.	2.0	6

#	ARTICLE	IF	CITATIONS
2109	NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World Journal of Hepatology, 2014, 6, 326.	2.0	9
2110	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World Journal of Hepatology, 2014, 6, 660.	2.0	13
2111	Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World Journal of Hepatology, 2015, 7, 1606.	2.0	3
2112	Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology, 2015, 7, 1617.	2.0	71
2113	New treatment strategies for hepatitis C infection. World Journal of Hepatology, 2015, 7, 2100.	2.0	20
2114	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. World Journal of Hepatology, 2015, 7, 2543.	2.0	11
2115	Comparison of peg-interferon, ribavirin plus telaprevir vs sofosbuvir by propensity score matching. World Journal of Hepatology, 2015, 7, 2841.	2.0	5
2116	Oxidative stress modulation in hepatitis C virus infected cells. World Journal of Hepatology, 2015, 7, 2880.	2.0	45
2117	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World Journal of Hepatology, 2015, 7, 725.	2.0	47
2118	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World Journal of Hepatology, 2015, 7, 806.	2.0	50
2119	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World Journal of Hepatology, 2015, 7, 1133.	2.0	24
2120	Chronic hepatitis C: This and the new era of treatment. World Journal of Hepatology, 2016, 8, 92.	2.0	69
2121	Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World Journal of Hepatology, 2016, 8, 902.	2.0	5
2122	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.	2.0	5
2123	Sofosbuvir treatment and hepatitis C virus infection. World Journal of Hepatology, 2016, 8, 183.	2.0	15
2124	Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology, 2016, 8, 331.	2.0	5
2125	Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World Journal of Hepatology, 2017, 9, 551.	2.0	2
2126	Is the 25-year hepatitis C marathon coming to an end to declare victory?. World Journal of Hepatology, 2017, 9, 921.	2.0	6

#	ARTICLE	IF	CITATIONS
2127	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology, 2017, 9, 352.	2.0	50
2128	Interferons and hepatitis C virus. Swiss Medical Weekly, 2012, 142, w13586.	1.6	23
2129	Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Medical Weekly, 2013, 143, w13793.	1.6	23
2130	The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors. Gut and Liver, 2011, 5, 406-417.	2.9	34
2131	Emerging Therapies for Hepatitis C. Gut and Liver, 2014, 8, 471-479.	2.9	34
2132	Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut and Liver, 2017, 11, 335-348.	2.9	16
2133	Hepatitis C Virus and Antiviral Drug Resistance. Gut and Liver, 2016, 10, 890-895.	2.9	24
2134	Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. Gut and Liver, 2017, 11, 711-720.	2.9	6
2135	Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. Gut and Liver, 2018, 12, 201-207.	2.9	22
2136	Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. Gut and Liver, 2018, 12, 694-703.	2.9	18
2137	Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?. Turkish Journal of Gastroenterology, 2016, 27, 165-172.	1.1	1
2138	Role of IL28B genotype in older hepatitis C virus-infected patients. World Journal of Immunology, 2013, 3, 54.	0.5	3
2139	Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients. Medicine Science, 2014, 3, 1655.	0.1	1
2140	What's new in clinical solid organ transplantation by 2013. World Journal of Transplantation, 2014, 4, 243.	1.6	19
2141	Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World Journal of Virology, 2015, 4, 1.	2.9	22
2142	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World Journal of Virology, 2015, 4, 178.	2.9	4
2143	The changing therapeutic landscape for hepatitis C. Medical Journal of Australia, 2012, 196, 629-632.	1.7	64
2144	Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. Hepatitis Monthly, 2015, 15, e28879.	0.2	2

#	ARTICLE	IF	CITATIONS
2145	Hepatitis C Virus Treatment Revolution: Eastern European Story. Hepatitis Monthly, 2015, 15, e28969.	0.2	9
2146	A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. Hepatitis Monthly, 2018, In Press, .	0.2	1
2147	Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics, 2017, 72, 378-385.	1.5	3
2148	Chronic Hepatitis C. , 2022, , 163-201.		0
2150	Clinical Aspects of Liver Transplantation. , 2011, , 577-598.		0
2152	Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. Journal of the Nepal Medical Association, 2013, 51, .	0.4	1
2153	Peripheral Neuropathy and Central Nervous System Involvement in Cryoglobulinemia. , 2012, , 209-217.		0
2155	Peginterferon, Ribavirin and Anti-viral Triple Therapy. , 2012, , 251-260.		0
2156	Boceprevir and Telaprevir. Hospital Pharmacy, 2011, 46, 779-796.	1.0	0
2158	Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepatitis Monthly, 2011, 11, 918-924.	0.2	7
2159	Viral Liver Diseases. , 2012, , 383-390.		0
2160	Oral Direct-Acting Antiviral Therapy for Hepatitis C. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	0
2161	Treatment of chronic hepatitis C. Journal of the Korean Medical Association, 2012, 55, 1113.	0.3	1
2162	COBAS® AmpliPrep/COBAS® TaqMan® HCV Test. , 2012, , 153-170.		0
2163	Hepatitis C therapy: now more than a coin toss to achieve the cure. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2012, , .	1.4	0
2167	Therapie der chronischen Hepatitis C. Pharma-Kritik (discontinued), 2012, 34, .	0.0	0
2168	Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. Acta Hepatologica Japonica, 2013, 54, 731-740.	0.1	0
2169	Targeting Viral and Host Factors During the Hepatitis C Virus Replication for Efficient Antiviral Treatment. Immuno-gastroenterology, 2013, 2, 162.	0.4	0

#	ARTICLE	IF	CITATIONS
2172	Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Research, 2013, 6, 161-170.	1.3	10
2174	Leber, Gallenwege, Pankreas. , 2013, , 144-169.		0
2175	Emerging therapies in pipeline for chronic hepatitis C. International Journal of Basic and Clinical Pharmacology, 2013, 2, 500.	0.1	0
2179	Retransplantation for HCV-Related Liver Disease. , 2014, , 95-106.		0
2180	Treatment of Hepatitis C Before Liver Transplantation. , 2014, , 1-14.		0
2181	Update on the Development of Anti-Viral Agents Against Hepatitis C. Journal of Clinical and Translational Hepatology, 2013, 1, 9-21.	1.4	2
2182	Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. , 2014, , 65-76.		0
2183	Treatment of Hepatitis C After Liver Transplantation. , 2014, , 45-63.		0
2184	Recent Advancement in the Treatment of Chronic Hepatitis C. Korean Journal of Medicine, 2014, 86, 563.	0.3	0
2185	Real-World Virologic Response Rates and Prediction of Outcomes with Peginterferon Alfa-2a/Ribavirin in Hungarian HCV Genotype 1 Patients. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, .	0.2	0
2186	Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions. North American Journal of Medicine & Science, 2014, 07, 033.	3.8	0
2187	Prevention and Management of Infectious Complications in Kidney Transplant Recipients. , 2014, , 301-318.		1
2188	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
2189	Developments in the treatment of hepatitis C virus infection. , 2014, , 135-144.		0
2190	Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, .	0.1	0
2191	IL28B Genotyping: A Step towards HCV-Personalized Therapy. International Journal of Gastroenterology Research and Practice, 0, , 1-16.	0.0	0
2192	Waiting for Interferon-free Regimens for Chronic Hepatitis C Patients: A Multicenter Observational Study. Viral Hepatitis Journal, 2014, 20, 95-100.	0.1	0
2193	Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries. Journal of Clinical and Translational Hepatology, 2014, 2, 247-52.	1.4	5

#	ARTICLE	IF	CITATIONS
2194	Antiviral Drugs against Hepatitis Viruses. , 2015, , 563-575.e3.		0
2195	Chronische Hepatitis. , 2015, , 1-10.		0
2196	Protease Inhibitor Resistance. , 2015, , 1-17.		0
2197	Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 35-41.	0.2	0
2198	Solid Organ Transplantation. , 2015, , 433-454.		1
2199	HEPATITIS C VIRUS AND HEPATITIS C-INFECTION. Brazilian Journal of Medicine and Human Health, 2015, 3, 19-28.	0.0	0
2203	Estradiol and/or Ibandronate Therapy Ameliorates A Case Series Describing the Outcomes of Treatment in Co-infected Patients with HIV and Hepatitis C on the United States-Mexico Border. British Journal of Medicine and Medical Research, 2016, 15, 1-7.	0.2	0
2204	Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. Journal of Postgraduate Medicine, 2016, 62, 20-25.	0.4	0
2205	Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000248.	0.1	0
2206	Evaluation of serum iron and ferritin in different treatment regimens for chronic hepatitis C virus. IOSR Journal of Pharmacy and Biological Sciences, 2016, 11, 13-19.	0.1	1
2207	Chronic Hepatitis B, C, and D. , 0, , 69-95.		0
2208	Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. Journal of Clinical and Translational Hepatology, 2016, 4, 97-112.	1.4	5
2209	Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. Open Medicine Journal, 2016, 3, 58-69.	0.7	0
2210	Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. Journal of Clinical and Translational Hepatology, 2016, 4, 228-233.	1.4	1
2211	MATHEMATICAL MODELS PREDICTING LEUKOPENIA AND NEUTROPENIA IN PATIENTS WITH CHRONIC HEPATITIS C IN THE BACKGROUND INTERFERON-CONTAINING SCHEMES. Russian Archives of Internal Medicine, 2016, 6, 53-62.	0.2	0
2212	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. Journal of Clinical and Translational Hepatology, 2016, 4, 320-327.	1.4	18
2213	Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000Research, 2016, 5, 223.	1.6	4
2214	Resistance to Cyclophilin Inhibitors. , 2017, , 59-85.		0

#	ARTICLE	IF	CITATIONS
2215	Quasispecies and Drug Resistance. , 2017, , 123-147.		2
2216	Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients. ARS Medica Tomitana, 2017, 23, 47-52.	0.1	0
2217	The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. Journal of Clinical and Translational Hepatology, 2017, 5, 59-66.	1.4	14
2219	Chronic Viral Hepatitis. , 2017, , .		0
2220	The influence of correction of vitamin D deficiency on the formation of the stable virological response during therapy of genotype-1 chronic hepatitis C with PEGylated interferon-alpha-2 and ribavirin. Klinicheskaia Meditsina, 2017, 95, 438-444.	0.1	1
2222	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology, 2017, 6, 59-72.	2.9	7
2223	Treatment of Hepatitis C. , 2018, , 446-463.e3.		0
2224	The Curative HCV Treatments in China. Journal of Biosciences and Medicines, 2018, 06, 42-59.	0.2	0
2225	A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. Experimental and Clinical Transplantation, 2018, 16, 61-67.	0.5	2
2226	Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Experimental and Clinical Transplantation, 2018, 16, 182-190.	0.5	2
2227	Triple Regimen Therapy Response in HCV Patients of Genotype-III. International Journal of Scientific and Engineering Research, 2018, 9, 763-767.	0.1	0
2228	Scientific and Ethical Considerations for Increasing Minority Participation in Clinical Trials. , 0, , .		0
2229	GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. Acta Pharmacologica Sinica, 2018, 39, 1746-1752.	6.1	2
2231	Antiviral therapy of hepatitis C with 1 genotype after liver transplantation. Vestnik Transplantologii I Iskusstvennykh Organov, 2018, 20, 105-115.	0.4	0
2233	Hepatitis C Virus and Innate Interferon Response: Pathogen Biology, Drug Resistance, Novel Drug Targets, and Therapeutic Strategies. , 2019, , 233-249.		0
2234	Therapeutic Apheresis in Critically Ill Patients. , 2019, , 1154-1160.e2.		0
2235	Current issues and perspectives in the therapy of hepatitis C virus infection. Medic Ro, 2019, 6, 46.	0.0	0
2236	Management of Viral Hepatitis C in Children. , 2019, , 163-168.		0

#	ARTICLE	IF	CITATIONS
2237	Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience. Cureus, 2019, 11, e4012.	0.5	1
2238	Planning a Programme of Pre-authorisation Clinical Trials of Medicines for the Treatment of Chronic Hepatitis C. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2019, 9, 6-13.	0.2	1
2239	Chronic hepatitis C: modern condition of the problem. Nephrology (Saint-Petersburg), 2019, 23, 36-46.	0.4	2
2240	Actualización en el tratamiento de la coinfección por VIH y VHC en pacientes adultos. Revista De Investigación Y Educación En Ciencias De La Salud (RIECS), 2019, 4, 71-83.	0.0	0
2242	Hepatitis C Virus Treatment Update. Sohag Medical Journal (SMJ), 2019, .	0.1	0
2244	Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos De Saude Publica, 2020, 36, e00036619.	1.0	0
2245	Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site. Australian Journal of Chemistry, 2020, 73, 212.	0.9	0
2247	Hepatitis C virus treatment complicated by rheumatoid arthritis. Gastroenterology and Hepatology, 2011, 7, 774-6.	0.1	0
2248	Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex. Biotechnology Healthcare, 2011, 8, 26-8.	0.2	1
2249	Advances in the treatment of hepatitis C virus infection. Gastroenterology and Hepatology, 2012, 8, 91-101.	0.1	8
2250	Boceprevir: A new hope against hepatitis C virus. Journal of Pharmacology and Pharmacotherapeutics, 2012, 3, 213-5.	0.4	1
2251	Management of anemia in patients receiving protease inhibitors. Gastroenterology and Hepatology, 2012, 8, 254-6.	0.1	1
2253	Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterology and Hepatology, 2012, 8, 1-16.	0.1	9
2254	Hepatitis C virus and its renal manifestations: a review and update. Gastroenterology and Hepatology, 2012, 8, 434-45.	0.1	25
2256	New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2013, 72, 6-13.	0.4	4
2257	The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents. European Gastroenterology & Hepatology Review, 2012, 1, 33-39.	0.0	2
2258	Hepatitis C treatment & management. Journal of Medicine and Life, 2014, 7, 31-6.	1.3	2
2259	Recurrence of hepatitis C after liver transplantation. Annals of Gastroenterology, 2013, 26, 304-313.	0.6	38

#	ARTICLE	IF	CITATIONS
2260	Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterology and Hepatology, 2012, 8, 727-65.	0.1	4
2261	Protease inhibitor-based therapy for hepatitis C virus infection-why wait?. Gastroenterology and Hepatology, 2012, 8, 674-6.	0.1	0
2262	Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient. Topics in Antiviral Medicine, 2012, 20, 134-8.	0.1	1
2263	Frontiers in the treatment of hepatitis C virus infection. Gastroenterology and Hepatology, 2014, 10, 90-100.	0.1	7
2264	HCV infection treatment: a future full of hope. Gastroenterology and Hepatology From Bed To Bench, 2013, 6, 1-5.	0.6	65
2265	Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P and T, 2014, 39, 345-52.	0.9	12
2268	Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Annals of Gastroenterology, 2015, 28, 55-65.	0.6	39
2269	Hepatitis C screening. Ochsner Journal, 2014, 14, 664-8.	1.1	13
2272	Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P and T, 2015, 40, 256-76.	0.9	40
2274	Is response-guided therapy being applied in the clinical setting? The hepatitis C example. American Health and Drug Benefits, 2015, 8, 22-8.	0.5	2
2276	Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. Annals of Gastroenterology, 2015, 28, 481-6.	0.6	2
2277	Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. International Journal of Organ Transplantation Medicine, 2016, 7, 38-45.	0.5	19
2278	Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. Gastroenterology and Hepatology, 2014, 10, 706-715.	0.1	0
2279	Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. Topics in Antiviral Medicine, 2014, 22, 685-9.	0.1	1
2280	Update of the past year: a review from IDSA 2011. Topics in Antiviral Medicine, 2011, 19, 187-92.	0.1	1
2281	Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Topics in Antiviral Medicine, 2012, 20, 139-45.	0.1	38
2282	Managing adverse effects and complications in completing treatment for hepatitis C virus infection. Topics in Antiviral Medicine, 2012, 20, 125-8.	0.1	11
2283	Advances in the treatment of hepatitis C virus infection. Topics in Antiviral Medicine, 2012, 20, 5-10.	0.1	26

#	ARTICLE	IF	CITATIONS
2284	Hepatitis C virus therapeutics: at the end of the beginning. Topics in Antiviral Medicine, 2012, 20, 17-9.	0.1	2
2285	Genotypic resistance testing of HCV - is there a clinical need?. GMS Infectious Diseases, 2016, 4, Doc05.	0.8	0
2286	Management of Hepatitis C in Patients With HIV. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 15S-19S.	0.6	0
2287	Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon- α 2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iranian Journal of Public Health, 2018, 47, 1845-1853.	0.5	1
2288	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. Gastroenterology and Hepatology, 2018, 14, 687-705.	0.1	2
2289	Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastro-Enterologica Belgica, 2021, 84, 633-652.	1.0	10
2291	Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	4.0	9
2292	Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. Journal of Infection and Public Health, 2022, 15, 277-281.	4.1	5
2293	The knowledge on HCV. Infectious Microbes & Diseases, 2022, Publish Ahead of Print, .	1.3	2
2294	Present and future management of viral hepatitis. World Journal of Gastroenterology, 2021, 27, 8081-8102.	3.3	2
2295	Mutations in Main Protease of SARS CoV-2 Decreased Boceprevir Affinity. Brazilian Archives of Biology and Technology, 0, 64, .	0.5	1
2296	Preferred Therapy for Specific Viral Pathogens. , 2022, , 173-189.		0
2305	PEG-Interferon- α ± ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria, 2015, 39, 29-43.	0.6	1
2306	HARVONI VERSUS 3D REGIMENS OUTCOMES AMONG HCV INFECTED PATIENTS VISITED KURDISTAN CENTRE FOR GASTROENTEROLOGY AND HEPATOLOGY (KCGH). Journal of Sulaimani Medical College, 2022, 12, 1-9.	0.0	0
2307	Case study of hepatitis C virus control in Egypt: impact of access program. Antiviral Therapy, 2022, 27, 135965352110675.	1.0	6
2308	Risk Factors for Treatment Failure with Oral Antivirals in HCV. International Journal of Medical Science and Clinical Research Studies, 2022, 02, .	0.0	0
2309	Zn Mediated Urea Bond Formation: A Novel and Convenient Method. ChemistrySelect, 2022, 7, .	1.5	5
2310	O vÃrus da Hepatite C e a Hepatite C. , 2021, , 53-76.		0

#	ARTICLE	IF	CITATIONS
2311	Gestion des effets secondaires de la trithérapie en pratique libérale. HEGEL - HEpato-GastroEntérologie Libérale, 2012, N° 4, 27-29.	0.0	0
2312	Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World Journal of Hepatology, 2022, 14, 985-992.	2.0	0
2313	Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World Journal of Hepatology, 2022, 14, 984-991.	2.0	1
2314	HCV Treatment in Decompensated Disease. Current Hepatology Reports, 0, , .	0.9	0
2315	Breakthroughs in hepatitis C research: from discovery to cure. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 533-550.	17.8	62
2316	Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice. Viruses, 2022, 14, 1325.	3.3	12
2318	The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV. Beni-Suef University Journal of Basic and Applied Sciences, 2023, 12, .	2.0	1
2319	Preparing Unnatural Amino Acids. , 2022, , .		0
2320	Hepatitis C: epidemiology, natural history, and diagnosis. , 2023, , 229-250.		0
2321	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. International Journal of Molecular Sciences, 2023, 24, 4401.	4.1	4
2322	Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	0
2324	Preferred Therapy for Specific Viral Pathogens. , 2023, , .		0
2325	Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study. Balkan Medical Journal, 0, , .	0.8	1
2326	Elimination of hepatitis C virus in a prison: An 18-year experience. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2023, , .	0.3	0
2327	Synthesis of 3-azabicyclo[3.1.0]hexane Derivates. Chemistry - A European Journal, 2023, 29, .	3.3	1
2328	Palladium-catalyzed intramolecular asymmetric hydrocyclopropanylation of alkynes: synthesis of cyclopropane-fused β -lactams. Chemical Science, 2023, 14, 7564-7568.	7.4	1
2329	Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation. Gastroenterology Insights, 2023, 14, 249-270.	1.2	1
2330	Programmable Proteolysis-Activated Transcription for Highly Sensitive Ratiometric Electrochemical Detection of Viral Protease. Analytical Chemistry, 2023, 95, 10728-10735.	6.5	1

#	ARTICLE	IF	CITATIONS
2331	Medicinal plant molecules against hepatitis C virus: Current status and future prospect. <i>Phytotherapy Research</i> , 2023, 37, 4353-4374.	5.8	2
2332	Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Antiviral Effects of Different Medicinal Plants Against Infection. <i>Reference Series in Phytochemistry</i> , 2023, , 1-31.	0.4	0
2333	Oncoviruses: How do they hijack their host and current treatment regimes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188960.	7.4	1
2334	Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients. <i>Medicine (United States)</i> , 2023, 102, e34125.	1.0	1
2335	Catalytic Olefin Cyclopropanation with In Situ-Generated Dialkyl Diazomethanes via Co(II)-Based Metalloradical Catalysis. <i>ACS Catalysis</i> , 2023, 13, 11851-11856.	11.2	2
2337	Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions. <i>Cureus</i> , 2023, , .	0.5	0
2338	Experience with direct-acting antivirals in genotype 1 infected chronic hepatitis C patients in Turkey. <i>Annals of Saudi Medicine</i> , 2023, 43, 308-314.	1.1	1
2339	A Ten-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China. <i>Infectious Microbes & Diseases</i> , 0, , .	1.3	0
2340	Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Anti-Viral Effects of Different Medicinal Plants Against Infection. <i>Reference Series in Phytochemistry</i> , 2024, , 341-371.	0.4	0
2341	Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis. <i>Nature Communications</i> , 2023, 14, .	12.8	1
2342	Detection of Hepatitis C Virus Genotype 1a among Patients from Al-Nasiriya City and Determining its Transmission Risk Factors. , 2021, 34, 27.		1
2343	Hepatitis C Virus. , 2022, , 1-28.		0
2344	Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals. <i>European Journal of Medicinal Chemistry</i> , 2024, 264, 116051.	5.5	0
2345	Toxicology Studies of Anisole and Glyoxylic Acid Derivatives by Computational Methods. , 2023, , 125-158.		0
2346	Morphometric, biochemical and histopathological effects of sofosbuvir (sovaldi) on testes of adult male albino rats. <i>Ultrastructural Pathology</i> , 2024, 48, 94-107.	0.9	0
2347	A Non-Active-Site Inhibitor with Selectivity for Zika Virus NS2B-NS3 Protease. <i>ACS Infectious Diseases</i> , 2024, 10, 412-425.	3.8	0
2348	Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients. <i>Chinese Medical Journal</i> , 2013, 126, 4568-4574.	2.3	0
2349	Preferred Therapy for Specific Viral Pathogens. , 2024, , .		0

#	ARTICLE	IF	CITATIONS
2350	The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes. Scientific Reports, 2024, 14, .	3.3	0
2351	An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine, 2024, 16, .	12.4	0
2352	Triple Combination with Direct Acting Antivirals in the Treatment of Hepatitis C Does not Prolong the QT Interval. Acta Medica (Hradec Kralove), 2023, 66, 101-106.	0.5	0